

Article

Combinatorial Synthesis of Structurally Diverse Triazole-Bridged Flavonoid Dimers and Trimers

Tze Han Sum¹, Tze Jing Sum¹, Warren R. J. D. Galloway¹, S uil Collins^{1,2}, David G. Twigg¹, Florian Hollfelder² and David R. Spring^{1,*}

¹ Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK; ths29@cam.ac.uk (T.H.S.); tjs76@cam.ac.uk (T.J.S.); wrjdg2@cam.ac.uk (W.R.J.D.G.); sc806@cam.ac.uk (S.C.); dgt24@cam.ac.uk (D.G.T.)

² Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA, UK; fh111@cam.ac.uk

* Correspondence: spring@ch.cam.ac.uk; Tel.: +44-1223-336-498

Academic Editor: Andrea Trabocchi

Received: 29 July 2016; Accepted: 8 September 2016; Published: 16 September 2016

Abstract: Flavonoids are a large family of compounds associated with a broad range of biologically useful properties. In recent years, synthetic compounds that contain two flavonoid units linked together have attracted attention in drug discovery and development projects. Numerous flavonoid dimer systems, incorporating a range of monomers attached via different linkers, have been reported to exhibit interesting bioactivities. From a medicinal chemistry perspective, the 1,2,3-triazole ring system has been identified as a particularly attractive linker moiety in dimeric derivatives (owing to several favourable attributes including proven biological relevance and metabolic stability) and triazole-bridged flavonoid dimers possessing anticancer and antimalarial activities have recently been reported. However, there are relatively few examples of libraries of triazole-bridged flavonoid dimers and the diversity of flavonoid subunits present within these is typically limited. Thus, this compound type arguably remains underexplored within drug discovery. Herein, we report a modular strategy for the synthesis of novel and biologically interesting triazole-bridged flavonoid heterodimers and also very rare heterotrimers from readily available starting materials. Application of this strategy has enabled step-efficient and systematic access to a library of structurally diverse compounds of this sort, with a variety of monomer units belonging to six different structural subclasses of flavonoid successfully incorporated.

Keywords: flavonoid; triazole; dimer; trimer; hybridization; structural diversity

1. Introduction

Flavonoids are a large family of polyphenolic compounds that represent dietary constituents of importance to good health as well as a potentially important new class of pharmaceutical lead substrates [1–3]. There are several subclasses of flavonoids, including aurones, chalcones, coumarins, flavones and isoflavones, which serve as the core structural units of numerous biologically active molecules [4–7]. In recent years, synthetic compounds that contain two such flavonoid units linked together (so-called flavonoid dimers) have garnered attention from the synthetic and medicinal chemistry communities [8–17]. The generation of species that integrate two pharmacophoric entities (both homo- and hetero-dimers) is a common strategy in drug discovery [18,19] and numerous flavonoid dimer systems, incorporating a range of monomers linked in a variety of ways, have been reported to exhibit biologically useful properties [8–17]. From a medicinal chemistry perspective, the 1,2,3-triazole ring system has been identified as a particularly attractive linker moiety owing to various favourable properties including ease of synthesis, proven biological relevance and metabolic

stability [11,18,20]; indeed, triazole-bridged flavonoid dimers possessing anticancer [10,11] and antimalarial [11] activities have recently been reported (Figure 1). However, there are relatively few examples of libraries of triazole-bridged flavonoid dimers, and the diversity of flavonoid subunits present within these is typically limited. Thus, the triazole-bridged flavonoid dimer compound type arguably remains underexplored within drug discovery. We were interested in investigating the biological potential of triazole-bridged flavonoid dimers further and so sought access to a more structurally diverse collection of such compounds incorporating a wide range of flavonoid units. In addition, we were also interested in accessing triazole-bridged trimeric derivatives, which are also expected to have interesting biological properties. Though the synthesis of triazole-bridged flavonoid trimers has previously been reported [10], compounds of this sort are very rare and they have received relatively little attention from synthetic and medicinal chemists. Herein, we report the development of a modular strategy for the synthesis of novel triazole-bridged flavonoid heterodimers and heterotrimers. Application of this strategy has enabled concise and systematic access to a library of 46 structurally diverse compounds of this sort (41 dimers and five trimers) from readily available starting materials.





Figure 1. Three examples of biologically active triazole-linked flavonoid dimers. The flavonoid subunits in each example are highlighted in colours. (a) A modulator of multidrug resistance in some cancers [10]; (b) A modulator of multidrug resistance in some cancers [10]; (c) A compound with anticancer activity and antimalarial activity [11].

2. Results and Discussion

2.1. Outline of the Synthetic Strategy

Inspired by previous studies on the synthesis of triazole-linked flavonoid libraries [10,11] we envisaged a branching-type strategy to access triazole-bridged flavonoid dimers and trimers, based around the use of iterative copper-catalysed “click”-type alkyne-azide 1,3-dipolar cycloadditions (Scheme 1) [21]. It was anticipated that flavonoid monomer units bearing a terminal alkyne group (“alkyne-flavonoid” building blocks) could be reacted with a range of flavonoid monomer units bearing a terminal azide group (“azido-flavonoid” building blocks) to furnish diverse and novel triazole-bridged flavonoid homo- and hetero-dimers (of the general structure **A**, Scheme 1). The presence of a free hydroxyl functionality in either monomer unit would allow for post-cyclisation introduction of a terminal alkyne group in the dimers, thus providing the necessary synthetic handle for a further cycloaddition with varied alkyne-flavonoids to furnish structurally diverse triflavonoid derivatives of the general forms **B** and **C** (Scheme 1). The presence of additional synthetic handles in any given monomer unit should also allow for further elaboration of the dimers and trimers. Overall, it was anticipated that this modular strategy would enable step-efficient and facile access to a structurally diverse library of triazole-bridged flavonoid dimers and trimers through the use of a variety of different flavonoid building blocks belonging to different flavonoid structural subclasses.



Scheme 1. Overview of the branching-type strategy towards structurally diverse triazole-bridged flavonoid heterodimers and heterotrimers. It was anticipated that homo- dimers and trimers could also be accessed through the use of appropriate building blocks.


2.2. Building Block Design and Synthesis

In order to facilitate the generation of structural diversity in the final compound collection, building blocks belonging to a variety of flavonoid structural subclasses (chalcone, coumarin, flavone, aurone, flavonol and isoflavone, see Scheme 1) and derivatives thereof were targeted. Structural diversity, including functional group diversity, within building blocks of some subclasses was also sought in order to further increase the overall structural diversity of the final library (as well as providing a means of introducing additional biomolecular-interacting elements into the library compounds, for example, additional bio-relevant heterocyclic motifs and hydrogen-bonding functionalities). Variation in the position of the key alkyne/azide ligation handles around the flavonoid structures was also envisaged as a strategy to further increase library structural diversity, since this would enable access to different structural isomers of any given dimers/trimers. On the basis of synthetic tractability, various alkyne-chalcones, flavones and isoflavones and azido-chalcone, flavonols and flavones were targeted. Hydroxyl-substituted building blocks were also required in order to allow access to trimeric species (as outlined in Scheme 1). Based on predicted synthetic accessibility, the syntheses of a hydroxyl-substituted alkyne-chalcone, alkyne-flavonol, azido-chalcone and azido-flavonol were targeted.

2.2.1. Synthesis of the Alkyne-Flavonoid Building-Blocks


Alkyne-Chalcones

Hydroxyl-substituted alkyne-chalcone **4** was accessed from phenol **1** via a two-step sequence: alkylation with propargyl bromide proceeded smoothly to yield aldehyde **2** and subsequent Claisen-Schmidt aldol reaction with acetophenone **3** yielded the target compound **4** (Scheme 2) [22].



Scheme 2. Synthesis of hydroxyl-substituted alkyne-chalcone building block **4**.


Structurally diverse alkyne-chalcone building blocks **20–26**, including chalconoid derivatives incorporating a range of heteroaromatic scaffolds and an unusual ferrocenyl motif, were generated from aldehydes **5–9** respectively by Claisen-Schmidt aldol condensation with various acetophenone derivatives followed by propargylation (Scheme **3**).



Scheme 3. Synthesis of alkyne-chalcone building blocks **20–26**.

Alkyne-Flavones


Propargylation of commercially available flavones **27–29** proceeded smoothly to furnish alkyne-flavones **30–32** with the alkyne synthetic handle appended at various positions on the flavone core unit (Scheme 4) [23,24].



Scheme 4. Synthesis of alkyne-flavone building blocks **30–32**.

Alkyne-Flavonol


The preparation of alkyne-flavonol **36** commenced with the synthesis of chalcone **35** via the Claisen-Schmidt reaction of the alkyne-substituted benzaldehyde **34** with acetophenone **10**. Subsequent Algar-Flynn-Oyamada (AFO) oxidation [22] of the chalcone **35** proceeded smoothly to furnish **36** (Scheme 5).



Scheme 5. Synthesis of alkyne-flavonol building block **36**.

Alkyne-Isoflavones


The preparation of the alkyne-isoflavone building blocks **45** and **46** commenced with the acylation of commercially available substituted phenols **37** and **38** with phenylacetic acids **39** and **40** to afford the deoxybenzoins **41** and **42** [25]. Subsequent cyclization of **41** and **42** in methanesulfonyl chloride afforded the corresponding isoflavones **43** and **44** which then underwent propargylation to yield the desired alkyne-isoflavones **45** and **46** (Scheme 6) [25].



Scheme 6. Synthesis of alkyne-isoflavones **45** and **46**.

Alkyne-Coumarin


Alkyne-coumarin **48** was synthesised by propargylation of hydroxycoumarin **47** in the presence of anhydrous potassium carbonate (Scheme 7) [11].



Scheme 7. Synthesis of alkyne-coumarin **48**.

Alkyne-Aurone

Alkyne-aurone **56** was prepared from commercially available phloroglucinol **49** (Scheme 8). Condensation with chloroacetonitrile in the presence of ZnCl_2 furnished imine **50** [26]. Subsequent hydrolysis under acidic conditions afforded ketone **51** which was then treated with methanolic sodium methoxide to give hydroxybenzofuranone **52** [26]. Methyl protection of the free hydroxyl groups afforded benzofuranone **53** which was then condensed with 3-hydroxybenzaldehyde **54** under basic conditions to yield hydroxyaurone **55**. Subsequent propargylation gave the desired alkyne-aurone **56** in an excellent yield (Scheme 8).




Scheme 8. Synthesis of alkyne-aurone **56**.

2.2.2. Synthesis of the Azido-Flavonoid Building Blocks

Azido-Coumarin



Azido-coumarin **58** was prepared from readily available hydroxycoumarin **47** by alkylation (to form **57**) followed by reaction with sodium azide (Scheme 9) [27].



Scheme 9. Synthesis of azido-coumarin **58**.


Azido-Chalcones

Hydroxyl-substituted azido-chalcone **61** was prepared by a three step sequence from phenolic aldehyde **33** (Scheme 10). Reaction with 1,2-dibromoethane generated aldehyde **59** and subsequent nucleophilic substitution with sodium azide produced azide **60** in an excellent yield. Claisen-Schmidt aldol condensation with ketone **10b** then yielded the target compound **61** [22]. Alternatively, Claisen-Schmidt aldol condensation of aldehydes **64–66** and **7** with readily-prepared azido-ketone **63** furnished azido-chalcone building blocks **67–70** respectively (Scheme 11) [22].

Scheme 10. Synthesis of azido-chalcone **61**.Scheme 11. Synthesis of azido-chalcones **67–70**.

Azido-Flavonols


Aldehydes **59** and **72** and **73**, generated by alkylation of **33**, **71** and **1** respectively with 1,2-dibromoethane, were reacted with sodium azide to form **60** and **74** and **75** respectively (Scheme 12). Subsequent aldol condensation with acetophenones **10** or **3** (see Scheme 12) furnished chalcones **61** and **76–78** and AFO proceeded smoothly in all cases to furnish azido-flavonols **79** and **80–82** in good yields [22].




Scheme 12. Synthesis of azido-flavonols 79–82.

Azido-Flavones

Azido-flavones **85** and **86** were readily accessed from commercially available hydroxyflavones **28** and **29** by reaction with 1,2-dibromoethane to forge **83** and **84** followed by nucleophilic substitution with sodium azide (Scheme 13) [10,28]. Azido-flavone **87** was prepared in an excellent yield from chalcone **76** by an iodine-mediated oxidative cyclization (Scheme 14).




Scheme 13. Synthesis of azido-flavones 85–86.



Scheme 14. Synthesis of azido-flavone 87.

Azido-Aurones

Mercury(II) acetate-mediated oxidative cyclization of chalcones **61** and **76** furnished azido-aurones **88** and **89** respectively in excellent yields (Scheme 15) [29].



Scheme 15. Synthesis of azido-aurones 88–89.

2.2.3. Synthesis of Triazole-Bridged Flavonoid Dimers

With the alkyne- and azido-flavonoid building blocks in hand, we were ready to forge a series of dimeric combinations via triazole formation. Thus, various pairs of building blocks were subjected to standard copper-mediated “click” cycloaddition conditions to generate 41 distinct and diverse triazole-bridged flavonoid dimers (compounds **90–130**, Schemes 16–20). The reactions generally proceeded smoothly and with high levels of regioselectivity and isolated yields of the target compounds were typically moderate-to-good. Six different biologically-relevant flavonoid structural subclasses (chalcone, flavonol, aurone, flavone, coumarin and isoflavone) were successfully incorporated into the dimer library together with other biologically-relevant features, and variation within building blocks belonging to certain subclasses allowed for the generation of additional structural diversity in the library and the concomitant introduction of additional biomolecule-interacting elements (for example, the varied heterocyclic motifs exhibited by the chalcone-chalcone dimers **90–97**). Several compounds also featured groups that could provide synthetic handles for further elaboration or diversification (for example, compounds **96** and **97** and **105** and **106** contain a hydroxyl group and the aryl-bromide group present in **107** and **108** could conceivably be exploited in various metal-catalysed cross-coupling processes).

2.2.4. Synthesis of Triazole-Bridged Flavonoid Trimers


Propargylation of the free phenolic hydroxyl groups of triazole-bridged flavonoid dimers **126**, **122**, **92** and **110** and **106** led to the formation of alkyne-capped derivatives **131–135** respectively. These were successfully coupled with three azido-flavonoid building blocks (**86** for **131** and **132**; **87** for **133**; and **89** for **134** and **135**) via copper-catalysed triazole formation to furnish five structurally diverse triazole-bridged flavonoid trimers **136–140** (Scheme 21).

2.3. Preliminary Biological Screening


A representative sample of 13 final triazole-bridged dimers (**90–93**, **112–114**, **122**, **123**, **125**, **126**, **129** and **130**) was screened for inhibitory activity against the aggregation of amyloid beta (**1–42**) (Aβ₄₂), a pathological hallmark of Alzheimer’s disease [30]. Aggregation of the monomeric form of the peptide into oligomeric and fibrillar species is associated with disease onset and progression. As such, the identification of compounds capable of inhibiting the aggregation process holds great potential for the development of therapeutic agents [31]. Flavonoid and chalcone derivatives have previously shown activity in perturbing the aggregation of Aβ, with compounds such as EGCG myricetin and morin displaying inhibitory activity in a variety of biophysical and in vivo tests [32–35]. It has also been shown that dimeric flavonoids can display enhanced inhibitory activity than their monomeric counterparts [36], suggesting that the libraries synthesised may be effective at targeting this peptide aggregation pathway. The ability of the triazole-linked dimers to inhibit the Aβ₄₂ aggregation was assessed using a thioflavin T (THT) assay (Figure 2). Three of the compounds screened were found

to have moderate inhibitory activity, with **92** found to be the most potent and comparable to the inhibitor morin.


It is difficult to draw any firm conclusions at this time regarding structure-activity relationships in the triazole-bridged dimer compound class due to the relatively small sample size and some issues with the solubility and fluorescence behaviour of some compounds under the assay conditions. Nevertheless, this preliminary screen has identified structurally novel $A\beta_{42}$ aggregation inhibitors which could represent interesting scaffolds for further study in this regard.




Scheme 16. Synthesis of triazole-bridged chalcone-chalcone dimers.




Scheme 17. Synthesis of triazole-bridged flavone-chalcone dimers.




Scheme 18. Synthesis of triazole-bridged chalcone-flavonol dimers.



Scheme 19. Synthesis of some triazole-bridged dimers.



Scheme 20. Synthesis of some triazole-bridged dimers.



Scheme 21. Synthesis of triazole-bridged trimers.





Compound	% Inhibition
 92	65.2 ± 1
 122	58.2 ± 2
 126	20.6 ± 4
 Morin	49.0 ± 4

Figure 2. Percentage inhibition of A β ₄₂ aggregation achieved by compounds **92**, **122** and **126** (50 μ M concentration) relative to that of A β ₄₂ alone (10 μ M), where 100% represents complete aggregation inhibition and 0% shows no inhibition. The data represents the averages and standard error from the results of three independent biological repeats. Inhibitory effect of morin determined under identical assay conditions.

3. Materials and Methods

3.1. Chemical Synthesis

3.1.1. General Information

All non-aqueous reactions were performed under a constant stream of dry nitrogen using oven-dried glassware. Standard practices were employed when handling moisture and air-sensitive materials. All reagents and solvents were purchased from commercial sources and used without further purification unless otherwise stated. Room temperature refers to ambient temperature. Temperatures of 0 °C were maintained using an ice-water bath. Petroleum ether was distilled before use. Ethyl acetate and methanol were distilled from calcium hydride. Melting points were measured using a Büchi B545 melting point apparatus and are uncorrected. Thin layer chromatography (TLC) was performed on pre-coated silica gel GF254 plates (Merck, Kenilworth, NJ, USA). Infrared (IR) spectra were recorded on a Spectrum One (FT-IR) spectrophotometer (Perkin-Elmer, Waltham, MA, USA) with internal referencing. Absorption maxima (ν_{\max}) are reported in wavenumbers (cm^{-1}). Flash column chromatography was performed on silica gel (230–400 mesh). ¹H-NMR and ¹³C-NMR were recorded on an Avance 500 MHz instrument (Bruker, Billerica, MA, USA) in CDCl₃ or (CD₃)₂CO. Chemical shifts (δ) are quoted in ppm, to the nearest 0.01 ppm (¹H-NMR) or 0.1 ppm (¹³C-NMR) and are referenced

to the residual non-deuterated solvent peak. $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ data for all compounds can be found in Supplementary Materials. LCMS analysis was performed on an ACQUITY H-Class UPLC (Waters, Milford, MA, USA) with an ESCi Multi-Mode Ionisation Waters SQ Detector 2 spectrometer using MassLynx 4.1 software. LC system: solvent A: 2 mM NH_4OAc in $\text{H}_2\text{O}/\text{MeCN}$ (95:5); solvent B: MeCN; solvent C: 2% aqueous formic acid; gradient: 5%–95% B with constant 5% C over 1 min at flow rate of 0.6 mL/min. High resolution mass spectrometry (HRMS) measurements were recorded on a Q-TOF mass spectrometer (Micromass, Cary, NC, USA) or a Waters LCT Premier Time of Flight mass spectrometer. Mass values are quoted within the error limits of ± 5 ppm mass units. ESI+ refers to the mass ionisation technique.

3.1.2. General Synthetic Procedures

General Procedure A: Synthesis of Biflavonoid Triazole Hybrids (GP-A). To a stirred solution of alkyne flavonoid (1.0 equiv.) and azide flavonoid (1.0 equiv.) in $t\text{-BuOH}/\text{H}_2\text{O}$ (1:1, 40 mL) were added $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (1.1 equiv.) and sodium ascorbate (2.5 equiv.). The reaction mixture was stirred at room temperature for 24 h or until TLC analysis indicated complete consumption of starting material. The resulting mixture was poured into H_2O (100 mL) and the aqueous solution was extracted with CHCl_3 (3×100 mL). The combined organic layer was washed with H_2O (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO_4 , filtered and the solvent removed under reduced pressure. The crude residue was purified by flash column chromatography over silica and recrystallized from MeOH to afford the corresponding biflavonoid triazole hybrids.

General Procedure B: Synthesis of Alkyne Biflavonoid Triazole Hybrids (GP-B). To a stirred solution of the corresponding biflavonoid triazole hybrid (1.0 equiv.) in dry acetone (50 mL) were added propargyl bromide (3.0 equiv.) and anhydrous K_2CO_3 (3.0 equiv.). The reaction mixture was heated at reflux with stirring for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The resulting mixture was allowed to cool to room temperature and the solvent removed in vacuo. The crude residue was re-suspended in CHCl_3 (50 mL) and the organic layer was washed with H_2O (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO_4 , filtered and evaporated to dryness. The crude residue was purified by flash column chromatography over silica to afford the corresponding propynyloxy biflavonoid triazole hybrid.

General Procedure C: Synthesis of Propynyloxy flavonoids or benzaldehydes (GP-C). To a stirred solution of the corresponding flavonoid or benzaldehyde (1.0 equiv.) in dry acetone (50 mL) were added anhydrous K_2CO_3 (3.0 equiv.) and propargyl bromide (3.0 equiv.). The reaction mixture was heated at reflux with stirring for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The resulting mixture was allowed to cool to room temperature and the solvent removed in vacuo. The crude residue was re-suspended in CHCl_3 (100 mL) and the organic layer was washed with H_2O (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO_4 , filtered and evaporated to dryness. The crude residue was purified by flash column chromatography over silica to afford the corresponding propynyloxy flavonoids or benzaldehydes.

General Procedure D: Synthesis of Chalcones (GP-D). To a stirred solution of KOH (12.0 equiv.) in absolute EtOH (100 mL) cooled to 0°C in an ice-bath were added dropwise a solution of the corresponding acetophenone (1.0 equiv.) and aldehyde (1.0 equiv.) in EtOH (20 mL). The reaction mixture was stirred at 0°C for 1 h and then at room temperature for 72 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The resulting mixture was then poured into ice-water (100 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was extracted with CHCl_3 (3×100 mL) and the combined organic layer was washed with satd NaHCO_3 (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO_4 , filtered and the solvent removed under reduced pressure. The crude residue was purified by flash column chromatography over silica and/or recrystallized from MeOH or absolute EtOH to afford the corresponding chalcones.

General Procedure E: Synthesis of Indole or Pyrrole 2-hydroxychalcones (GP-E). To a stirred solution of indole or pyrrole aldehyde (1.0 equiv.) and the corresponding 2-hydroxyacetophenone (1.0 equiv.) in absolute EtOH (100 mL) was added piperidine (1.0 equiv.). The reaction mixture was heated at reflux for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The reaction mixture was allowed to cool to room temperature, poured into ice-water (100 mL) and then acidified to pH 3–4 with 3 M HCl. The resulting suspension was filtered and the precipitate washed with ice-water (2×100 mL), suction-dried and recrystallized from MeOH to afford the corresponding indole or pyrrole chalcones.

General Procedure F: Synthesis of Flavonols (GP-F). To a stirred solution of the corresponding chalcone (0.30 mmol) in MeOH (20 mL) were added 16% NaOH (aq) (0.60 mL) and 15% H₂O₂ (0.30 mL). The reaction mixture was stirred at room temperature for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The resulting mixture was then poured into ice-water (50 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was extracted with CHCl₃ (3×50 mL) and the combined organic layer was washed with satd NaHCO₃ (2×50 mL), brine (2×50 mL), dried over anhydrous MgSO₄, filtered and the solvent removed under reduced pressure. The crude residue was purified by flash column chromatography over silica to afford the corresponding flavonols.

General Procedure G: Synthesis of Phenylethanones (GP-G). To a stirred solution of substituted phenol (1.2 equiv.) in BF₃·OEt₂ (50 mL) was added the corresponding phenylacetic acid (1.0 equiv.) and the reaction mixture was heated at 80 °C for 8 h under a nitrogen atmosphere. The resulting dark solution was allowed to cool to room temperature and slowly poured into ice-water (100 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layer was washed with satd NaHCO₃ (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness. The crude residue was purified by flash column chromatography over silica to afford the corresponding phenylethanones.

General Procedure H: Synthesis of Isoflavones (GP-H). To a stirred solution of the corresponding phenylethanone (1.0 equiv.) in dry DMF (15 mL) was carefully added BF₃·OEt₂ (4.0 equiv.) over 10 min under a nitrogen atmosphere. To this mixture, methanesulfonyl chloride (3.0 equiv.) was added at 55 °C, stirred for 1 h and then heated at 80 °C for 24 h. The resulting dark solution was allowed to cool to room temperature and then poured with rapid stirring into ice-water (100 mL). The resulting precipitate was filtered, washed with H₂O (2×100 mL), suction-dried and re-dissolved in EtOAc (100 mL). The organic solution was washed with H₂O (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness. The crude residue was purified by flash column chromatography over silica to afford the corresponding isoflavones.

General Procedure I: Synthesis of Bromoalkylated flavonoids or benzaldehydes (GP-I). To a stirred solution of the corresponding flavonoid or benzaldehyde (1.0 equiv.) in dry acetone (50 mL) or dry DMF (50 mL) were added anhydrous K₂CO₃ (3.0 equiv.) and 1,2-dibromoethane (3.0 equiv.). The reaction mixture was heated at reflux with stirring for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of starting material. The resulting mixture was allowed to cool to room temperature and the solvent removed in vacuo. The crude residue was re-suspended in CHCl₃ (100 mL) and the organic layer was washed with H₂O (2×100 mL), brine (2×100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness. The crude residue was purified by flash column chromatography over silica to afford the corresponding bromoalkylated flavonoids or benzaldehydes.

General Procedure J: Synthesis of Azido flavonoids or benzaldehydes (GP-J). To a stirred solution of the corresponding bromoalkylated flavonoids or benzaldehydes (1.0 equiv.) in dry DMF (30 mL) was added NaN₃ (3.0 equiv.). The reaction mixture was heated at 100 °C with stirring for 3 h under a nitrogen atmosphere. The resulting mixture was allowed to cool to room temperature and poured

into H₂O (100 mL). The aqueous solution was extracted with CHCl₃ (3 × 100 mL) and the combined organic layer was washed with H₂O (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness to afford the corresponding azido flavonoids or benzaldehydes and were used without further purification.

General Procedure K: Synthesis of Aurones (GP-K). To a stirred solution of the corresponding chalcone (1.0 equiv.) in pyridine (10 mL) was added Hg(OAc)₂ (1.0 equiv.). The reaction mixture was heated at 110 °C with stirring for 1 h under a nitrogen atmosphere. The resulting mixture was then poured into ice-water (50 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was extracted with CHCl₃ (3 × 50 mL) and the combined organic layer was washed with H₂O (2 × 50 mL), brine (2 × 50 mL), dried over anhydrous MgSO₄, filtered and the solvent removed under reduced pressure. The crude residue was purified by flash column chromatography over silica to afford the corresponding aurones.

3.2. Synthetic Procedures

3.2.1. Building Block Synthesis

4-Methoxy-3-(prop-2-yn-1-yloxy)benzaldehyde (**2**). A mixture of isovanillin (**1**, 10.0 g, 65.7 mmol), propargyl bromide (8.78 mL, 98.6 mmol) and anhydrous K₂CO₃ (18.2 g, 131 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO₂, CH₂Cl₂) to afford benzaldehyde **2** (9.23 g, 74%) as a white fluffy solid. m.p. 78–80 °C. TLC R_f = 0.21 (CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3229m (C≡C-H str), 3096w (C-H str), 2839w (C-H str), 2124w (C≡C str), 1671s (C=O str), 1599s (C=C str), 1586s (C=C str), 1508s (C=C str), 1436m, 1407m, 1387m, 1261s, 1229s, 1161s, 1129s, 1012s. ¹H-NMR (500 MHz, CDCl₃): δ 2.55 (1H, t, J = 2.4 Hz, -OCH₂C≡CH), 3.97 (3H, s, -OCH₃), 4.83 (2H, d, J = 2.4 Hz, -OCH₂C≡CH), 7.01 (1H, d, J = 8.0 Hz, ArH), 7.53 (1H, dd, J = 8.0, 1.6 Hz, ArH), 7.55 (1H, d, J = 1.6 Hz, ArH), 9.87 (1H, s, CHO). ¹³C-NMR (500 MHz, CDCl₃): δ 56.2, 56.6, 76.4, 77.7, 110.9, 112.0, 127.3, 129.9, 147.3, 154.9, 190.7. LCMS (ES+) m/z = 191.2 ([M + H]⁺, t_R = 3.09 min). These characterisation data are in accordance with that previously reported in the literature [37].

(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (**4**). A mixture of benzaldehyde **2** (2.05 g, 10.8 mmol), acetophenone **3** (1.80 g, 10.8 mmol) and KOH (3.02 g, 53.8 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone **4** (1.42 g, 39%) as a bright yellow-orange fluffy solid. m.p. 144–146 °C. TLC R_f = 0.37 (PE/EtOAc; 2:1). IR ν_{max} (neat)/cm⁻¹: 3506w (br) (O-H str), 3229 m (C≡C-H str), 3081w (C-H str), 2973w (C-H str), 2111w (C≡C str), 1633m (C=O str), 1572 m (C=C str), 1556s (C=C str), 1507s (C=C str), 1466 m, 1440s, 1361s, 1339s, 1260s, 1206s, 1170m, 1126s, 1018s. ¹H-NMR (500 MHz, CDCl₃): δ 2.58 (1H, t, J = 2.0 Hz, -OCH₂C≡CH), 3.87 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 4.85 (2H, d, J = 2.4 Hz, -OCH₂C≡CH), 6.49–6.52 (2H, m, ArH), 6.94 (1H, d, J = 8.4 Hz, ArH), 7.32 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.35 (1H, d, J = 1.2 Hz, ArH), 7.45 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.83 (1H, d, J = 8.4 Hz, ArH), 7.85 (1H, d, J = 15.6 Hz, -CH=CHCO-), 13.53 (1H, s, OH). ¹³C-NMR (500 MHz, CDCl₃): δ 55.6, 56.0, 56.9, 76.3, 78.1, 101.0, 107.7, 111.7, 113.8, 114.1, 118.3, 124.3, 127.7, 131.1, 144.3, 146.9, 152.2, 166.1, 166.6, 191.7. LCMS (ES+) m/z = 339.2 ([M + H]⁺, t_R = 1.70 min). HRMS (ESI+) m/z = 339.1224 [M + H]⁺ found, C₂₀H₁₉O₅⁺ required 339.1227.

(E)-1-(4-Hydroxy-3-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (**13**). A mixture of aldehyde **5** (7.40 mL, 60.8 mmol), acetophenone **11** (10.0 g, 60.3 mmol) and KOH (16.9 g, 302 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 5:1) to afford chalcone **13** (10.7 g, 63%) as a bright yellow-orange powdery solid. m.p. 148–150 °C. TLC R_f = 0.40 (PE/EtOAc; 1:1). IR ν_{max} (neat)/cm⁻¹: 3180m (br) (O-H str), 2991w (C-H str), 2836w (C-H str), 1643m (C=O str), 1602m (C=C str), 1560s (C=C str), 1508s

(C=C str), 1461w, 1424s, 1338m, 1296s, 1278s, 1248s, 1166s, 1048m, 1026s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.86 (3H, s, $-\text{OCH}_3$), 3.98 (3H, s, $-\text{OCH}_3$), 6.23 (1H, s, OH), 6.94 (2H, d, $J = 9.0$ Hz, ArH), 7.00 (1H, d, $J = 8.0$ Hz, ArH), 7.45 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$), 7.61 (2H, d, $J = 8.5$ Hz, ArH), 7.64–7.66 (2H, m, ArH), 7.79 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 55.4, 56.1, 110.5, 113.7, 114.3, 119.3, 123.5, 127.8, 130.1, 131.2, 143.8, 146.8, 150.2, 161.5, 188.6. LCMS (ES+) $m/z = 285.2$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.75$ min). These characterisation data are in accordance with that previously reported in the literature [38].

(*E*)-1-(5-Bromo-2-hydroxyphenyl)-3-(1-methyl-1H-indol-3-yl)prop-2-en-1-one (**14**). A mixture of indole aldehyde **6** (1.03 g, 6.47 mmol), acetophenone **12** (1.38 g, 6.42 mmol) and piperidine (0.62 mL, 6.28 mmol) in absolute EtOH (100 mL) was reacted according to GP-E. The crude residue was purified by recrystallization from MeOH to afford chalcone **14** (2.15 g, 94%) as a bright orange fluffy solid. m.p. 250–252 °C. TLC $R_f = 0.45$ (PE/EtOAc 2:1). IR ν_{max} (neat)/ cm^{-1} : 3101w (C-H str), 2885w (C-H str), 1626s (C=O str), 1541m (C=C str), 1513s (C=C str), 1462m, 1387m, 1375m, 1344m, 1295m, 1252s, 1177s, 1126s, 1074s, 1028s, 1014m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.88 (3H, s, $-\text{NCH}_3$), 6.93 (1H, d, $J = 8.8$ Hz, ArH), 7.38–7.40 (3H, m, ArH), 7.49–7.56 (2H, m, ArH), 7.55 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 8.00–8.03 (2H, m, ArH), 8.23 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 13.25 (1H, br s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 33.5, 110.2, 110.3, 113.1, 113.6, 120.5, 120.8, 121.7, 122.1, 123.6, 126.1, 131.5, 135.6, 138.1, 138.4, 140.4, 162.4, 192.5. LCMS (ES+) $m/z = 358.0$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 4.96$ min). HRMS (ESI+) $m/z = 356.0279$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{15}\text{O}_2\text{NBr}^+$ required 356.0281.

(*E*)-1-(2-Hydroxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (**15**). A mixture of pyrrole aldehyde **7** (4.00 mL, 37.2 mmol), acetophenone **10** (4.50 mL, 37.4 mmol) and piperidine (3.80 mL, 38.5 mmol) in absolute EtOH (100 mL) was reacted according to GP-E. The crude residue was purified by recrystallization from MeOH to afford chalcone **15** (2.28 g, 27%) as a bright yellow-orange powdery solid. m.p. 98–100 °C. TLC $R_f = 0.45$ (PE/EtOAc; 3:1). IR ν_{max} (neat)/ cm^{-1} : 3112w (C-H str), 2937w (C-H str), 1627s (C=O str), 1579w (C=C str), 1549s (C=C str), 1479s, 1440m, 1412m, 1384m, 1356w, 1338m, 1290m, 1260s, 1249s, 1203s, 1182w, 1155s, 1092w, 1061s, 1025s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.81 (3H, s, $-\text{NCH}_3$), 6.26–6.27 (1H, m, ArH), 6.87 (1H, t, $J = 2.0$ Hz, ArH), 6.91–6.96 (2H, m, ArH), 7.02 (1H, dd, $J = 8.4, 0.8$ Hz, ArH), 7.40 (1H, d, $J = 14.8$ Hz, $-\text{CH}=\text{CHCO}-$), 7.48 (1H, t, $J = 8.4$ Hz, ArH), 7.89 (1H, dd, $J = 8.0, 2.0$ Hz, ArH), 7.92 (1H, d, $J = 14.8$ Hz, $-\text{CH}=\text{CHCO}-$), 13.14 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 34.4, 110.2, 113.3, 114.5, 118.5, 118.7, 120.2, 128.6, 129.2, 130.2, 132.8, 135.8, 163.4, 193.1. LCMS (ES+) $m/z = 228.1$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.68$ min). HRMS (ESI+) $m/z = 228.1020$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{14}\text{H}_{14}\text{O}_2\text{N}^+$ required 228.1019.

(*E*)-1-(4-Hydroxy-3-methoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (**16**). A mixture of pyrrole aldehyde **7** (3.30 mL, 30.7 mmol), acetophenone **11** (5.02 g, 30.2 mmol) and KOH (10.2 g, 182 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) and recrystallized from absolute EtOH to afford chalcone **16** (4.28 g, 55%) as a dark red-brown powdery solid. m.p. 150–152 °C. TLC $R_f = 0.31$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 3177m(br) (O-H str), 2958w (C-H str), 2930w (C-H str), 1630m (C=O str), 1600m (C=C str), 1587m (C=C str), 1543s (C=C str), 1508s (C=C str), 1478m, 1380w, 1333m, 1270s, 1218m, 1196s, 1169s, 1052s, 1031s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.77 (3H, s, $-\text{NCH}_3$), 3.99 (3H, s, $-\text{OCH}_3$), 6.18 (1H, s, OH), 6.23 (1H, t, $J = 3.2$ Hz, ArH), 6.81 (1H, t, $J = 2.0$ Hz, ArH), 6.84 (1H, dd, $J = 4.0, 1.6$ Hz, ArH), 6.99 (1H, d, $J = 8.8$ Hz, ArH), 7.32 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 7.62–7.64 (2H, m, ArH), 7.81 (1H, d, $J = 14.8$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 34.3, 56.1, 109.6, 110.4, 112.0, 113.7, 116.4, 123.1, 127.5, 130.3, 131.5, 131.5, 146.8, 150.0, 188.1. LCMS (ES+) $m/z = 258.1$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.40$ min). HRMS (ESI+) $m/z = 280.0935$ $[\text{M} + \text{Na}]^+$ found, $\text{C}_{15}\text{H}_{15}\text{O}_3\text{NNa}^+$ required 280.0944.

(*E*)-1-(5-Bromo-2-hydroxyphenyl)-3-(furan-2-yl)prop-2-en-1-one (**17**). A mixture of furan aldehyde **8** (1.20 mL, 14.5 mmol), acetophenone **12** (3.06 g, 14.2 mmol) and KOH (4.70 g, 83.8 mmol) in absolute

EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **17** (1.97 g, 47%) as a bright yellow-orange fluffy solid. m.p. 80–82 °C. TLC $R_f = 0.50$ (PE/EtOAc; 3:1). IR ν_{\max} (neat)/ cm^{-1} : 3128w (C-H str), 3046w (C-H str), 2868w (C-H str), 1638m (C=O str), 1567s (C=C str), 1548s (C=C str), 1467s, 1364m, 1335s, 1296m, 1258s, 1202s, 1177s, 1077w, 1013s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 6.56–6.57 (1H, m, ArH), 6.82 (1H, d, $J = 3.6$ Hz, ArH), 6.93 (1H, d, $J = 8.8$ Hz, ArH), 7.45 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 7.56 (1H, dd, $J = 9.2$, 2.4 Hz, ArH), 7.60 (1H, d, $J = 0.8$ Hz, ArH), 7.70 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 8.00 (1H, d, $J = 2.4$ Hz, ArH), 12.83 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 110.4, 113.0, 116.8, 117.8, 120.5, 121.2, 131.8, 131.9, 138.8, 145.8, 151.3, 162.4, 192.3. LCMS (ES+) $m/z = 293.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.85$ min). These characterisation data are in accordance with that previously reported in the literature [39].

(*E*)-3-(Ferrocenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (**18**). A mixture of ferrocene aldehyde **9** (4.77 g, 22.3 mmol), acetophenone **10** (2.70 mL, 22.4 mmol) and KOH (7.63 g, 136 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **18** (4.99 g, 67%) as a dark purple microcrystalline solid. m.p. 162–164 °C. TLC $R_f = 0.43$ (PE/EtOAc; 7:1). IR ν_{\max} (neat)/ cm^{-1} : 3315w(br) (O-H str), 3088w (C-H str), 1742w (C=O str), 1627m, 1554s (C=C str), 1489s, 1440m, 1383w, 1347m, 1302s, 1271m, 1246m, 1206s, 1158m, 1104m, 1048w, 1023m, 1002w. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 4.21 (5H, s, $-\text{C}_5\text{H}_5$), 4.55 (2H, t, $J = 2.0$ Hz, $-\text{C}_5\text{H}_4$), 4.65 (2H, t, $J = 2.0$ Hz, $-\text{C}_5\text{H}_4$), 6.94 (1H, t, $J = 8.0$ Hz, ArH), 7.03 (1H, dd, $J = 8.5$, 1.0 Hz, ArH), 7.26 (1H, d, $J = 15.0$ Hz, $-\text{CH}=\text{CHCO}-$, overlain by CDCl_3), 7.49 (1H, t, $J = 8.5$ Hz, ArH), 7.87 (1H, dd, $J = 8.0$, 1.0 Hz, ArH), 7.91 (1H, d, $J = 15.0$ Hz, $-\text{CH}=\text{CHCO}-$), 13.07 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 69.3, 69.9, 71.8, 78.8, 116.7, 118.6, 118.6, 120.0, 129.3, 135.9, 147.9, 163.6, 192.7. LCMS (ES+) $m/z = 333.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.87$ min). These characterisation data are in accordance with that previously reported in the literature [40].

(*E*)-3-(Ferrocenyl)-1-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one (**19**). A mixture of ferrocene aldehyde **9** (3.86 g, 18.0 mmol), acetophenone **11** (3.05 g, 18.4 mmol) and KOH (6.10 g, 109 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) to afford chalcone **19** (5.61 g, 86%) as a dark purple microcrystalline solid. m.p. 78–80 °C. TLC $R_f = 0.29$ (PE/EtOAc; 2:1). IR ν_{\max} (neat)/ cm^{-1} : 3098w (C-H str), 2835w (C-H str), 1743w, 1642m, (C=O str) 1588s (C=C str), 1563s (C=C str), 1511s (C=C str), 1462m, 1424s, 1359m, 1347m, 1281s, 1264s, 1189s, 1162s, 1026s, 1001w. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.95 (3H, s, $-\text{OCH}_3$), 4.17 (5H, s, $-\text{C}_5\text{H}_5$), 4.47 (2H, t, $J = 2.0$ Hz, $-\text{C}_5\text{H}_4$), 4.59 (2H, t, $J = 2.0$ Hz, $-\text{C}_5\text{H}_4$), 6.54 (1H, br s, OH), 7.00 (1H, d, $J = 8.0$ Hz, ArH), 7.16 (1H, d, $J = 15.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.60 (1H, dd, $J = 8.5$, 1.5 Hz, ArH), 7.63 (1H, d, $J = 1.5$ Hz, ArH), 7.76 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 56.0, 68.8, 69.7, 71.2, 79.3, 110.5, 113.8, 118.5, 123.2, 131.1, 145.8, 146.8, 150.1, 187.9. LCMS (ES+) $m/z = 363.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.66$ min). HRMS (ESI+) $m/z = 363.0595$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{20}\text{H}_{19}\text{O}_3\text{Fe}^+$ required 363.0600.

(*E*)-1-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (**20**). A mixture of chalcone **13** (1.02 g, 3.57 mmol), propargyl bromide (0.63 mL, 7.07 mmol) and anhydrous K_2CO_3 (1.49 g, 10.8 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford chalcone **20** (1.07 g, 93%) as a pale yellow powdery solid. m.p. 168–170 °C. TLC $R_f = 0.41$ (CH_2Cl_2). IR ν_{\max} (neat)/ cm^{-1} : 3251w (C \equiv C-H str), 2990w (C-H str), 2835w (C-H str), 2116w (C \equiv C str), 1651s (C=O str), 1598s (C=C str), 1577s (C=C str), 1508s (C=C str), 1466m, 1421s, 1382w, 1323m, 1257s, 1229s, 1165s, 1145s, 1056w, 1015s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 2.57 (1H, t, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 3.87 (3H, s, $-\text{OCH}_3$), 3.98 (3H, s, $-\text{OCH}_3$), 4.87 (2H, d, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 6.95 (2H, d, $J = 8.8$ Hz, ArH), 7.11 (2H, d, $J = 8.4$ Hz, ArH), 7.44 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.62 (2H, d, $J = 8.8$ Hz, ArH), 7.65 (1H, d, $J = 2.0$ Hz, ArH), 7.68 (1H, dd, $J = 8.4$, 2.0 Hz, ArH), 7.80 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 55.4, 56.1, 56.6, 76.4, 77.8, 111.3, 112.3, 114.4, 119.3, 122.3, 127.7, 130.1, 132.6, 144.0, 149.7,

150.7, 161.6, 188.7. LCMS (ES+) $m/z = 323.2$ ($[M + H]^+$, $t_R = 1.56$ min). HRMS (ESI+) $m/z = 323.1265$ $[M + H]^+$ found, $C_{20}H_{19}O_4^+$ required 323.1278.

(*E*)-1-(5-Bromo-2-(prop-2-yn-1-yloxy)phenyl)-3-(1-methyl-1H-indol-3-yl)prop-2-en-1-one (**21**). A mixture of indole chalcone **14** (2.07 g, 5.81 mmol), propargyl bromide (1.50 mL, 16.8 mmol) and anhydrous K_2CO_3 (2.52 g, 18.2 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford chalcone **21** (2.20 g, 96%) as a bright yellow powdery solid. m.p. 126–128 °C. TLC $R_f = 0.20$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3257w ($C\equiv C-H$ str), 3070w ($C-H$ str), 2942w ($C-H$ str), 2114w ($C\equiv C$ str), 1638s ($C=O$ str), 1587m ($C=C$ str), 1544s ($C=C$ str), 1524s ($C=C$ str), 1473m, 1373s, 1269s, 1213m, 1176s, 1133m, 1073m, 1006s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.55 (1H, t, $J = 2.4$ Hz, $-OCH_2C\equiv CH$), 3.82 (3H, s, $-NCH_3$), 4.79 (2H, d, $J = 2.4$ Hz, $-OCH_2C\equiv CH$), 7.03 (1H, d, $J = 9.2$ Hz, ArH), 7.26–7.38 (3H, m, ArH), 7.38 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$), 7.41 (1H, s, ArH), 7.55 (1H, dd, $J = 8.8, 2.4$ Hz, ArH), 7.77 (1H, d, $J = 2.4$ Hz, ArH), 7.88 (1H, d, $J = 15.6$ Hz, $-CH=CHCO-$), 8.01 (1H, d, $J = 8.0$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 33.3, 56.6, 76.4, 77.8, 110.0, 112.9, 114.3, 115.3, 121.0, 121.5, 121.6, 123.2, 126.0, 132.6, 132.9, 134.3, 134.8, 138.2, 138.6, 154.6, 191.0. LCMS (ES+) $m/z = 396.1$ ($[M + H]^+$, $t_R = 1.98$ min). HRMS (ESI+) $m/z = 394.0425$ $[M + H]^+$ found, $C_{21}H_{17}NO_2Br^+$ required 394.0443.

(*E*)-1-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (**22**). A mixture of pyrrole chalcone **16** (1.00 g, 3.89 mmol), propargyl bromide (0.70 mL, 7.86 mmol) and anhydrous K_2CO_3 (1.61 g, 1.17 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 3:1) to afford chalcone **22** (1.06 g, 92%) as a bright yellow powdery solid. m.p. 164–166 °C. TLC $R_f = 0.41$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 3234m ($C\equiv C-H$ str), 2995w ($C-H$ str), 2866w ($C-H$ str), 1739m ($C=O$ str), 1645m, 1598s, ($C=C$ str), 1561s ($C=C$ str), 1515m ($C=C$ str), 1483m, 1416w, 1374m, 1346s, 1272s, 1179m, 1129s, 1087w, 1042m, 1012m. 1H -NMR (500 MHz, $CDCl_3$): δ 2.56 (1H, t, $J = 2.5$ Hz, $-OCH_2C\equiv CH$), 3.78 (3H, s, $-NCH_3$), 3.98 (3H, s, $-OCH_3$), 4.86 (1H, d, $J = 2.5$ Hz, $-OCH_2C\equiv CH$), 6.23–6.24 (1H, m, ArH), 6.82 (1H, t, $J = 2.0$ Hz, ArH), 6.85 (1H, dd, $J = 4.0, 1.0$ Hz, ArH), 7.10 (1H, d, $J = 8.0$ Hz, ArH), 7.32 (1H, d, $J = 15.0$ Hz, $-CH=CHCO-$), 7.64–7.67 (2H, m, ArH), 7.82 (1H, d, $J = 15.0$ Hz, $-CH=CHCO-$). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 34.4, 56.1, 56.6, 76.4, 77.8, 109.7, 111.2, 112.1, 112.4, 116.4, 122.0, 127.6, 130.3, 131.7, 132.9, 149.6, 150.5, 188.1. LCMS (ES+) $m/z = 296.2$ ($[M + H]^+$, $t_R = 1.57$ min). HRMS (ESI+) $m/z = 294.1119$ $[M - H]^+$ found, $C_{18}H_{16}O_3N^+$ required 294.1125.

(*E*)-3-(1-Methyl-1H-pyrrol-2-yl)-1-(2-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (**23**). A mixture of pyrrole chalcone **15** (308 mg, 1.32 mmol), propargyl bromide (0.25 mL, 2.81 mmol) and anhydrous K_2CO_3 (568 mg, 4.11 mmol) in dry acetone (20 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 3:1) to afford chalcone **23** (352 mg, 98%) as a bright yellow viscous oil. TLC $R_f = 0.34$ (PE/EtOAc; 2:1). IR ν_{max} (neat)/ cm^{-1} : 3283w ($C\equiv C-H$ str), 3072w ($C-H$ str), 2923w ($C-H$ str), 2120w ($C\equiv C$ str), 1698w ($C=O$ str), 1647m, 1598s ($C=C$ str), 1580s ($C=C$ str), 1564s ($C=C$ str), 1480s, 1450m, 1330m, 1287s, 1217s, 1113w, 1057m, 1018s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.54 (1H, t, $J = 2.4$ Hz, $-OCH_2C\equiv CH$), 3.74 (3H, s, $-NCH_3$), 4.79 (2H, d, $J = 2.4$ Hz, $-OCH_2C\equiv CH$), 6.20–6.21 (1H, m, ArH), 6.78–6.80 (2H, m, ArH), 7.08–7.12 (2H, m, ArH), 7.19 (1H, d, $J = 15.2$ Hz, $-CH=CHCO-$), 7.47 (1H, t, $J = 8.8$ Hz, ArH), 7.65 (1H, d, $J = 15.6$ Hz, $-CH=CHCO-$), 7.66 (1H, dd, $J = 7.6, 2.0$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 34.5, 56.4, 75.9, 78.2, 109.6, 112.8, 113.3, 121.8, 121.9, 127.7, 130.2, 130.5, 130.5, 131.1, 132.2, 155.7, 191.9. LCMS (ES+) $m/z = 266.1$ ($[M + H]^+$, $t_R = 1.57$ min). HRMS (ESI+) $m/z = 266.1183$ $[M + H]^+$ found, $C_{17}H_{16}NO_2^+$ required 266.1181.

(*E*)-1-(5-Bromo-2-(prop-2-yn-1-yloxy)phenyl)-3-(furan-2-yl)prop-2-en-1-one (**24**). A mixture of furan chalcone **17** (2.02 g, 6.89 mmol), propargyl bromide (1.30 mL, 14.6 mmol) and anhydrous K_2CO_3 (2.90 g, 21.0 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford chalcone **24** (2.14 g, 94%) as a pale yellow-brown powdery solid. m.p. 82–84 °C. TLC $R_f = 0.21$ (PE/ CH_2Cl_2 ; 1:1). IR ν_{max} (neat)/ cm^{-1} :

3224m (C≡C-H str), 3118w (C-H str), 2118w (C≡C str), 1660m (C=O str), 1600s (C=C str), 1586m (C=C str), 1554m (C=C str), 1476m, 1394m, 1313w, 1276m, 1211s, 1180m, 1131m, 1079w, 1048m, 1012s. ¹H-NMR (500 MHz, CDCl₃): δ 2.54 (1H, t, *J* = 2.4 Hz, -OCH₂C≡CH), 4.78 (2H, d, *J* = 2.4 Hz, -OCH₂C≡CH), 6.50–6.51 (1H, m, ArH), 6.70 (1H, d, *J* = 3.6 Hz, ArH), 7.03 (1H, d, *J* = 8.8 Hz, ArH), 7.21 (1H, d, *J* = 15.6 Hz, -CH=CHCO-), 7.40 (1H, d, *J* = 15.6 Hz, -CH=CHCO-), 7.52 (1H, d, *J* = 1.2 Hz, ArH), 7.56 (1H, dd, *J* = 8.8, 2.4 Hz, ArH), 7.73 (1H, d, *J* = 2.4 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 56.6, 76.5, 77.6, 112.6, 114.3, 115.4, 116.2, 123.8, 130.4, 131.6, 133.0, 135.0, 145.1, 151.5, 154.8, 190.5. LCMS (ES+) *m/z* = 333.0 ([M + H]⁺, *t*_R = 1.89 min). HRMS (ESI+) *m/z* = 330.9973 [M + H]⁺ found, C₁₆H₁₂O₃Br⁺ required 330.9970.

(*E*)-3-(Ferrocenyl)-1-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (**25**). A mixture of ferrocene chalcone **19** (1.01 g, 2.79 mmol), propargyl bromide (0.50 mL, 5.61 mmol) and anhydrous K₂CO₃ (1.18 g, 8.56 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO₂, CH₂Cl₂) to afford chalcone **25** (1.01 g, 91%) as a dark red-purple microcrystalline solid. m.p. 128–130 °C. TLC *R*_f = 0.47 (0.5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3225m (C≡C-H str), 3008w (C-H str), 2939w (C-H str), 2114w (C≡C str), 1646s (C=O str), 1595m (C=C str), 1567s (C=C str), 1506m (C=C str), 1456m, 1413s, 1345w, 1295s, 1259s, 1194m, 1159s, 1136s, 1107m, 1060w, 1044m, 1020s. ¹H-NMR (500 MHz, CDCl₃): δ 2.56 (1H, t, *J* = 2.5 Hz, -OCH₂C≡CH), 3.96 (3H, s, -OCH₃), 4.18 (5H, s, -C₅H₅), 4.48 (2H, t, *J* = 2.0 Hz, -C₅H₄), 4.60 (2H, t, *J* = 2.0 Hz, -C₅H₄), 4.85 (2H, d, *J* = 2.0 Hz, -OCH₂C≡CH), 7.09 (1H, d, *J* = 8.5 Hz, ArH), 7.15 (1H, d, *J* = 15.5 Hz, -CH=CHCO-), 7.61–7.63 (2H, m, ArH), 7.75 (1H, d, *J* = 15.0 Hz, -CH=CHCO-). ¹³C-NMR (500 MHz, CDCl₃): δ 56.0, 56.5, 68.9, 69.7, 71.2, 76.3, 77.8, 79.3, 111.2, 112.3, 118.5, 122.1, 132.6, 146.0, 149.5, 150.4, 187.9. LCMS (ES+) *m/z* = 401.1 ([M + H]⁺, *t*_R = 1.81 min). HRMS (ESI+) *m/z* = 401.0823 [M + H]⁺ found, C₂₃H₂₁O₃Fe⁺ required 401.0840.

(*E*)-3-(Ferrocenyl)-1-(2-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (**26**). A mixture of chalcone **18** (1.02 g, 3.07 mmol), propargyl bromide (0.54 mL, 6.02 mmol) and anhydrous K₂CO₃ (1.20 g, 8.68 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO₂, PE/CH₂Cl₂; 1:1) to afford chalcone **26** (919 mg, 81%) as a bright red powdery solid. m.p. 90–92 °C. TLC *R*_f = 0.38 (CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3257m (C≡C-H str), 2924w (C-H str), 2850w (C-H str), 2117w (C≡C str), 1654s (C=O str), 1587s (C=C str), 1480m, 1448m, 1356w, 1345w, 1289m, 1211s, 1159w, 1104m, 1058m, 1016s, 1001s. ¹H-NMR (500 MHz, CDCl₃): δ 2.56 (1H, t, *J* = 2.5 Hz, -OCH₂C≡CH), 4.19 (5H, s, -C₅H₅), 4.46 (2H, t, *J* = 2.0 Hz, -C₅H₄), 4.56 (2H, t, *J* = 2.0 Hz, -C₅H₄), 4.79 (2H, d, *J* = 2.5 Hz, -OCH₂C≡CH), 6.95 (1H, d, *J* = 16.0 Hz, -CH=CHCO-), 7.09–7.13 (2H, m, ArH), 7.47 (1H, t, *J* = 9.0 Hz, ArH), 7.50 (1H, d, *J* = 15.5 Hz, -CH=CHCO-), 7.58 (1H, dd, *J* = 7.5, 1.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 56.3, 69.0, 69.8, 71.2, 76.0, 78.2, 79.0, 113.3, 121.7, 124.6, 130.1, 130.5, 131.9, 146.2, 155.4, 192.5. LCMS (ES+) *m/z* = 371.1 ([M + H]⁺, *t*_R = 1.96 min). HRMS (ESI+) *m/z* = 370.0639 [M]⁺ found, C₂₂H₁₈O₂Fe⁺ required 370.0651.

3-(Prop-2-yn-1-yloxy)flavone (**30**). A mixture of 3-hydroxyflavone **27** (2.06 g, 8.65 mmol), propargyl bromide (1.50 mL, 16.8 mmol) and anhydrous K₂CO₃ (3.48 g, 25.2 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO₂, CH₂Cl₂) to afford flavone **30** (2.38 g, 99%) as a pale yellow-white powdery solid. m.p. 104–106 °C. TLC *R*_f = 0.24 (CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3254m (C≡C-H str), 2946w (C-H str), 2114w (C≡C str), 1612s (C=O str), 1600s, 1557s (C=C str), 1468s, 1445m, 1399s, 1354m, 1345m, 1279w, 1234w, 1195s, 1185s, 1148s, 1110m, 1079w, 1036m. ¹H-NMR (500 MHz, CDCl₃): δ 2.33 (1H, t, *J* = 2.4 Hz, -OCH₂C≡CH), 5.00 (2H, d, *J* = 2.4 Hz, -OCH₂C≡CH), 7.42 (1H, t, *J* = 8.0 Hz, ArH), 7.50–7.54 (3H, m, ArH), 7.56 (1H, d, *J* = 8.4 Hz, ArH), 7.70 (1H, t, *J* = 8.4 Hz, ArH), 8.14–8.16 (2H, m, ArH), 8.27 (1H, dd, *J* = 8.0, 1.6 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 59.1, 76.1, 78.5, 118.0, 123.9, 124.7, 125.7, 128.3, 128.9, 130.7, 130.9, 133.5, 138.5, 155.2, 156.7, 174.8. LCMS (ES+) *m/z* = 277.5 ([M + H]⁺, *t*_R = 4.47 min). These characterisation data are in accordance with that previously reported in the literature [23].

6-(Prop-2-yn-1-yloxy)flavone (31). A mixture of 6-hydroxyflavone **28** (2.00 g, 8.39 mmol), propargyl bromide (1.50 mL, 16.8 mmol) and anhydrous K_2CO_3 (3.50 g, 25.3 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavone **31** (2.03 g, 87%) as a white crystalline solid. m.p. 170–172 °C. TLC R_f = 0.44 (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3266m (C≡C-H str), 3059w (C-H str), 2116w (C≡C str), 1623s (C=O str), 1606s, 1582s (C=C str), 1568s (C=C str), 1497m, 1482m, 1455s, 1365s, 1283m, 1259m, 1234m, 1186s, 1144s, 1075m, 1048m, 1007s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.57 (1H, t, J = 2.4 Hz, $-OCH_2C\equiv CH$), 4.76 (2H, d, J = 2.4 Hz, $-OCH_2C\equiv CH$), 6.77 (1H, s, $-C=CH$), 7.31 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.46–7.51 (4H, m, ArH), 7.65 (1H, d, J = 3.2 Hz, ArH), 7.86–7.88 (2H, m, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 56.3, 76.0, 77.7, 106.4, 106.7, 119.6, 123.9, 124.4, 126.1, 128.9, 131.4, 131.6, 151.3, 154.7, 163.0, 177.9. LCMS (ES+) m/z = 277.0 ($[M + H]^+$, t_R = 1.56 min). These characterisation data are in accordance with that previously reported in the literature [24].

7-(Prop-2-yn-1-yloxy)flavone (32). A mixture of 7-hydroxyflavone **29** (990 mg, 4.16 mmol), propargyl bromide (0.748 mL, 8.39 mmol) and anhydrous K_2CO_3 (1.75 g, 12.7 mmol) and in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavone **32** (1.10 g, 95%) as an off-white powdery solid. m.p. 216–218 °C. TLC R_f = 0.44 (2% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3194w (C≡C-H str), 2921w (C-H str), 2115w (C≡C str), 1619s (C=O str), 1591s (C=C str), 1568s (C=C str), 1496m, 1451s, 1435s, 1378s, 1350m, 1268m, 1229m, 1168s, 1135s, 1091s, 1017s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.62 (1H, t, J = 2.4 Hz, $-OCH_2C\equiv CH$), 4.83 (2H, d, J = 2.4 Hz, $-OCH_2C\equiv CH$), 6.77 (1H, s, $-C=CH$), 7.05 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.09 (1H, d, J = 2.4 Hz, ArH), 7.51–7.55 (3H, m, ArH), 7.90–7.93 (2H, m, ArH), 8.17 (1H, d, J = 8.8 Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 56.2, 76.6, 77.3, 101.8, 107.6, 114.7, 118.4, 126.2, 127.2, 129.0, 131.5, 131.8, 157.7, 161.9, 163.1, 177.7. LCMS (ES+) m/z = 277.0 ($[M + H]^+$, t_R = 1.54 min). These characterisation data are in accordance with that previously reported in the literature [24].

4-(Prop-2-yn-1-yloxy)benzaldehyde (34). A mixture of benzaldehyde **33** (10.2 g, 83.7 mmol), propargyl bromide (14.6 mL, 164 mmol) and anhydrous K_2CO_3 (22.7 g, 165 mmol) in dry acetone (200 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford benzaldehyde **34** (12.2 g, 91%) as a white crystalline solid. m.p. 88–90 °C. TLC R_f = 0.49 (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3205m (C≡C-H str), 2971w (C-H str), 2837w (C-H str), 2123w (C≡C str), 1739s (C=O str), 1679s, 1601s, 1576s (C=C str), 1508m (C=C str), 1428w, 1384s, 1245s, 1217s, 1170s, 1009s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.58 (1H, t, J = 2.4 Hz, $-OCH_2C\equiv CH$), 4.77 (2H, d, J = 2.4 Hz, $-OCH_2C\equiv CH$), 7.08 (2H, d, J = 8.8 Hz, ArH), 7.85 (2H, d, J = 8.8 Hz, ArH), 9.89 (1H, s, CHO). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 55.9, 76.3, 77.5, 115.1, 130.5, 131.8, 162.3, 190.7. LCMS (ES+) m/z = 161.1 ($[M + H]^+$, t_R = 1.65 min). These characterisation data are in accordance with that previously reported in the literature [41].

(E)-1-(2-Hydroxyphenyl)-3-(4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (35). A mixture of benzaldehyde **34** (5.04 g, 31.5 mmol), acetophenone **10** (3.76 mL, 31.2 mmol), and KOH (10.6 g, 189 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **35** (6.67 g, 77%) as a bright yellow powdery solid. m.p. 144–146 °C. TLC R_f = 0.45 (PE/EtOAc; 3:1). IR ν_{max} (neat)/ cm^{-1} : 3487w (O-H str), 3240m (C≡C-H str), 2923w (C-H str), 2124w (C≡C str), 1634s (C=O str), 1604m, 1559s (C=C str), 1509s (C=C str), 1488s, 1442m, 1368m, 1299s, 1270m, 1203m, 1177s, 1159s, 1027s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.58 (1H, t, J = 2.4 Hz, $-OCH_2C\equiv CH$), 4.75 (2H, d, J = 2.4 Hz, $-OCH_2C\equiv CH$), 6.94 (1H, t, J = 7.6 Hz, ArH), 7.03 (3H, d, J = 8.4 Hz, ArH), 7.49 (1H, t, J = 8.4 Hz, ArH), 7.54 (1H, d, J = 15.2 Hz, $-CH=CHCO-$), 7.63 (2H, d, J = 8.8 Hz, ArH), 7.89 (1H, d, J = 15.2 Hz, $-CH=CHCO-$), 7.90–7.92 (1H, m, ArH), 12.93 (1H, s, OH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 55.8, 76.1, 77.9, 115.3, 118.0, 118.5, 118.7, 120.0, 128.0, 129.5, 130.4, 136.1, 145.0, 159.7, 163.5, 193.5. LCMS (ES+) m/z = 279.1 ($[M + H]^+$, t_R = 1.75 min). HRMS (ESI+) m/z = 279.1005 $[M + H]^+$ found, $C_{18}H_{15}O_3^+$ required 279.1016.

3-Hydroxy-4'-(prop-2-yn-1-yloxy)flavone (36). A mixture of chalcone **35** (2.02 g, 7.26 mmol), 16% NaOH (14.4 mL) and 15% H₂O₂ (7.19 mL) in MeOH (50 mL) was reacted according to GP-F. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford flavonol **36** (1.56 g, 73%) as a pale yellow-white powdery solid. m.p. 194–196 °C. TLC R_f = 0.44 (0.5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3271s (C≡C-H str), 3260w (O-H str), 2979w (C-H str), 2119w (C≡C str), 1599s (C=O str), 1562s (C=C str), 1507m (C=C str), 1483m, 1470m, 1427m, 1411m, 1233s, 1216m, 1180s, 1120s, 1109s, 1017s. ¹H-NMR (500 MHz, CDCl₃): δ 2.58 (1H, t, J = 2.4 Hz, -OCH₂C≡CH), 4.79 (2H, d, J = 2.4 Hz, -OCH₂C≡CH), 7.00 (1H, br s, OH), 7.14 (2H, d, J = 9.2 Hz, ArH), 7.42 (1H, t, J = 8.0 Hz, ArH), 7.58 (1H, d, J = 8.4 Hz, ArH), 7.70 (1H, t, J = 8.4 Hz, ArH), 8.25–8.28 (3H, m, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 55.8, 76.0, 78.0, 115.0, 118.2, 120.7, 124.4, 124.4, 125.4, 129.5, 133.4, 137.8, 145.0, 155.3, 158.9, 173.2. LCMS (ES+) m/z = 293.1 ([M + H]⁺, t_R = 1.62 min). HRMS (ESI+) m/z = 315.0618 [M + Na]⁺ found, C₁₈H₁₂O₄Na⁺ required 315.0628.

1-(2-Hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)ethan-1-one (41). A mixture of phenol **37** (8.70 mL, 79.32 mmol) and phenylacetic acid **39** (10.1 g, 66.3 mmol) in BF₃·OEt₂ (85.0 mL, 677 mmol) was reacted according to GP-G. The crude residue was purified by flash column chromatography (SiO₂, CH₂Cl₂) to afford phenylethanone **41** (13.2 g, 78%) as a white powdery solid. m.p. 158–160 °C. TLC R_f = 0.38 (1% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3469w(br) (O-H str), 3221w(br) (O-H str), 2984w (C-H str), 2904w (C-H str), 1706w (C=O str), 1613s (C=C str), 1518s (C=C str), 1450m, 1437s, 1381m, 1354s, 1291s, 1224s, 1202s, 1127s, 1021m. ¹H-NMR (500 MHz, (CD₃)₂CO): δ 3.85 (3H, s, -OCH₃), 4.19 (2H, s, -COCH₂), 6.42 (1H, d, J = 2.8 Hz, ArH), 6.49 (1H, dd, J = 8.8, 2.4 Hz, ArH), 6.80 (2H, d, J = 8.8 Hz, ArH), 7.16 (2H, d, J = 8.4 Hz, ArH), 7.98 (1H, d, J = 9.2 Hz, ArH), 8.29 (1H, br s, OH), 12.80 (1H, s, OH). ¹³C-NMR (500 MHz, (CD₃)₂CO): δ 43.7, 55.4, 101.0, 107.5, 113.2, 115.6, 125.9, 130.6, 133.1, 156.6, 166.0, 166.5, 203.5. LCMS (ES+) m/z = 259.1 ([M + H]⁺, t_R = 1.47 min). These characterisation data are in accordance with that previously reported in the literature [42].

1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethan-1-one (42). A mixture of phenol **38** (8.00 g, 72.7 mmol) and phenylacetic acid **40** (10.2 g, 61.5 mmol) in BF₃·OEt₂ (70.0 mL, 557 mmol) was reacted according to GP-G. The crude residue was purified by recrystallization from CHCl₃ to afford phenylethanone **42** (5.67 g, 36%) as a pale yellow-white powdery solid. m.p. 168–170 °C. TLC R_f = 0.50 (1% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3349s(br) (O-H str), 2917w (C-H str), 2838w (C-H str), 1614s (C=O str), 1607s (C=C str), 1590s (C=C str), 1510s (C=C str), 1500m (C=C str), 1436m, 1412w, 1351s, 1299m, 1239m, 1174s, 1129m, 1105w, 1023s. ¹H-NMR (500 MHz, (CD₃)₂CO): δ 3.76 (3H, s, -OCH₃), 4.22 (2H, s, -COCH₂), 6.33 (1H, d, J = 2.0 Hz, ArH), 6.44 (1H, dd, J = 9.2, 2.4 Hz, ArH), 6.88 (2H, d, J = 8.8 Hz, ArH), 7.26 (2H, d, J = 8.8 Hz, ArH), 7.96 (1H, d, J = 8.8 Hz, ArH), 9.46 (1H, s, OH), 12.73 (1H, s, OH). ¹³C-NMR (500 MHz, (CD₃)₂CO): δ 43.6, 54.8, 103.0, 108.2, 112.8, 114.1, 127.3, 130.7, 133.7, 159.0, 165.0, 166.1, 203.1. LCMS (ES+) m/z = 259.1 ([M + H]⁺, t_R = 1.52 min). These characterisation data are in accordance with that previously reported in the literature [43].

4'-Hydroxy-7-methoxyisoflavone (43). A mixture of phenylethanone **41** (2.00 g, 7.74 mmol), BF₃·OEt₂ (3.90 mL, 31.1 mmol) and MeSO₂Cl (1.80 mL, 23.3 mmol) in dry DMF (50 mL) was reacted according to GP-H. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 2:1) to afford isoflavone **43** (1.18 g, 57%) as a white powdery solid. m.p. 232–234 °C. TLC R_f = 0.39 (PE/EtOAc; 1:1). IR ν_{max} (neat)/cm⁻¹: 3210m(br) (O-H str), 3014w (C-H str), 1621s (C=O str), 1583s (C=C str), 1563m (C=C str), 1517s (C=C str), 1439s, 1373w, 1253s, 1205w, 1170w, 1095m, 1050m, 1019m. ¹H-NMR (500 MHz, (CD₃)₂CO): δ 3.97 (3H, s, -OCH₃), 6.89 (2H, d, J = 8.4 Hz, ArH), 7.04–7.07 (2H, m, ArH), 7.48 (2H, d, J = 8.8 Hz, ArH), 8.10 (1H, d, J = 8.8 Hz, ArH), 8.19 (1H, s, -C=CH), 8.44 (1H, s, OH). ¹³C-NMR (500 MHz, (CD₃)₂CO): δ 55.8, 100.4, 114.7, 115.2, 118.5, 123.7, 124.7, 127.4, 130.4, 152.7, 157.6, 158.2, 164.4, 175.1. LCMS (ES+) m/z = 269.1 ([M + H]⁺, t_R = 1.41 min). These characterisation data are in accordance with that previously reported in the literature [42].

7-Hydroxy-4'-methoxyisoflavone (44). A mixture of phenylethanone **42** (2.02 g, 7.82 mmol), $\text{BF}_3 \cdot \text{OEt}_2$ (3.90 mL, 31.1 mmol) and MeSO_2Cl (1.80 mL, 23.2 mmol) in dry DMF (50 mL) was reacted according to GP-H. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 1:1) and recrystallized from CHCl_3 to afford isoflavone **44** (1.62 g, 77%) as a dark yellow powdery solid. m.p. 242–244 °C. TLC $R_f = 0.26$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 3126s(br) (O-H str), 2993w (C-H str), 2836w (C-H str), 1637m (C=O str), 1621m, 1594s (C=C str), 1568m (C=C str), 1512s (C=C str), 1451s, 1384m, 1273m, 1178s, 1099m, 1045m, 1025s. $^1\text{H-NMR}$ (500 MHz, $(\text{CD}_3)_2\text{CO}$): δ 3.20 (1H, br s, OH), 3.83 (3H, s, $-\text{OCH}_3$), 6.92 (1H, d, $J = 2.0$ Hz, ArH), 6.98 (2H, d, $J = 9.2$ Hz, ArH), 7.01 (1H, dd, $J = 8.8$, 2.4 Hz, ArH), 7.56 (2H, d, $J = 8.8$ Hz, ArH), 8.07 (1H, d, $J = 8.4$ Hz, ArH), 8.18 (1H, s, $-\text{C}=\text{CH}$). $^{13}\text{C-NMR}$ (500 MHz, $(\text{CD}_3)_2\text{CO}$): δ 54.9, 102.5, 113.7, 115.1, 117.9, 124.3, 124.9, 127.8, 130.4, 152.8, 158.2, 159.8, 162.6, 175.0. LCMS (ES+) $m/z = 269.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.47$ min). These characterisation data are in accordance with that previously reported in the literature [44].

7-Methoxy-(4'-(prop-2-yn-1-yloxy)isoflavone (45). A mixture of isoflavone **43** (602 mg, 2.25 mmol), propargyl bromide (0.50 mL, 5.61 mmol) and anhydrous K_2CO_3 (1.09 g, 7.91 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford isoflavone **45** (641 mg, 93%) as a white powdery solid. m.p. 162–164 °C. TLC $R_f = 0.45$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3289m ($\text{C}\equiv\text{C-H}$ str), 3083w (C-H str), 2953w (C-H str), 1645s (C=O str), 1624s, 1606s, 1579m (C=C str), 1513s (C=C str), 1456m, 1442s, 1378s, 1285m, 1262s, 1245s, 1192s, 1176s, 1103s, 1050w, 1017s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 2.54 (1H, t, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 3.92 (3H, s, $-\text{OCH}_3$), 4.73 (2H, d, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 6.86 (2H, d, $J = 2.0$ Hz, ArH), 7.00 (1H, dd, $J = 8.8$, 2.0 Hz, ArH), 7.05 (2H, d, $J = 8.8$ Hz, ArH), 7.52 (2H, d, $J = 8.8$ Hz, ArH), 7.93 (1H, s, $-\text{C}=\text{CH}$), 8.21 (2H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 55.8, 75.6, 78.5, 100.1, 114.5, 114.9, 118.4, 124.7, 125.2, 127.8, 130.1, 152.1, 157.5, 157.9, 164.0, 175.7. LCMS (ES+) $m/z = 307.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.59$ min). HRMS (ESI+) $m/z = 307.0959$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{19}\text{H}_{15}\text{O}_4^+$ required 307.0965.

4'-Methoxy-7-(prop-2-yn-1-yloxy)isoflavone (46). A mixture of isoflavone **44** (810 mg, 3.02 mmol), propargyl bromide (0.55 mL, 6.17 mmol) and anhydrous K_2CO_3 (1.25 g, 9.01 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford isoflavone **46** (550 mg, 60%) as a white powdery solid. m.p. 150–152 °C. TLC $R_f = 0.32$ (0.5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3281m ($\text{C}\equiv\text{C-H}$ str), 3259m, 3078w (C-H str), 2950w (C-H str), 2116w ($\text{C}\equiv\text{C}$ str), 1624s (C=O str), 1608s, 1597s (C=C str), 1565m (C=C str), 1513s (C=C str), 1440s, 1373m, 1326w, 1295m, 1271s, 1237s, 1176s, 1109w, 1095s, 1052m, 1033s, 1016s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 2.61 (1H, t, $J = 2.0$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 3.85 (3H, s, $-\text{OCH}_3$), 4.81 (1H, d, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 6.98 (2H, d, $J = 8.4$ Hz, ArH), 6.98 (1H, d, $J = 2.4$ Hz, ArH), 7.05 (1H, dd, $J = 8.8$, 2.4 Hz, ArH), 7.51 (2H, d, $J = 8.8$ Hz, ArH), 7.93 (1H, s, $-\text{C}=\text{CH}$), 8.24 (1H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 55.3, 56.2, 76.6, 77.3, 101.5, 113.9, 114.8, 119.0, 124.1, 124.9, 127.9, 130.1, 152.1, 157.6, 159.6, 161.6, 175.8. LCMS (ES+) $m/z = 307.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.62$ min). These characterisation data are in accordance with that previously reported in the literature [45].

4-(Prop-2-yn-1-yloxy)-2H-chromen-2-one (48). A mixture of 4-hydroxycoumarin **47** (5.06 g, 31.2 mmol), propargyl bromide (6.20 mL, 69.6 mmol) and anhydrous K_2CO_3 (8.74 g, 63.2 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford coumarin **48** (3.60 g, 58%) as a white fluffy solid. m.p. 154–156 °C. TLC $R_f = 0.24$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3281m ($\text{C}\equiv\text{C-H}$ str), 3240m, 3078w (C-H str), 2131w ($\text{C}\equiv\text{C}$ str), 1714s (C=O str), 1688m, 1622s, 1610m (C=C str), 1568m (C=C str), 1493m, 1453m, 1409m, 1361m, 1329w, 1274s, 1248s, 1194w, 1179m, 1155w, 1145m, 1107s, 1032w. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 2.68 (1H, t, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 4.88 (2H, d, $J = 2.4$ Hz, $-\text{OCH}_2\text{C}\equiv\text{CH}$), 5.84 (1H, s, $-\text{C}=\text{CH}$), 7.29–7.34 (2H, m, ArH), 7.57 (1H, t, $J = 8.4$ Hz, ArH), 7.84 (1H, dd, $J = 8.0$, 1.2 Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 56.8, 75.7, 77.9, 91.7, 115.4, 116.8, 123.1, 124.0, 132.6, 153.3, 162.4, 164.2.

LCMS (ES+) $m/z = 201.1$ ($[M + H]^+$, $t_R = 1.47$ min). These characterisation data are in accordance with that previously reported in the literature [46].

2-(2-Chloro-1-iminoethyl)-1,3,5-benzotriol hydrochloride (50). To a stirred solution of phloroglucinol **49** (5.02 g, 39.8 mmol) and chloroacetonitrile (2.50 mL, 39.5 mmol) in Et₂O (100 mL) was added anhydrous ZnCl₂ (0.558 g, 4.09 mmol). The reaction mixture was cooled to 0 °C and HCl gas was bubbled through the solution for 30 min. The resulting mixture was stirred at 0 °C for 3 h and further 24 h at room temperature. The resulting suspension was filtered and the precipitate was washed with ice-cold Et₂O (2 × 50 mL) and suction-dried to afford hydrochloric salt **50** (1.87 g, 20%) as a pale yellow-white powdery solid and was used without further purification in the next step. m.p. 240–242 °C. IR ν_{\max} (neat)/cm⁻¹: 3389m (N-H str), 3257m(br) (O-H str), 3184s(br) (O-H str), 2968w (C-H str), 1646m, 1616s (C=C str), 1591s (C=C str), 1531w (C=C str), 1457m, 1383m, 1366s, 1291m, 1248s, 1175s, 1128w, 1065m, 1050s, 1024w. ¹H-NMR (500 MHz, DMSO-*d*₆): δ 5.46 (2H, s, -CH₂-), 6.07 (1H, d, $J = 1.2$ Hz, ArH), 6.26 (1H, d, $J = 1.2$ Hz, ArH), 9.90 (1H, s, OH), 10.84 (1H, s, OH), 11.80 (1H, br s, NH), 12.54 (1H, s, OH). ¹³C-NMR (500 MHz, DMSO-*d*₆): δ 75.3, 90.1, 96.9, 99.3, 160.4, 172.8, 173.7, 176.0. These characterisation data are in accordance with that previously reported in the literature [47].

2,4,6-Trihydroxy-2-chloroacetophenone (51). A mixture of imine salt **50** (1.80 g, 7.56 mmol) and 1 M HCl (100 mL) were heated at reflux with stirring for 1 h. The resulting red solution was blown under a steady stream of nitrogen and the residual solid was re-suspended in H₂O (50 mL). The precipitate was filtered, washed with ice-water (2 × 50 mL), suction-dried and re-dissolved in EtOAc (50 mL). The organic solution was washed with H₂O (2 × 50 mL), brine (2 × 50 mL), dried over anhydrous Na₂SO₄, filtered and evaporated to dryness. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 1:1) to afford acetophenone **51** (389 mg, 25%) as a white powdery solid. m.p. 236–238 °C. TLC $R_f = 0.32$ (PE/EtOAc; 1:1). IR ν_{\max} (neat)/cm⁻¹: 3422m (br) (O-H str), 3372s(br) (O-H str), 3068w (C-H str), 2962w (C-H str), 1640m (C=O str), 1598s (C=C str), 1521m (C=C str), 1456s, 1376s, 1331w, 1279m, 1213s, 1164s, 1073s, 1017m. ¹H-NMR (500 MHz, DMSO-*d*₆): δ 4.98 (2H, s, -COCH₂-), 5.84 (2H, s, ArH), 10.55 (1H, s, OH), 12.07 (2H, s, OH). ¹³C-NMR (500 MHz, DMSO-*d*₆): δ 51.0, 94.7, 102.5, 163.9, 165.5, 194.7. LCMS (ES+) $m/z = 203.0$ ($[M + H]^+$, $t_R = 1.26$ min). These characterisation data are in accordance with that previously reported in the literature [26].

Dihydroxybenzofuran-3(2H)-one (52). To a stirred solution of acetophenone **51** (5.00 g, 24.7 mmol) in MeOH (100 mL) was added NaOMe (4.88 g, 90.3 mmol) and the mixture was heated at reflux for 2 h under nitrogen. The reaction mixture was allowed to cool to room temperature, acidified with 1 M HCl and the solvent removed under reduced pressure. The resulting dark residue was then re-dissolved in EtOAc (100 mL). The organic solution was washed with H₂O (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 1:1) to afford benzofuranone **52** (2.90 g, 71%) as a pale brown-white powdery solid. m.p. 280–282 °C. TLC $R_f = 0.16$ (PE/EtOAc; 1:1). IR ν_{\max} (neat)/cm⁻¹: 3331s(br) (O-H str), 3164m(br) (O-H str), 3062w (C-H str), 1671m (C=O str), 1607s (C=C str), 1533w (C=C str), 1457m, 1422w, 1399m, 1369m, 1336m, 1261w, 1227m, 1157s, 1064s, 1042m, 1012m. ¹H-NMR (500 MHz, DMSO-*d*₆): δ 4.55 (2H, s, -OCH₂CO-), 5.91 (2H, s, ArH), 10.59 (2H, br s, OH). ¹³C-NMR (500 MHz, DMSO-*d*₆): δ 74.9, 90.1, 96.2, 102.7, 157.5, 167.6, 175.6, 194.0. LCMS (ES+) $m/z = 167.1$ ($[M + H]^+$, $t_R = 1.27$ min). These characterisation data are in accordance with that previously reported in the literature [26].

4,6-Dimethoxybenzofuran-3(2H)-one (53). To a stirred solution of dihydroxybenzofuranone **52** (2.02 g, 12.2 mmol) in dry DMF (50 mL) were added CH₃I (2.30 mL, 37.0 mmol) and anhydrous K₂CO₃ (3.35 g, 24.2 mmol). The resulting dark red-brown suspension was heated at 80 °C for 1 h under a nitrogen atmosphere. The reaction mixture was then allowed to cool to room temperature, poured into ice-water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layer was washed with H₂O (3 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness.

The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 1:1) to afford benzofuranone **53** (1.87 g, 79%) as a pale yellow-white powdery solid. m.p. 148–150 °C. TLC R_f = 0.23 (PE/EtOAc; 1:1). IR ν_{max} (neat)/cm⁻¹: 2979w (C-H str), 2949w (C-H str), 1699s (C=O str), 1616s (C=C str), 1585s (C=C str), 1500m (C=C str), 1463m, 1431m, 1366m, 1342m, 1288m, 1217s, 1186s, 1160s, 1099s, 1052m, 1021m. ¹H-NMR (500 MHz, CDCl₃): δ 3.83 (3H, s, -OCH₃), 3.87 (3H, s, -OCH₃), 4.55 (2H, s, -OCH₂CO-), 5.97 (1H, d, J = 1.6 Hz, ArH), 6.11 (1H, d, J = 2.0 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 55.9, 55.9, 75.4, 88.8, 92.9, 104.7, 158.7, 169.7, 177.0, 194.9. LCMS (ES+) m/z = 195.1 ([M + H]⁺, t_R = 1.52 min). These characterisation data are in accordance with that previously reported in the literature [26].

4,6-Dimethoxy-3'-hydroxyaurone (55). To a stirred solution of benzofuranone **53** (1.01 g, 5.20 mmol) in MeOH (20 mL) was added 3-hydroxybenzaldehyde **54** (0.760 g, 6.22 mmol) followed by the addition of KOH (1.50 g, 26.6 mmol) in H₂O (20 mL). The reaction mixture was stirred at room temperature for 2 h and then poured into H₂O (2 × 100 mL). The resulting suspension was neutralized to pH 7 with 3 M HCl and extracted with CHCl₃ (3 × 50 mL). The combined organic layer was washed with H₂O (3 × 100 mL), brine (100 mL), dried over anhydrous MgSO₄, filtered and evaporated to dryness under reduced pressure. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 1:1) and recrystallized from MeOH to afford aurone **55** (1.21 g, 78%) as a bright yellow powdery solid. m.p. 178–180 °C. TLC R_f = 0.35 (PE/EtOAc; 1:2). IR ν_{max} (neat)/cm⁻¹: 3254m(br) (O-H str), 2944w (C-H str), 2842w (C-H str), 1688m (C=O str), 1649m, 1612s (C=C str), 1586s (C=C str), 1501m (C=C str), 1447s, 1430w, 1338m, 1303m, 1249m, 1214s, 1153s, 1138m, 1087s, 1038w. ¹H-NMR (500 MHz, (CD₃)₂CO): δ 3.94 (3H, s, -OCH₃), 3.98 (3H, s, -OCH₃), 6.32 (1H, d, J = 2.0 Hz, ArH), 6.56 (1H, d, J = 1.6 Hz, ArH), 6.56 (1H, s, -C=CH), 6.91 (1H, ddd, J = 8.0, 2.4, 0.8 Hz, ArH), 7.30 (1H, t, J = 8.0 Hz, ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 7.47 (1H, t, J = 2.0 Hz, ArH), 8.57 (1H, s, OH). ¹³C-NMR (500 MHz, (CD₃)₂CO): δ 55.9, 56.2, 89.7, 94.4, 104.8, 109.4, 116.8, 117.5, 122.8, 130.0, 134.1, 148.1, 157.9, 159.7, 169.2, 169.5, 179.4. LCMS (ES+) m/z = 299.2 ([M + H]⁺, t_R = 1.71 min). These characterisation data are in accordance with that previously reported in the literature [48].

4,6-Dimethoxy-3'-(prop-2-yn-1-yloxy)aurone (56). A mixture of aurone **55** (505 mg, 1.69 mmol), propargyl bromide (0.30 mL, 3.37 mmol) and anhydrous K₂CO₃ (701 mg, 5.07 mmol) in dry acetone (30 mL) was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO₂, 0.5% MeOH/CH₂Cl₂) to afford aurone **56** (545 mg, 96%) as a pale yellow-white powdery solid. m.p. 152–154 °C. TLC R_f = 0.46 (1% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3219m (C≡C-H str), 3007w (C-H str), 2940w (C-H str), 2110w (C≡C str), 1686s (C=O str), 1654m, 1612s (C=C str), 1589s (C=C str), 1504s (C=C str), 1454m, 1423m, 1347m, 1313m, 1266m, 1215s, 1154m, 1094s, 1040m, 1019w. ¹H-NMR (500 MHz, CDCl₃): δ 2.57 (1H, t, J = 2.5 Hz, -OCH₂C≡CH), 3.91 (3H, s, -OCH₃), 3.95 (3H, s, -OCH₃), 4.75 (2H, d, J = 2.5 Hz, -OCH₂C≡CH), 6.12 (1H, d, J = 2.0 Hz, ArH), 6.37 (1H, d, J = 2.0 Hz, ArH), 6.72 (1H, s, -C=CH), 6.99 (1H, ddd, J = 8.0, 2.5, 1.0 Hz, ArH), 7.35 (1H, t, J = 8.0 Hz, ArH), 7.46 (1H, d, J = 7.5 Hz, ArH), 7.54 (1H, t, J = 1.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 55.9, 56.1, 56.2, 75.7, 78.3, 89.2, 94.0, 105.1, 110.3, 115.9, 117.1, 124.6, 129.7, 133.9, 148.0, 157.6, 159.4, 169.0, 180.6. LCMS (ES+) m/z = 337.2 ([M + H]⁺, t_R = 1.83 min). HRMS (ESI+) m/z = 337.1062 [M + H]⁺ found, C₂₀H₁₇O₅⁺ required 337.1071.

4-(2-Bromoethoxy)-2H-chromen-2-one (57). A mixture of 4-hydroxycoumarin **47** (5.14 g, 31.7 mmol), 1,2-dibromoethane (3.19 mL, 37.0 mmol) and anhydrous K₂CO₃ (8.56 g, 61.9 mmol) in dry acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO₂, CH₂Cl₂) to afford coumarin **57** (1.33g, 16%) as a white powdery solid. m.p. 176–178 °C. TLC R_f = 0.41 (PE/EtOAc 1:1). IR ν_{max} (neat)/cm⁻¹: 3044w (C-H str), 2982w (C-H str), 1716s (C=O str), 1627s, 1607s, 1566m (C=C str), 1496m, 1454m, 1407s, 1369s, 1330m, 1272m, 1246s, 1225s, 1184s, 1147m, 1111s, 1067w, 1034s. ¹H-NMR (500 MHz, CDCl₃): δ 3.77 (2H, t, J = 6.0 Hz, -OCH₂CH₂Br), 4.46 (2H, t, J = 6.0 Hz, -OCH₂CH₂Br), 5.68 (1H, s, -C=CH), 7.31 (1H, t, J = 8.0 Hz, ArH), 7.34 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.58 (1H, t, J = 8.5 Hz, ArH), 7.88 (1H, dd, J = 7.5, 1.5 Hz, ArH).

^{13}C -NMR (500 MHz, CDCl_3): δ 27.6, 68.4, 90.9, 115.3, 116.8, 123.1, 124.0, 132.7, 153.3, 162.5, 164.9. LCMS (ES+) $m/z = 271.0$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.53$ min). These characterisation data are in accordance with that previously reported in the literature [49].

4-(2-Azidoethoxy)-2H-chromen-2-one (58). A mixture of coumarin **57** (679 mg, 2.52 mmol) and NaN_3 (370 mg, 5.69 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford coumarin **58** (571 mg, 98%) as an off-white powdery solid and was used without further purification. m.p. 150–152 °C. TLC $R_f = 0.40$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3075w (C-H str), 2947w (C-H str), 2125s (N_3 str), 1732s (C=O str), 1623s, 1609s, 1566s (C=C str), 1495s, 1453m, 1417s, 1371s, 1277m, 1236s, 1180s, 1147s, 1109s, 1032s. ^1H -NMR (500 MHz, CDCl_3): δ 3.75 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 4.32 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 5.70 (1H, s, $-\text{C}=\text{CH}$), 7.31 (1H, t, $J = 8.0$ Hz, ArH), 7.34 (1H, dd, $J = 8.5, 0.5$ Hz, ArH), 7.58 (1H, t, $J = 8.5$ Hz, ArH), 7.84 (1H, dd, $J = 8.0, 1.5$ Hz, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.6, 68.2, 90.9, 115.2, 116.8, 123.0, 124.1, 132.7, 153.3, 162.5, 165.1. LCMS (ES+) $m/z = 232.1$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.70$ min). These characterisation data are in accordance with that previously reported in the literature [27].

4-(2-Bromoethoxy)benzaldehyde (59). A mixture of benzaldehyde **33** (20.0 g, 164 mmol), 1,2-dibromoethane (28.5 mL, 331 mmol) and anhydrous K_2CO_3 (46.0 g, 333 mmol) in dry acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford benzaldehyde **59** (13.2 g, 35%) as a white powdery solid. m.p. 56–58 °C. TLC $R_f = 0.41$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2967w (C-H str), 1679s (C=O str), 1601s (C=C str), 1577s (C=C str), 1508m (C=C str), 1458m, 1422m, 1392m, 1317w, 1300m, 1282m, 1249s, 1229s, 1211s, 1160s, 1107w, 1068s, 1008s. ^1H -NMR (500 MHz, CDCl_3): δ 3.68 (2H, t, $J = 6.4$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 4.39 (2H, t, $J = 6.4$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 7.03 (2H, d, $J = 8.8$ Hz, ArH), 7.86 (2H, d, $J = 8.8$ Hz, ArH), 9.91 (1H, s, CHO). ^{13}C -NMR (500 MHz, CDCl_3): δ 28.4, 67.9, 114.8, 130.5, 132.0, 163.0, 190.7. LCMS (ES+) $m/z = 231.0$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.56$ min). These characterisation data are in accordance with that previously reported in the literature [50].

4-(2-Azidoethoxy)benzaldehyde (60). A mixture of benzaldehyde **59** (12.8 g, 56.0 mmol) and NaN_3 (7.36 g, 113 mmol) in dry DMF (100 mL) was reacted according to GP-J. The reaction mixture was worked up to afford benzaldehyde **60** (10.6 g, 99%) as a pale yellow viscous oil and was used without further purification. TLC $R_f = 0.38$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2942w (C-H str), 2837w (C-H str), 2100s (N_3 str), 1682s (C=O str), 1598s (C=C str), 1578s (C=C str), 1508s (C=C str), 1427w, 1395w, 1304m, 1247s, 1213s, 1157s, 1110m, 1052m, 1008w. ^1H -NMR (500 MHz, CDCl_3): δ 3.64 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 4.22 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 7.02 (2H, d, $J = 8.5$ Hz, ArH), 7.84 (2H, d, $J = 9.0$ Hz, ArH), 9.88 (1H, s, CHO). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.9, 67.1, 114.7, 130.3, 131.9, 163.0, 190.7. LCMS (ES+) $m/z = 193.2$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.62$ min). These characterisation data are in accordance with that previously reported in the literature [50].

(E)-3-(4-(2-Azidoethoxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (61). A mixture of benzaldehyde **60** (4.90 g, 25.6 mmol), acetophenone **10** (3.09 mL, 25.7 mmol) and KOH (8.70 g, 155 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **61** (6.13 g, 77%) as a bright yellow powdery solid. m.p. 142–144 °C. TLC $R_f = 0.48$ (PE/EtOAc; 2:1). IR ν_{max} (neat)/ cm^{-1} : 2932w (C-H str), 2874w (C-H str), 2107m (N_3 str), 2070m, 1636s (C=O str), 1602s, 1575s (C=C str), 1560s (C=C str), 1508s (C=C str), 1488s, 1424m, 1345m, 1299m, 1271m, 1244m, 1201m, 1059m, 1031m. ^1H -NMR (500 MHz, CDCl_3): δ 3.63 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 4.19 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.93–6.98 (3H, m, ArH), 7.03 (1H, dd, $J = 8.5, 1.0$ Hz, ArH), 7.49 (1H, t, $J = 8.5$ Hz, ArH), 7.54 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$), 7.63 (2H, d, $J = 8.5$ Hz, ArH), 7.89 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$), 7.92 (1H, dd, $J = 8.5, 2.0$ Hz, ArH), 12.94 (1H, s, OH). ^{13}C -NMR (500 MHz, CDCl_3): δ 50.0, 67.0, 115.0, 117.9, 118.5, 118.7, 120.0, 127.9, 129.5, 130.5, 136.2, 145.0, 160.5, 163.5, 193.5. LCMS (ES+) $m/z = 310.1$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.80$ min). These characterisation data are in accordance with that previously reported in the literature [51].

1-(4-(2-Bromoethoxy)-3-methoxyphenyl)ethan-1-one (62). A mixture of acetophenone **11** (10.0 g, 60.3 mmol), 1,2-dibromoethane (10.5 mL, 122 mmol) and anhydrous K_2CO_3 (12.6 g, 91.5 mmol) in dry DMF (100 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford acetophenone **62** (3.90 g, 24%) as a white powdery solid. m.p. 98–100 °C. TLC $R_f = 0.16$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3075w (C-H str), 2971w (C-H str), 1760w, 1671s (C=O str), 1585s (C=C str), 1507s (C=C str), 1460m, 1412s, 1385w, 1359m, 1263s, 1220s, 1171m, 1144s, 1076s, 1030s, 1008s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.58 (3H, s, $-COCH_3$), 3.70 (2H, t, $J = 6.8$ Hz, $-OCH_2CH_2Br$), 3.94 (3H, s, $-OCH_3$), 4.41 (2H, t, $J = 6.8$ Hz, $-OCH_2CH_2Br$), 6.91 (1H, d, $J = 8.8$ Hz, ArH), 7.55–7.57 (2H, m, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 26.3, 28.2, 56.1, 68.7, 111.0, 112.2, 123.0, 131.4, 149.5, 151.7, 196.7. LCMS (ES+) $m/z = 275.0$ ($[M + H]^+$, $t_R = 1.43$ min). These characterisation data are in accordance with that previously reported in the literature [52].

1-(4-(2-Azidoethoxy)-3-methoxyphenyl)ethan-1-one (63). A mixture of acetophenone **62** (3.50 g, 12.8 mmol) and NaN_3 (1.25 g, 19.2 mol) in DMF (30 mL) was reacted according to GP-J. The reaction mixture was worked up to afford phenylethanone **63** (2.94 g, 98%) as a pale brown residual oil which solidified upon standing to give a pale brown crystalline solid and used without further purification. m.p. 58–60 °C. TLC $R_f = 0.30$ (0.5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3088w (C-H str), 2956w (C-H str), 2110s (N_3 str), 2067m, 1742w, 1671s (C=O str), 1589s (C=C str), 1508s (C=C str), 1471m, 1419s, 1355m, 1270s, 1216s, 1177m, 1151s, 1080m, 1036s. 1H -NMR (500 MHz, $CDCl_3$): δ 2.56 (3H, s, $-COCH_3$), 3.68 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 3.91 (3H, s, $-OCH_3$), 4.23 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 6.89 (1H, d, $J = 8.0$ Hz, ArH), 7.53–7.55 (2H, m, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 26.2, 50.0, 56.0, 67.7, 110.7, 111.9, 122.9, 131.2, 149.4, 151.9, 196.7. LCMS (ES+) $m/z = 236.0$ ($[M + H]^+$, $t_R = 1.45$ min). These characterisation data are in accordance with that previously reported in the literature [52].

(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (67). A mixture of benzaldehyde **64** (1.48 g, 8.91 mmol), acetophenone **63** (2.04 g, 8.67 mmol) and KOH (2.41 g, 43.0 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone **67** (2.61 g, 79%) as a pale yellow-green powdery solid. m.p. 106–108 °C. TLC $R_f = 0.28$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 2940w (C-H str), 2838w (C-H str), 2112s (N_3 str), 2068m, 1648s (C=O str), 1595s (C=C str), 1568s (C=C str), 1509s (C=C str), 1458m, 1419m, 1355w, 1312m, 1261s, 1242s, 1199m, 1159m, 1139s, 1036s, 1021s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.67 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 3.91 (3H, s, $-OCH_3$), 3.93 (3H, s, $-OCH_3$), 3.94 (3H, s, $-OCH_3$), 4.23 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 6.88 (1H, d, $J = 8.4$ Hz, ArH), 6.92 (1H, d, $J = 8.0$ Hz, ArH), 7.15 (1H, d, $J = 2.0$ Hz, ArH), 7.22 (1H, dd, $J = 8.4, 2.0$ Hz, ArH), 7.39 (1H, d, $J = 15.6$ Hz, $-CH=CHCO-$), 7.61–7.65 (2H, m, ArH), 7.75 (1H, d, $J = 15.2$ Hz, $-CH=CHCO-$). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.9, 55.8, 56.0, 67.7, 110.1, 111.0, 111.4, 111.9, 119.4, 122.4, 122.8, 127.8, 132.2, 144.2, 149.1, 149.6, 151.2, 151.7, 188.5. LCMS (ES+) $m/z = 384.2$ ($[M + H]^+$, $t_R = 3.98$ min). These characterisation data are in accordance with that previously reported in the literature [52].

(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (68). A mixture of benzaldehyde **65** (1.70 g, 8.66 mmol), acetophenone **63** (2.02 g, 8.59 mmol) and KOH (2.39 g, 42.6 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone **68** (2.61 g, 74%) as a pale yellow-green powdery solid. m.p. 114–116 °C. TLC $R_f = 0.35$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 2945w (C-H str), 2836w (C-H str), 2119s (N_3 str), 2072m, 1743w, 1644m (C=O str), 1588m (C=C str), 1560s (C=C str), 1519m (C=C str), 1494s, 1466m, 1420s, 1246s, 1149s, 1093s, 1042s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.66 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 3.87 (3H, s, $-OCH_3$), 3.88 (3H, s, $-OCH_3$), 3.92 (3H, s, $-OCH_3$), 3.93 (3H, s, $-OCH_3$), 4.23 (2H, t, $J = 5.0$ Hz, $-OCH_2CH_2N_3$), 6.70 (1H, d, $J = 8.8$ Hz, ArH), 6.91 (1H, d, $J = 8.8$ Hz, ArH), 7.37 (1H, d, $J = 8.8$ Hz, ArH), 7.55 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$), 7.61–7.63 (2H, m, ArH), 7.97 (1H, d, $J = 15.6$ Hz, $-CH=CHCO-$). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.9, 55.9, 60.8, 61.2, 67.7, 107.5, 111.5, 112.0, 120.8, 121.9, 122.4, 123.7, 132.4, 139.3, 142.3,

149.6, 151.6, 153.6, 155.6, 188.9. LCMS (ES+) $m/z = 414.1$ ($[M + H]^+$, $t_R = 1.64$ min). HRMS (ESI+) $m/z = 414.1653$ $[M + H]^+$ found, $C_{21}H_{24}O_6N_3^+$ required 414.1660.

(*E*)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (**69**). A mixture of benzaldehyde **66** (1.69 g, 8.61 mmol), acetophenone **63** (2.06 g, 8.76 mmol) and KOH (2.44 g, 43.5 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **69** (2.91 g, 82%) as a pale yellow-green powdery solid. m.p. 132–134 °C. TLC $R_f = 0.29$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 3005w (C-H str), 2939w (C-H str), 2840w (C-H str), 2112m (N_3 str), 1647m (C=O str), 1596m (C=C str), 1567s (C=C str), 1518m (C=C str), 1493w, 1451m, 1417m, 1320s, 1266m, 1213s, 1147s, 1119s, 1026s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.70 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 3.87 (3H, s, $-OCH_3$), 3.92 (6H, s, $2 \times -OCH_3$), 3.96 (3H, s, $-OCH_3$), 4.27 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 6.16 (2H, s, ArH), 6.95 (1H, d, $J = 8.4$ Hz, ArH), 7.62–7.65 (2H, m, ArH), 7.88 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$), 8.24 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 50.1, 55.4, 55.8, 56.1, 67.8, 90.5, 106.6, 111.8, 112.2, 121.8, 122.4, 133.3, 135.4, 149.6, 151.2, 161.6, 163.0, 190.5. LCMS (ES+) $m/z = 414.1$ ($[M + H]^+$, $t_R = 1.67$ min). HRMS (ESI+) $m/z = 414.1654$ $[M + H]^+$ found, $C_{21}H_{24}O_6N_3^+$ required 414.1660.

(*E*)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (**70**). A mixture of pyrrole aldehyde **7** (1.40 mL, 13.0 mmol), acetophenone **63** (3.03 g, 12.9 mmol) and KOH (4.33 g, 77.2 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude product was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone **70** as a bright yellow powdery solid (1.56 g, 37%). m.p. 124–126 °C. TLC $R_f = 0.32$ (PE/EtOAc; 1:1). IR ν_{max} (neat)/ cm^{-1} : 2946w (C-H str), 2107m (N_3 str), 2064w, 1739w, 1644m (C=O str), 1595s (C=C str), 1562s (C=C str), 1515m (C=C str), 1485m, 1342s, 1272s, 1238s, 1196s, 1174s, 1125s, 1059m, 1034s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.70 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N_3$), 3.78 (3H, s, $-NCH_3$), 3.96 (3H, s, $-OCH_3$), 4.27 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N_3$), 6.23–6.24 (1H, m, ArH), 6.82 (1H, t, $J = 1.6$ Hz, ArH), 6.85 (1H, dd, $J = 4.0, 1.6$ Hz, ArH), 6.94 (1H, d, $J = 8.8$ Hz, ArH), 7.31 (1H, d, $J = 14.8$ Hz, $-CH=CHCO-$), 7.62–7.64 (2H, m, ArH), 7.81 (1H, d, $J = 15.2$ Hz, $-CH=CHCO-$). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 34.4, 50.1, 56.1, 67.8, 109.7, 111.5, 112.1, 112.1, 116.4, 122.2, 127.6, 130.3, 131.7, 132.7, 149.7, 151.6, 188.1. LCMS (ES+) $m/z = 327.2$ ($[M + H]^+$, $t_R = 1.82$ min). HRMS (ESI+) $m/z = 327.1447$ $[M + H]^+$ found, $C_{17}H_{19}O_3N_4^+$ required 327.1452.

4-(2-Bromoethoxy)-3-methoxy benzaldehyde (**72**). A mixture of benzaldehyde **71** (10.0 g, 65.9 mmol), 1,2-dibromoethane (7.40 mL, 85.9 mmol) and anhydrous K_2CO_3 (11.8 g, 85.5 mmol) in dry acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford benzaldehyde **72** (4.24 g, 25%) as a white crystalline solid. m.p. 84–86 °C. TLC $R_f = 0.37$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2967w (C-H str), 2849w (C-H str), 1697m (C=O str), 1682s, 1672s, 1585s (C=C str), 1508s (C=C str), 1459m, 1444m, 1427m, 1397m, 1349w, 1279m, 1266s, 1233s, 1215w, 1159w, 1134s, 1015s, 1003m. 1H -NMR (500 MHz, $CDCl_3$): δ 3.70 (2H, t, $J = 6.5$ Hz, $-OCH_2CH_2Br$), 3.94 (3H, s, $-OCH_3$), 4.42 (2H, t, $J = 6.5$ Hz, $-OCH_2CH_2Br$), 6.99 (1H, d, $J = 8.0$ Hz, ArH), 7.43–7.46 (2H, m, ArH), 9.87 (1H, s, CHO). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 28.1, 56.1, 68.7, 109.8, 112.4, 126.4, 130.8, 150.0, 152.9, 190.8. LCMS (ES+) $m/z = 261.0$ ($[M + H]^+$, $t_R = 1.49$ min). These characterisation data are in accordance with that previously reported in the literature [53].

3-(2-Bromoethoxy)-4-methoxy benzaldehyde (**73**). A mixture of isovanillin **1** (10.3 g, 68.0 mmol), 1,2-dibromoethane (7.36 mL, 85.4 mmol) and anhydrous K_2CO_3 (11.8 g, 85.7 mmol) in dry acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford benzaldehyde **73** (3.81 g, 22%) as a white powdery solid. m.p. 88–90 °C. TLC $R_f = 0.38$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2978w (C-H str), 2840w (C-H str), 1677s (C=O str), 1595m (C=C str), 1582s (C=C str), 1509s (C=C str), 1462w, 1434s, 1392m, 1259s, 1238s, 1162s, 1131s, 1072w, 1013s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.69 (2H, t, $J = 6.4$ Hz, $-OCH_2CH_2Br$), 3.96 (3H, s, $-OCH_3$), 4.39 (2H, t, $J = 6.4$ Hz, $-OCH_2CH_2Br$), 7.00 (1H, d, $J = 8.0$ Hz, ArH), 7.41 (1H, d, $J = 1.6$ Hz,

ArH), 7.50 (1H, dd, $J = 8.0, 1.6$ Hz, ArH), 9.84 (1H, s, CHO). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 28.5, 56.2, 68.8, 111.1, 111.6, 127.4, 130.0, 148.0, 155.0, 190.6. LCMS (ES+) $m/z = 261.0$ ($[\text{M} + \text{H}]^+$, $t_R = 1.47$ min). These characterisation data are in accordance with that previously reported in the literature [53].

4-(2-Azidoethoxy)-3-methoxybenzaldehyde (74). A mixture of benzaldehyde **72** (3.40 g, 13.1 mmol) and NaN_3 (1.74 g, 26.8 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford benzaldehyde **74** (2.84 g, 98%) as a pale yellow viscous oil and was used without further purification. TLC $R_f = 0.21$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2938w (C-H str), 2831w (C-H str), 2106s (N_3 str), 1679s (C=O str), 1586s (C=C str), 1507s (C=C str), 1457m, 1424m, 1396w, 1339w, 1263s, 1236m, 1194w, 1158w, 1134s, 1051w, 1030m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.66 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.88 (3H, s, $-\text{OCH}_3$), 4.22 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.95 (1H, d, $J = 8.0$ Hz, ArH), 7.38–7.41 (2H, m, ArH), 9.81 (1H, s, CHO). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.8, 55.8, 67.7, 109.5, 112.0, 126.1, 130.6, 149.9, 153.0, 190.7. LCMS (ES+) $m/z = 222.0$ ($[\text{M} + \text{H}]^+$, $t_R = 1.66$ min). HRMS (ESI+) $m/z = 222.0863$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{10}\text{H}_{12}\text{O}_3\text{N}_3^+$ required 222.0834.

3-(2-Azidoethoxy)-4-methoxybenzaldehyde (75). A mixture of benzaldehyde **73** (3.63 g, 14.0 mmol) and NaN_3 (1.80 g, 27.7 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford benzaldehyde **75** (3.03 g, 98%) as a pale yellow viscous oil and was used without further purification. TLC $R_f = 0.26$ (CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2940w (C-H str), 2838w (C-H str), 2094s (N_3 str), 1682s (C=O str), 1596s (C=C str), 1583s (C=C str), 1508s (C=C str), 1435s, 1397w, 1339w, 1261s, 1236s, 1161m, 1134s, 1125s, 1051w, 1019s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.68 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.96 (3H, s, $-\text{OCH}_3$), 4.25 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 7.00 (1H, d, $J = 8.0$ Hz, ArH), 7.42 (1H, d, $J = 2.0$ Hz, ArH), 7.50 (1H, dd, $J = 8.4, 2.0$ Hz, ArH), 9.85 (1H, s, CHO). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.0, 56.1, 67.9, 110.9, 111.1, 127.5, 129.9, 148.3, 155.1, 190.7. LCMS (ES+) $m/z = 222.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.69$ min). HRMS (ESI+) $m/z = 244.0683$ $[\text{M} + \text{Na}]^+$ found, $\text{C}_{10}\text{H}_{11}\text{O}_3\text{N}_3\text{Na}^+$ required 244.0693.

(E)-3-(4-(2-Azidoethoxy)phenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one (76). A mixture of benzaldehyde **60** (5.00 g, 26.2 mmol), acetophenone **3** (4.39 g, 26.4 mmol) and KOH (9.42 g, 168 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from MeOH to afford chalcone **76** (5.72 g, 64%) as a bright yellow-orange powdery solid. m.p. 124–126 °C. TLC $R_f = 0.36$ (PE/EtOAc; 2:1). IR ν_{max} (neat)/ cm^{-1} : 2940w (C-H str), 2873w (C-H str), 2109m (N_3 str), 2073m, 1634m (C=O str), 1604m, 1573s (C=C str), 1513s (C=C str), 1445m, 1426m, 1361s, 1328m, 1307w, 1279s, 1250w, 1209s, 1184s, 1119s, 1057m, 1015s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.65 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.87 (3H, s, $-\text{OCH}_3$), 4.22 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.49–6.51 (2H, m, ArH), 6.98 (2H, d, $J = 8.8$ Hz, ArH), 7.48 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 7.63 (2H, d, $J = 8.8$ Hz, ArH), 7.84 (1H, d, $J = 9.2$ Hz, ArH), 7.87 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 13.52 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.6, 55.6, 67.1, 101.0, 107.7, 114.1, 115.0, 118.3, 128.2, 130.4, 131.1, 144.0, 160.3, 166.1, 166.6, 191.8. LCMS (ES+) $m/z = 340.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.74$ min). HRMS (ESI+) $m/z = 340.1295$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_4^+$ required 340.1297.

(E)-3-(4-(2-Azidoethoxy)-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (77). A mixture of benzaldehyde **74** (2.70 g, 12.2 mmol), acetophenone **10** (1.50 mL, 12.5 mmol) and KOH (4.30 g, 76.6 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) to afford chalcone **77** (1.91 g, 46%) as a bright yellow-orange powdery solid. m.p. 84–86 °C. TLC $R_f = 0.25$ (PE/EtOAc; 3:1). IR ν_{max} (neat)/ cm^{-1} : 2935w (C-H str), 2876w (C-H str), 2106s (N_3 str), 1635s (C=O str), 1580m (C=C str), 1562s (C=C str), 1508s (C=C str), 1489s, 1462w, 1441w, 1421w, 1372w, 1313w, 1255s, 1201s, 1168w, 1138s, 1057w, 1028s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.68 (2H, t, $J = 5.5$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.95 (3H, s, $-\text{OCH}_3$), 4.24 (2H, t, $J = 5.5$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.92 (1H, d, $J = 8.0$ Hz, ArH), 6.93–6.96 (1H, m, ArH), 7.03 (1H, dd, $J = 8.5, 1.5$ Hz, ArH), 7.19 (1H, d, $J = 2.0$ Hz, ArH), 7.25 (1H, dd, $J = 8.5, 1.5$ Hz, ArH), 7.50 (1H, t, $J = 8.5$ Hz, ArH), 7.53 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$), 7.87 (1H, d, $J = 15.5$ Hz, $-\text{CH}=\text{CHCO}-$), 7.93

(1H, dd, $J = 8.0, 1.5$ Hz, ArH), 12.91 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.1, 56.1, 67.9, 111.2, 113.4, 118.2, 118.5, 118.7, 120.0, 123.1, 128.5, 129.5, 136.2, 145.4, 149.9, 150.5, 163.5, 193.5. LCMS (ES+) $m/z = 340.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.96$ min). HRMS (ESI+) $m/z = 340.1296$ ($[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_4^+$ required 340.1297).

(*E*)-3-(3-(2-Azidoethoxy)-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (**78**). A mixture of benzaldehyde **75** (3.00 g, 13.6 mmol), acetophenone **10** (1.63 mL, 13.6 mmol) and KOH (4.57 g, 81.4 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column chromatography (SiO_2 , PE/EtOAc; 5:1) to afford chalcone **78** (2.72 g, 59%) as a bright yellow powdery solid. m.p. 98–100 °C. TLC $R_f = 0.33$ (PE/EtOAc; 3:1). IR ν_{max} (neat)/ cm^{-1} : 3009w (C-H str), 2970w (C-H str), 2112m (N_3 str), 2067w, 1738s (C=O str), 1634s, 1567s (C=C str), 1511s (C=C str), 1490s, 1440m, 1374s, 1315m, 1266s, 1227s, 1204s, 1142s, 1024s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.66 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.89 (3H, s, $-\text{OCH}_3$), 4.22 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.90 (1H, d, $J = 8.5$ Hz, ArH), 6.91 (1H, t, $J = 8.5$ Hz, ArH), 7.00 (1H, dd, $J = 8.5, 1.0$ Hz, ArH), 7.19 (1H, d, $J = 2.5$ Hz, ArH), 7.27 (1H, dd, $J = 8.0, 2.0$ Hz, ArH, overlain by CDCl_3), 7.46 (1H, t, $J = 7.5$ Hz, ArH), 7.48 (1H, d, $J = 15.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.82 (1H, d, $J = 15.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.90 (1H, dd, $J = 8.0, 1.5$ Hz, ArH), 12.95 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.1, 55.8, 68.2, 111.7, 113.4, 117.7, 118.4, 118.6, 119.9, 124.6, 127.3, 129.4, 136.1, 145.2, 147.9, 152.5, 163.4, 193.3. LCMS (ES+) $m/z = 340.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.97$ min). HRMS (ESI+) $m/z = 340.1301$ ($[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_4^+$ required 340.1297).

4'-(2-Azidoethoxy)-3-hydroxyflavone (**79**). A mixture of chalcone **61** (2.02 g, 6.53 mmol), 16% NaOH (12.9 mL) and 15% H_2O_2 (6.47 mL) in MeOH (50 mL) was reacted according to GP-F. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavonol **79** (1.68 g, 80%) as an off-white fluffy solid. m.p. 158–160 °C. TLC $R_f = 0.39$ (0.5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3235w(br) (O-H str), 2957w (C-H str), 2942w (C-H str), 2140m (N_3 str), 2091m, 1739w, 1604s (C=O str), 1574m (C=C str), 1512s (C=C str), 1478m, 1425m, 1406m, 1346m, 1254s, 1201s, 1182s, 1117s, 1107s, 1057s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.66 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 4.24 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 7.03 (1H, br s, OH), 7.07 (2H, d, $J = 8.8$ Hz, ArH), 7.41 (1H, t, $J = 7.6$ Hz, ArH), 7.58 (1H, d, $J = 8.4$ Hz, ArH), 7.70 (1H, t, $J = 8.4$ Hz, ArH), 8.25 (3H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.1, 67.0, 114.6, 118.1, 120.7, 124.2, 124.4, 125.4, 129.6, 133.4, 137.7, 145.0, 155.2, 159.6, 173.1. LCMS (ES+) $m/z = 324.1$ ($[\text{M} + \text{H}]^+$, $t_R = 1.66$ min). These characterisation data are in accordance with that previously reported in the literature [51].

4'-(2-Azidoethoxy)-3-hydroxy-7-methoxyflavone (**80**). A mixture of chalcone **74** (1.06 g, 3.12 mmol), 16% NaOH (5.89 mL) and 15% H_2O_2 (2.95 mL) in MeOH (30 mL) was reacted according to GP-F. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavonol **80** (677 mg, 61%) as an off-white powdery solid. m.p. 172–174 °C. TLC $R_f = 0.39$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3269w(br) (O-H str), 2932w (C-H str), 2116s (N_3 str), 2073m, 1597s (C=O str), 1561s (C=C str), 1504s (C=C str), 1451m, 1403m, 1256s, 1239s, 1203s, 1171s, 1114m, 1098m, 1050m, 1026m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.66 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.94 (3H, s, $-\text{OCH}_3$), 4.23 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 6.94 (1H, d, $J = 2.0$ Hz, ArH), 6.98 (1H, dd, $J = 8.8, 2.0$ Hz, ArH), 7.04 (1H, br s, OH), 7.05 (2H, d, $J = 9.2$ Hz, ArH), 8.12 (1H, d, $J = 8.8$ Hz, ArH), 8.21 (2H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.1, 55.8, 67.0, 99.8, 114.5, 114.6, 114.7, 124.3, 126.6, 129.2, 137.4, 144.3, 157.1, 159.3, 164.1, 172.6. LCMS (ES+) $m/z = 354.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.90$ min). HRMS (ESI+) $m/z = 354.1074$ ($[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{16}\text{O}_5\text{N}_3^+$ required 354.1084).

4'-(2-Azidoethoxy)-3-hydroxy-3'-methoxyflavone (**81**). A mixture of chalcone **77** (519 mg, 1.53 mmol), 16% NaOH (2.95 mL) and 15% H_2O_2 (1.47 mL) in MeOH (20 mL) was reacted according to GP-F. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavonol **81** (418 mg, 77%) as a pale yellow-white powdery solid. m.p. 118–120 °C. TLC $R_f = 0.45$ (0.5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3224w(br) (O-H str), 2924w (C-H str), 2125s (N_3 str), 1614s (C=O str), 1567m (C=C str), 1514s (C=C str), 1481m, 1470m, 1409s, 1269s, 1202s, 1183m, 1146s,

1121m, 1035m, 1006m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.71 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.99 (3H, s, $-\text{OCH}_3$), 4.29 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 7.01 (1H, br s, OH), 7.05 (1H, d, $J = 9.2$ Hz, ArH), 7.43 (1H, t, $J = 7.2$ Hz, ArH), 7.60 (1H, d, $J = 8.4$ Hz, ArH), 7.72 (1H, t, $J = 8.4$ Hz, ArH), 7.87–7.89 (2H, m, ArH), 8.26 (1H, dd, $J = 8.0, 1.2$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.1, 56.2, 67.9, 111.6, 113.3, 118.2, 120.6, 121.3, 124.5, 124.8, 125.4, 133.5, 137.9, 144.8, 149.5, 149.5, 155.3, 173.2. LCMS (ES+) $m/z = 354.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.86$ min). HRMS (ESI+) $m/z = 354.1095$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}_5^+$ required 354.1090.

3'-(2-Azidoethoxy)-3-hydroxy-4'-methoxyflavone (82). A mixture of chalcone **78** (513 mg, 1.51 mmol), 16% NaOH (2.95 mL) and 15% H_2O_2 (1.47 mL) in MeOH (20 mL) was reacted according to GP-F. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavonol **82** (419 mg, 78%) as a pale yellow-white powdery solid. m.p. 164–166 °C. TLC $R_f = 0.31$ (0.5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3199m(br) (O-H str), 2974w (C-H str), 2942w (C-H str), 2105s (N_3 str), 1611s (C=O str), 1599m (C=O str), 1564s (C=C str), 1516s (C=C str), 1480s, 1463m, 1412s, 1350m, 1264s, 1203s, 1179s, 1141s, 1012s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.71 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 3.97 (3H, s, $-\text{OCH}_3$), 4.31 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}_3$), 7.01 (1H, br s, OH), 7.06 (1H, d, $J = 8.4$ Hz, ArH), 7.43 (1H, t, $J = 7.6$ Hz, ArH), 7.60 (1H, d, $J = 8.4$ Hz, ArH), 7.71 (1H, t, $J = 8.4$ Hz, ArH), 7.91 (1H, d, $J = 2.0$ Hz, ArH), 7.96 (1H, dd, $J = 8.8, 2.0$ Hz, ArH), 8.26 (1H, dd, $J = 8.0, 1.2$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 50.2, 56.0, 68.3, 111.7, 113.8, 118.2, 120.6, 122.6, 123.7, 124.5, 125.4, 133.5, 137.8, 144.8, 147.6, 151.6, 155.2, 173.1. LCMS (ES+) $m/z = 354.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.86$ min). HRMS (ESI+) $m/z = 354.1096$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}_5^+$ required 354.1090.

6-(2-Bromoethoxy)flavone (83). A mixture of flavone **28** (1.02 g, 4.28 mmol), 1,2-dibromoethane (0.47 mL, 5.46 mmol) and anhydrous K_2CO_3 (782 mg, 5.66 mmol) in dry acetone (50 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , CH_2Cl_2) to afford flavone **83** (328 mg, 22%) as a white powdery solid. m.p. 180–182 °C. TLC $R_f = 0.33$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3026w (C-H str), 2938w (C-H str), 2887w (C-H str), 1637s (C=O str), 1617m, 1586m (C=C str), 1568m (C=C str), 1482m, 1468m, 1447s, 1358s, 1313w, 1254m, 1200m, 1084m, 1030m, 1017s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.69 (2H, t, $J = 6.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 4.41 (2H, t, $J = 6.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 6.82 (1H, s, $-\text{C}=\text{CH}$), 7.34 (1H, dd, $J = 9.2, 3.2$ Hz, ArH), 7.50–7.54 (4H, m, ArH), 7.58 (1H, d, $J = 3.2$ Hz, ArH), 7.91–7.93 (2H, m, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 28.9, 68.4, 105.9, 106.8, 119.8, 124.1, 124.5, 126.2, 129.0, 131.5, 131.7, 151.3, 155.4, 163.2, 178.1. LCMS (ES+) $m/z = 347.0$ ($[\text{M} + \text{H}]^+$, $t_R = 1.66$ min). These characterisation data are in accordance with that previously reported in the literature [54].

7-(2-Bromoethoxy)flavone (84). A mixture of flavone **29** (1.59 g, 6.67 mmol), 1,2-dibromoethane (0.71 mL, 8.19 mmol) and anhydrous K_2CO_3 (1.20 g, 8.68 mmol) in dry acetone (50 mL) was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO_2 , 1% MeOH/ CH_2Cl_2) to afford flavone **84** (1.50 g, 65%) as a white powdery solid. m.p. 150–152 °C. TLC $R_f = 0.22$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3045w (C-H str), 2934w (C-H str), 2864w (C-H str), 1628s (C=O str), 1604s, 1594s (C=C str), 1567m (C=C str), 1494m, 1439m, 1372s, 1356s, 1282s, 1250s, 1227s, 1171s, 1131m, 1089s, 1013m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.70 (2H, t, $J = 6.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 4.41 (2H, t, $J = 6.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{Br}$), 6.76 (1H, s, $-\text{C}=\text{CH}$), 6.97 (1H, d, $J = 2.4$ Hz, ArH), 7.00 (1H, dd, $J = 8.8, 2.4$ Hz, ArH), 7.49–7.54 (3H, m, ArH), 7.88–7.91 (2H, m, ArH), 8.14 (1H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 28.3, 68.2, 101.3, 107.5, 114.4, 118.3, 126.1, 127.3, 129.0, 131.4, 131.7, 157.8, 162.4, 163.0, 177.7. LCMS (ES+) $m/z = 347.0$ ($[\text{M} + \text{H}]^+$, $t_R = 1.69$ min). These characterisation data are in accordance with that previously reported in the literature [28].

6-(2-Azidoethoxy)flavone (85). A mixture of flavone **83** (824 mg, 2.39 mmol) and NaN_3 (336 mg, 5.17 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford flavone **85** (686 mg, 93%) as a white powdery solid and was used without further purification. m.p. 138–140 °C. TLC $R_f = 0.27$ (1% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3073w (C-H str), 2930w

(C-H str), 2107s (N₃ str), 2063m, 1625s, 1616s (C=O str), 1603s, 1582s (C=C str), 1569s (C=C str), 1480s, 1455s, 1363s, 1291s, 1262m, 1242s, 1203s, 1130s, 1083m. ¹H-NMR (500 MHz, CDCl₃): δ 3.65 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N₃), 4.26 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N₃), 6.81 (1H, s, -C=CH), 7.34 (1H, dd, *J* = 8.8, 2.8 Hz, ArH), 7.51–7.54 (4H, m, ArH), 7.59 (1H, d, *J* = 2.8 Hz, ArH), 7.90–7.93 (2H, m, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 50.0, 67.5, 105.6, 106.9, 119.8, 124.2, 124.5, 126.2, 129.0, 131.5, 131.8, 151.3, 155.5, 163.3, 178.1. LCMS (ES+) *m/z* = 308.2 ([M + H]⁺, *t*_R = 1.68 min). HRMS (ESI+) *m/z* = 330.0836 [M + Na]⁺ found, C₁₇H₁₃O₃N₃Na⁺ required 330.0849.

7-(2-Azidoethoxy)flavone (**86**). A mixture of flavone **84** (1.03 g, 3.00 mmol) and NaN₃ (444 mg, 6.83 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford flavone **86** (838 mg, 91%) as an off-white powdery solid and was used without further purification. m.p. 108–110 °C. TLC *R*_f = 0.23 (1% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3073w (C-H str), 2979w (C-H str), 2926w (C-H str), 2105m (N₃ str), 1631s (C=O str), 1601s, 1578m (C=C str), 1569m (C=C str), 1493w, 1447s, 1375m, 1358m, 1303m, 1244s, 1177s, 1130m, 1085s. ¹H-NMR (500 MHz, CDCl₃): δ 3.68 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N₃), 4.26 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N₃), 6.75 (1H, s, -C=CH), 6.97 (1H, d, *J* = 2.0 Hz, ArH), 6.99 (1H, dd, *J* = 8.5, 2.0 Hz, ArH), 7.48–7.54 (3H, m, ArH), 7.88 (2H, dd, *J* = 8.0, 2.0 Hz, ArH), 8.13 (1H, d, *J* = 8.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.8, 67.4, 101.3, 107.5, 114.3, 118.2, 126.1, 127.2, 128.9, 131.4, 131.6, 157.7, 162.6, 163.0, 177.6. LCMS (ES+) *m/z* = 308.0 ([M + H]⁺, *t*_R = 4.43 min). These characterisation data are in accordance with that previously reported in the literature [10].

4'-(2-Azidoethoxy)-7-methoxyflavone (**87**). To a stirred solution of chalcone **76** (1.02 g, 3.01 mmol) in DMSO (20 mL) was added a catalytic amount of I₂ (103 mg, 0.407 mmol). The reaction mixture was heated at 130 °C with stirring for 24 h under a nitrogen atmosphere. The resulting mixture was allowed to cool to room temperature and poured into H₂O (50 mL). The aqueous solution was extracted with CHCl₃ (2 × 100 mL) and the combined organic layer was washed with H₂O (2 × 50 mL), brine (2 × 50 mL), dried over anhydrous MgSO₄, filtered and the solvent removed under reduced pressure. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford flavone **87** (924 mg, 91%) as a pale yellow-white powdery solid. m.p. 128–130 °C. TLC *R*_f = 0.35 (3% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2946w (C-H str), 2839w (C-H str), 2097s (N₃ str), 1644s (C=O str), 1626s, 1598s (C=C str), 1510s (C=C str), 1503s (C=C str), 1440s, 1376m, 1355s, 1247s, 1182s, 1164m, 1141w, 1091m, 1023m. ¹H-NMR (500 MHz, CDCl₃): δ 3.65 (2H, t, *J* = 5.2 Hz, -OCH₂CH₂N₃), 3.92 (3H, s, -OCH₃), 4.22 (2H, t, *J* = 5.2 Hz, -OCH₂CH₂N₃), 6.66 (1H, s, -C=CH), 6.94 (1H, d, *J* = 2.4 Hz, ArH), 6.96 (1H, dd, *J* = 8.8, 2.4 Hz, ArH), 7.02 (2H, d, *J* = 9.2 Hz, ArH), 7.85 (2H, d, *J* = 9.2 Hz, ArH), 8.11 (1H, d, *J* = 8.8 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 50.0, 55.8, 67.1, 100.3, 106.2, 114.2, 114.9, 117.7, 124.7, 126.9, 127.8, 157.8, 160.7, 162.7, 164.0, 177.7. LCMS (ES+) *m/z* = 338.2 ([M + H]⁺, *t*_R = 1.84 min). HRMS (ESI+) *m/z* = 338.1147 [M + H]⁺ found, C₁₈H₁₆N₃O₄⁺ required 338.1141.

4'-(2-Azidoethoxy)aurone (**88**). A mixture of chalcone **61** (403 mg, 1.30 mmol) and Hg(OAc)₂ (440 mg, 1.38 mmol) in dry pyridine (15 mL) was reacted according to GP-K. The crude residue was purified by flash column chromatography (SiO₂, PE/EtOAc; 3:1) to afford aurone **88** (354 mg, 88%) as a bright yellow powdery solid. m.p. 114–116 °C. TLC *R*_f = 0.37 (PE/EtOAc; 2:1). IR ν_{max} (neat)/cm⁻¹: 2945w (C-H str), 2888w (C-H str), 2096s (N₃ str), 2062m, 1699s (C=O str), 1649s, 1592s (C=C str), 1510m (C=C str), 1474m, 1461m, 1395w, 1347m, 1301s, 1257s, 1177s, 1130m, 1111m, 1097w, 1048s, 1009w. ¹H-NMR (500 MHz, CDCl₃): δ 3.65 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N₃), 4.22 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N₃), 6.89 (1H, s, -C=CH), 7.01 (2H, d, *J* = 8.8 Hz, ArH), 7.22 (1H, t, *J* = 7.6 Hz, ArH), 7.33 (1H, d, *J* = 8.4 Hz, ArH), 7.65 (1H, t, *J* = 8.4 Hz, ArH), 7.82 (1H, dd, *J* = 7.6, 0.4 Hz, ArH), 7.91 (2H, d, *J* = 8.8 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 50.0, 67.0, 112.9, 113.0, 115.0, 121.8, 123.3, 124.6, 125.7, 133.4, 136.6, 146.0, 159.6, 165.9, 184.6. LCMS (ES+) *m/z* = 308.2 ([M + H]⁺, *t*_R = 1.73 min). HRMS (ESI+) *m/z* = 308.1035 [M + H]⁺ found, C₁₇H₁₄O₃N₃⁺ required 308.1035.

4'-(2-Azidoethoxy)-6-methoxyaurone (89). A mixture of chalcone **76** (2.01 g, 5.91 mmol) and Hg(OAc)₂ (1.95 g, 6.13 mmol) in dry pyridine (50 mL) was reacted according to GP-K. The crude residue was purified by flash column chromatography (SiO₂, 0.5% MeOH/CH₂Cl₂) to afford aurone **89** (1.91 g, 96%) as a bright yellow-orange powdery solid. m.p. 108–110 °C. TLC R_f = 0.36 (0.5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3008w (C-H str), 2970w (C-H str), 2092s (N₃ str), 1694m (C=O str), 1652m, 1594s (C=C str), 1570m (C=C str), 1512m (C=C str), 1443m, 1414w, 1349m, 1315w, 1271m, 1248s, 1185m, 1131s, 1110s, 1068w, 1035m. ¹H-NMR (500 MHz, CDCl₃): δ 3.63 (2H, t, J = 4.8 Hz, -OCH₂CH₂N₃), 3.91 (3H, s, -OCH₃), 4.19 (2H, t, J = 4.8 Hz, -OCH₂CH₂N₃), 6.72–6.74 (2H, m, ArH), 6.76 (1H, s, -C=CH), 6.97 (2H, d, J = 8.8 Hz, ArH), 7.68 (1H, d, J = 8.8 Hz, ArH), 7.83 (2H, d, J = 8.8 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 50.0, 55.9, 66.9, 96.5, 111.7, 112.0, 114.9, 115.0, 125.6, 125.7, 133.1, 146.8, 159.3, 167.2, 168.2, 182.8. LCMS (ES+) *m/z* = 338.2 ([M + H]⁺, t_R = 1.65 min). HRMS (ESI+) *m/z* = 338.1146 [M + H]⁺ found, C₁₈H₁₆N₃O₄⁺ required 338.1141.

3.3. Synthesis of Triazole-Bridged Flavonoid Dimers and Trimers

(E)-3-(3,4-Dimethoxyphenyl)-1-(3-methoxy-4-(2-(4-((2-methoxy-4-((E)-3-(4-methoxyphenyl)acryloyl))methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)prop-2-en-1-one (90). A mixture of alkyne chalcone **20** (254 mg, 0.789 mmol), azide chalcone **67** (305 mg, 0.796 mmol), CuSO₄·5H₂O (225 mg, 0.900 mmol) and sodium ascorbate (389 mg, 1.97 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **90** (151 mg, 27%) as a pale yellow-brown powdery solid. m.p. 108–110 °C. TLC R_f = 0.41 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2942w (C-H str), 2837w (C-H str), 1652m (C=O str), 1595m (C=C str), 1572m (C=C str), 1509s (C=C str), 1464m, 1420m, 1335w, 1307w, 1255s, 1195w, 1143s, 1021s. ¹H-NMR (500 MHz, CDCl₃): δ 3.86 (3H, s, -OCH₃), 3.92 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 3.95 (3H, s, -OCH₃), 3.96 (3H, s, -OCH₃), 4.46 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.84 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.40 (2H, s, -OCH₂CN-), 6.82 (1H, d, J = 8.0 Hz, ArH), 6.90 (1H, d, J = 8.4 Hz, ArH), 6.93 (2H, d, J = 8.8 Hz, ArH), 7.14–7.17 (2H, m, ArH), 7.24 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.37 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.41 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.57–7.62 (6H, m, ArH), 7.75 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.77 (1H, d, J = 15.6 Hz, -CH=CHCO-), 8.04 (1H, s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.8, 55.4, 56.0, 56.0, 62.9, 67.6, 110.2, 111.1, 111.1, 111.5, 112.3, 112.4, 114.4, 119.2, 119.4, 122.5, 122.6, 123.0, 124.7, 127.7, 127.9, 130.1, 132.1, 132.8, 143.7, 144.0, 144.5, 149.2, 149.5, 149.7, 151.2, 151.4, 151.6, 161.5, 188.6. LCMS (ES+) *m/z* = 706.2 ([M + H]⁺, t_R = 1.65 min). HRMS (ESI+) *m/z* = 728.2576 [M + Na]⁺ found, C₄₀H₃₉O₉N₃Na⁺ required 728.2579.

(E)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (91). A mixture of alkyne chalcone **20** (234 mg, 0.727 mmol), azide chalcone **69** (303 mg, 0.732 mmol), CuSO₄·5H₂O (203 mg, 0.813 mmol) and sodium ascorbate (361 mg, 1.82 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **91** (250 mg, 47%) as a pale yellow-white flaky solid. m.p. 206–208 °C. TLC R_f = 0.44 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3150w (C-H str), 2942w (C-H str), 1661m (C=O str), 1601s (C=C str), 1572s (C=C str), 1514s (C=C str), 1459m, 1416m, 1324s, 1295m, 1262s, 1228m, 1166s, 1150s, 1126s, 1053w, 1015s. ¹H-NMR (500 MHz, CDCl₃): δ 3.86 (3H, s, -OCH₃), 3.87 (3H, s, -OCH₃), 3.91 (6H, s, 2 × -OCH₃), 3.92 (3H, s, -OCH₃), 3.95 (3H, s, -OCH₃), 4.46 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.84 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.40 (2H, s, -OCH₂CN-), 6.15 (2H, s, ArH), 6.85 (1H, d, J = 8.4 Hz, ArH), 6.94 (2H, d, J = 8.8 Hz, ArH), 7.17 (1H, d, J = 8.8 Hz, ArH), 7.42 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.58–7.65 (6H, m, ArH), 7.78 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.85 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.05 (1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.8, 55.4, 55.8, 55.9, 56.0, 62.9, 67.5, 90.5, 106.6, 111.1, 111.7, 112.3, 112.4, 114.4, 119.3, 121.6, 122.3, 122.6, 124.7, 127.8, 130.1, 132.1, 133.7, 135.6, 143.7, 143.9, 149.5, 149.5, 150.6, 151.6, 161.5, 161.7, 163.0, 188.6, 190.3. LCMS (ES+) *m/z* = 736.2 ([M + H]⁺, t_R = 1.67 min). HRMS (ESI+) *m/z* = 736.2892 [M + H]⁺ found, C₄₁H₄₂O₁₀N₃⁺ required 736.2865.

(*E*)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((*E*)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)prop-2-en-1-one (**92**). A mixture of alkyne chalcone **4** (167 mg, 0.494 mmol), azide chalcone **69** (206 mg, 0.498 mmol), CuSO₄·5H₂O (140 mg, 0.560 mmol) and sodium ascorbate (253 mg, 1.28 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **92** (236 mg, 64%) as a bright yellow flaky solid. m.p. 208–210 °C. TLC R_f = 0.48 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2931w (C-H str), 2842w (C-H str), 1632m (C=O str), 1597m (C=C str), 1568s (C=C str), 1509s (C=C str), 1455w, 1419w, 1371m, 1318m, 1259s, 1232s, 1211s, 1153s, 1123s, 1021m, 1004m. ¹H-NMR (500 MHz, CDCl₃): δ 3.86 (3H, s, -OCH₃), 3.87 (3H, s, -OCH₃), 3.91 (3H, s, -OCH₃), 3.91 (9H, s, 3 × -OCH₃), 4.45 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.84 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 5.38 (2H, s, -OCH₂CN-), 6.14 (2H, s, ArH), 6.46 (1H, d, J = 2.4 Hz, ArH), 6.50 (1H, dd, J = 8.8, 2.4 Hz, ArH), 6.81 (1H, d, J = 8.4 Hz, ArH), 6.89 (1H, d, J = 2.4 Hz, ArH), 7.21 (1H, dd, J = 8.0, 2.0 Hz, ArH), 7.45 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.46 (1H, d, J = 1.6 Hz, ArH), 7.55 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.61 (1H, d, J = 1.6 Hz, ArH), 7.77 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.85 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.89 (1H, d, J = 8.8 Hz, ArH), 8.05 (1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-), 13.55 (1H, s, OH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.8, 55.4, 55.5, 55.8, 55.9, 56.0, 63.2, 67.6, 90.5, 101.0, 106.6, 107.6, 111.5, 111.6, 112.3, 113.0, 114.2, 118.4, 121.5, 122.3, 124.3, 124.7, 127.8, 131.3, 133.7, 135.6, 144.0, 144.1, 147.8, 149.4, 150.6, 152.0, 161.7, 163.0, 166.0, 166.6, 190.3, 191.8. LCMS (ES+) *m/z* = 752.2 ([M + H]⁺, t_R = 1.74 min). HRMS (ESI+) *m/z* = 752.2822 [M + H]⁺ found, C₄₁H₄₂O₁₁N₃⁺ required 752.2814.

(*E*)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((*E*)-3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (**93**). A mixture of alkyne chalcone **20** (235 mg, 0.729 mmol), azide chalcone **68** (303 mg, 0.733 mmol), CuSO₄·5H₂O (271 mg, 1.09 mmol) and sodium ascorbate (414 mg, 2.09 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **93** (515 mg, 96%) as a pale yellow-green flaky solid. m.p. 128–130 °C. TLC R_f = 0.30 (4% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2937w (C-H str), 2836w (C-H str), 1652m (C=O str), 1595s (C=C str), 1572s (C=C str), 1510s (C=C str), 1494s, 1463s, 1415s, 1326w, 1255s, 1193w, 1148s, 1095s, 1021s. ¹H-NMR (500 MHz, CDCl₃): δ 3.86 (3H, s, -OCH₃), 3.90 (3H, s, -OCH₃), 3.92 (6H, s, 2 × -OCH₃), 3.95 (6H, s, 2 × -OCH₃), 4.47 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.84 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 5.40 (2H, s, -OCH₂CN-), 6.73 (1H, d, J = 8.8 Hz, ArH), 6.84 (1H, d, J = 8.4 Hz, ArH), 6.94 (2H, d, J = 8.8 Hz, ArH), 7.17 (1H, d, J = 8.8 Hz, ArH), 7.39 (1H, d, J = 8.8 Hz, ArH), 7.42 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.54 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.59–7.64 (6H, m, ArH), 7.78 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.98 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.05 (1H, s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 55.4, 56.0, 56.0, 56.1, 60.9, 61.4, 62.9, 67.5, 107.6, 111.1, 111.6, 112.3, 112.4, 114.4, 119.2, 120.8, 122.0, 122.5, 122.6, 123.9, 124.7, 127.7, 130.1, 132.1, 133.0, 139.7, 142.5, 143.7, 144.0, 149.5, 149.7, 151.1, 151.6, 153.8, 155.7, 161.5, 188.6, 189.0. LCMS (ES+) *m/z* = 736.2 ([M + H]⁺, t_R = 1.66 min). HRMS (ESI+) *m/z* = 736.2855 [M + H]⁺ found, C₄₁H₄₂O₁₀N₃⁺ required 736.2870.

(*E*)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((*E*)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-3-(1-methyl-1*H*-pyrrol-2-yl)prop-2-en-1-one (**94**). A mixture of alkyne chalcone **22** (217 mg, 0.734 mmol), azide chalcone **69** (305 mg, 0.737 mmol), CuSO₄·5H₂O (214 mg, 0.857 mmol) and sodium ascorbate (365 mg, 1.84 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **94** (367 mg, 70%) as a bright yellow flaky solid. m.p. 138–140 °C. TLC R_f = 0.31 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2941w (C-H str), 2838w (C-H str), 1646m (C=O str), 1596m (C=C str), 1566s (C=C str), 1512m (C=C str), 1470m, 1457m, 1414m, 1338w, 1321m, 1257s, 1198m, 1155s, 1146s, 1118s, 1027m. ¹H-NMR (500 MHz, CDCl₃): δ 3.77 (3H, s, -NCH₃), 3.86 (3H, s, -OCH₃), 3.91 (6H, s, 2 × -OCH₃), 3.91 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 4.45

(2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.83 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.38 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.14 (2H, s, ArH), 6.21–6.23 (1H, m, ArH), 6.80–6.86 (3H, m, ArH), 7.16 (1H, d, $J = 8.8$ Hz, ArH), 7.29 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.57–7.63 (4H, m, ArH), 7.79 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 7.85 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 8.05 (1H, s, $-\text{CHN}-$), 8.23 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 34.4, 49.7, 55.4, 55.8, 55.9, 56.0, 62.8, 67.5, 90.5, 106.5, 109.6, 111.1, 111.7, 112.1, 112.3, 112.4, 116.3, 121.5, 122.3, 122.3, 124.7, 127.6, 130.3, 131.6, 132.4, 133.7, 135.6, 143.7, 149.4, 149.5, 150.6, 151.4, 161.6, 163.0, 188.1, 190.3. LCMS (ES+) $m/z = 709.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.63$ min). HRMS (ESI+) $m/z = 709.2854$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{39}\text{H}_{41}\text{O}_9\text{N}_4^+$ required 709.2868.

(*E*)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((*E*)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (**95**). A mixture of alkyne chalcone **22** (271 mg, 0.918 mmol), azide chalcone **70** (301 mg, 0.924 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (316 g, 1.26 mmol) and sodium ascorbate (499 mg, 2.52 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **95** (555 mg, 97%) as a dark yellow-brown flaky solid. m.p. 118–120 °C. TLC $R_f = 0.38$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2941w (C-H str), 2844w (C-H str), 1644m (C=O str), 1594m (C=C str), 1564s (C=C str), 1511m (C=C str), 1480m, 1412m, 1381w, 1330m, 1258s, 1196m, 1153s, 1129m, 1055w, 1025m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.76 (3H, s, $-\text{NCH}_3$), 3.77 (3H, s, $-\text{NCH}_3$), 3.92 (3H, s, $-\text{OCH}_3$), 3.95 (3H, s, $-\text{OCH}_3$), 4.46 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.84 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.39 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.22–6.24 (2H, m, ArH), 6.82–6.86 (5H, m, ArH), 7.15 (1H, d, $J = 8.0$ Hz, ArH), 7.27 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$, overlain by CDCl_3), 7.29 (1H, d, $J = 14.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.57–7.62 (4H, m, ArH), 7.79 (2H, d, $J = 14.8$ Hz, $2 \times -\text{CH}=\text{CHCO}-$), 8.04 (1H, s, $-\text{CHN}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 34.4, 49.7, 55.9, 56.0, 62.9, 67.5, 109.6, 109.7, 111.1, 111.4, 112.1, 112.2, 112.3, 112.4, 116.2, 116.3, 122.1, 122.3, 124.7, 127.6, 127.7, 130.3, 130.3, 131.6, 131.8, 132.4, 133.1, 143.7, 149.4, 149.6, 150.9, 151.4, 188.0, 188.1. LCMS (ES+) $m/z = 622.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.62$ min). HRMS (ESI+) $m/z = 622.2648$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{35}\text{H}_{36}\text{O}_6\text{N}_5^+$ required 622.2660.

(*E*)-1-(2-Hydroxyphenyl)-3-(4-(2-(4-((*E*)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)prop-2-en-1-one (**96**). A mixture of alkyne chalcone **23** (337 mg, 1.27 mmol), azide chalcone **61** (400 mg, 1.29 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (429 mg, 1.72 mmol) and sodium ascorbate (641 mg, 3.23 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) to afford triazole hybrid **96** (399 mg, 55%) as a bright yellow-orange powdery solid. m.p. 98–100 °C. TLC $R_f = 0.40$ (3% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2933w (C-H str), 2884w (C-H str), 1635m (C=O str), 1597m (C=C str), 1562s (C=C str), 1509m (C=C str), 1480m, 1447m, 1329m, 1286m, 1268m, 1233m, 1202s, 1174s, 1156s, 1113w, 1055m, 1025s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.65 (3H, s, $-\text{NCH}_3$), 4.32 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.65 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.33 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.16–6.18 (1H, m, ArH), 6.63 (1H, dd, $J = 4.0, 1.2$ Hz, ArH), 6.76 (1H, t, $J = 2.0$ Hz, ArH), 6.85 (2H, d, $J = 8.8$ Hz, ArH), 6.95 (1H, t, $J = 8.0$ Hz, ArH), 7.03 (1H, dd, $J = 8.4, 0.8$ Hz, ArH), 7.08 (1H, d, $J = 7.6$ Hz, ArH), 7.12 (1H, d, $J = 8.4$ Hz, ArH), 7.16 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.44–7.59 (4H, m, ArH), 7.54 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.60 (1H, d, $J = 15.2$ Hz, $-\text{CH}=\text{CHCO}-$), 7.66 (1H, dd, $J = 8.0, 2.0$ Hz, ArH), 7.76 (1H, s, $-\text{CHN}-$), 7.86 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.93 (1H, dd, $J = 8.4, 1.6$ Hz, ArH), 12.89 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 34.3, 49.5, 63.0, 66.2, 109.6, 112.4, 113.0, 114.9, 118.2, 118.5, 118.8, 120.0, 121.4, 122.2, 123.9, 127.7, 128.2, 129.5, 130.0, 130.1, 130.5, 130.6, 132.7, 136.2, 144.1, 144.8, 156.5, 159.9, 163.5, 191.9, 193.5. LCMS (ES+) $m/z = 575.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.72$ min). HRMS (ESI+) $m/z = 575.2266$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{34}\text{H}_{31}\text{O}_5\text{N}_4^+$ required 575.2289.

(*E*)-3-(Ferrocenyl)-1-(4-((1-(2-(4-((*E*)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)prop-2-en-1-one (**97**). A mixture of alkyne chalcone **25** (301 mg, 0.753 mmol), azide chalcone **61** (235 mg, 0.760 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (225 mg, 0.900 mmol) and sodium ascorbate (398 mg, 2.01 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The

crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **97** (427 mg, 80%) as a dark red-brown powdery solid. m.p. 178–180 °C. TLC R_f = 0.28 (2% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2937w (C-H str), 1740m (C=O str), 1651m, 1637s, 1596s (C=C str), 1571s (C=C str), 1510s (C=C str), 1487m, 1444m, 1341w, 1300m, 1266s, 1203s, 1179s, 1159s, 1146s, 1048m, 1020s. ¹H-NMR (500 MHz, CDCl₃): δ 3.98 (3H, s, -OCH₃), 4.16 (5H, s, -C₅H₅), 4.42 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.47 (2H, t, J = 2.0 Hz, -C₅H₄), 4.56 (2H, t, J = 2.0 Hz, -C₅H₄), 4.80 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.43 (2H, s, -OCH₂CN-), 6.84 (2H, d, J = 8.8 Hz, ArH), 6.97 (1H, t, J = 8.0 Hz, ArH), 7.04 (1H, dd, J = 8.4, 0.8 Hz, ArH), 7.12 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.12 (1H, d, J = 8.4 Hz, ArH), 7.51 (1H, t, J = 8.4 Hz, ArH), 7.54–7.61 (3H, m, ArH), 7.59 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.64 (1H, d, J = 1.6 Hz, ArH), 7.74 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.86 (1H, s, -CHN-), 7.86 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.97 (1H, dd, J = 8.0, 1.6 Hz, ArH), 12.90 (1H, s, OH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 56.1, 62.8, 66.3, 68.9, 69.7, 71.3, 79.2, 111.1, 112.3, 114.9, 118.3, 118.5, 118.6, 118.8, 120.0, 122.4, 124.3, 128.4, 129.6, 130.6, 132.3, 136.3, 143.8, 144.7, 146.1, 149.5, 151.2, 159.8, 163.6, 187.9, 193.6. LCMS (ES+) m/z = 710.2 ([M + H]⁺, t_R = 2.09 min). HRMS (ESI+) m/z = 710.1889 [M + H]⁺ found, C₄₀H₃₆N₃O₆Fe⁺ required 710.1875.

(E)-3-((1-(2-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)-2-methoxyphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4H-chromen-4-one (**98**). A mixture of alkyne flavone **30** (806 mg, 2.92 mmol), azide chalcone **67** (1.01 g, 2.64 mmol), CuSO₄·5H₂O (716 mg, 2.87 mmol) and sodium ascorbate (1.29 g, 6.51 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **98** (622 mg, 36%) as a pale yellow-green powdery solid. m.p. 102–104 °C. TLC R_f = 0.24 (3% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2940w (C-H str), 2836w (C-H str), 1644m (C=O str), 1596m (C=C str), 1579m (C=C str), 1510s (C=C str), 1467m, 1420w, 1398w, 1260s, 1237s, 1196m, 1146s, 1138s, 1022s. ¹H-NMR (500 MHz, CDCl₃): δ 3.87 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 3.96 (3H, s, -OCH₃), 4.38 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.74 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.32 (2H, s, -OCH₂CN-), 6.84 (1H, d, J = 8.4 Hz, ArH), 6.90 (1H, d, J = 8.4 Hz, ArH), 7.16 (1H, d, J = 1.6 Hz, ArH), 7.24 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.39 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.39–7.44 (4H, m, ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 7.59 (1H, d, J = 1.6 Hz, ArH), 7.62 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.69 (1H, t, J = 8.4 Hz, ArH), 7.77 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.96 (1H, s, -CHN-), 7.97–8.00 (2H, m, ArH), 8.27 (1H, dd, J = 8.0, 1.6 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.4, 56.0, 56.0, 65.1, 67.4, 110.2, 111.1, 111.5, 112.2, 118.1, 119.5, 122.4, 123.0, 124.1, 124.8, 125.3, 125.7, 127.9, 128.3, 128.7, 130.6, 130.7, 132.7, 133.5, 139.4, 143.9, 144.5, 149.2, 149.7, 151.3, 151.3, 155.3, 156.4, 175.0, 188.6. LCMS (ES+) m/z = 660.2 ([M + H]⁺, t_R = 1.64 min). HRMS (ESI+) m/z = 660.2325 [M + H]⁺ found, C₃₈H₃₄O₈N₃⁺ required 660.2340.

(E)-3-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4H-chromen-4-one (**99**). A mixture of alkyne flavone **30** (205 mg, 0.742 mmol), azide chalcone **68** (306 mg, 0.739 mmol), CuSO₄·5H₂O (204 mg, 0.818 mmol) and sodium ascorbate (365 mg, 1.84 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **99** (178 mg, 35%) as an off-white powdery solid. m.p. 120–122 °C. TLC R_f = 0.28 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2941w (C-H str), 2838w (C-H str), 1740w, 1645s (C=O str), 1581s (C=C str), 1563m (C=C str), 1516w (C=C str), 1494s, 1466s, 1414m, 1403m, 1264s, 1238m, 1195m, 1148m, 1096s, 1039m, 1027m. ¹H-NMR (500 MHz, CDCl₃): δ 3.86 (3H, s, -OCH₃), 3.90 (3H, s, -OCH₃), 3.92 (3H, s, -OCH₃), 3.95 (3H, s, -OCH₃), 4.36 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.73 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.33 (2H, s, -OCH₂CN-), 6.73 (1H, d, J = 8.8 Hz, ArH), 6.84 (1H, d, J = 8.0 Hz, ArH), 7.38–7.44 (5H, m, ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 7.55 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.59–7.62 (2H, m, ArH), 7.69 (1H, t, J = 8.4 Hz, ArH), 7.95 (1H, s, -CHN-), 7.96–7.99 (2H, m, ArH), 7.99 (1H, d, J = 15.6 Hz, -CH=CHCO-), 8.28 (1H, dd, J = 8.0, 1.2 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.4, 55.9, 56.1, 60.9, 61.4, 65.1, 67.4, 107.6, 111.5, 112.2, 118.1, 120.9, 122.0, 122.4, 123.9, 124.1, 124.8, 125.3, 125.7, 128.3, 128.7, 130.6, 130.7, 132.8, 133.5, 139.4, 139.7, 142.5, 143.9, 149.6, 151.2, 153.7, 155.3, 155.7,

156.4, 175.0, 189.0. LCMS (ES+) $m/z = 690.2$ ($[M + H]^+$, $t_R = 1.95$ min). HRMS (ESI+) $m/z = 690.2425$ $[M + H]^+$ found, $C_{39}H_{36}O_9N_3^+$ required 690.2446.

(*E*)-3-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4*H*-chromen-4-one (**100**). A mixture of alkyne flavone **30** (207 mg, 0.749 mmol), azide chalcone **69** (306 mg, 0.741 mmol), $CuSO_4 \cdot 5H_2O$ (203 mg, 0.814 mmol) and sodium ascorbate (369 mg, 1.86 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **100** (342 mg, 67%) as a white powdery solid. m.p. 172–174 °C. TLC $R_f = 0.30$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2941w (C-H str), 2843w (C-H str), 1737w, 1643s (C=O str), 1599s (C=C str), 1575s (C=C str), 1515m (C=C str), 1465m, 1416m, 1322m, 1261m, 1231s, 1216m, 1192m, 1149s, 1125s, 1027s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.85 (3H, s, -OCH₃), 3.88 (3H, s, -OCH₃), 3.92 (6H, s, 2 × -OCH₃), 4.35 (2H, t, $J = 5.2$ Hz, -OCH₂CH₂N-), 4.72 (2H, t, $J = 5.2$ Hz, -OCH₂CH₂N-), 5.35 (2H, s, -OCH₂CN-), 6.16 (2H, s, ArH), 6.84 (1H, d, $J = 8.8$ Hz, ArH), 7.38–7.44 (4H, m, ArH), 7.50 (1H, d, $J = 8.4$ Hz, ArH), 7.60–7.62 (2H, m, ArH), 7.70 (1H, t, $J = 8.8$ Hz, ArH), 7.87 (1H, d, $J = 16.0$ Hz, -CH=CHCO-), 7.94 (1H, s, -CHN-), 7.95–7.98 (2H, m, ArH), 8.25 (1H, d, $J = 16.0$ Hz, -CH=CHCO-), 8.29 (1H, dd, $J = 8.4, 1.6$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.4, 55.4, 55.8, 55.8, 65.0, 67.3, 90.5, 106.5, 111.7, 112.3, 118.1, 121.6, 122.3, 124.1, 124.7, 125.2, 125.7, 128.2, 128.7, 130.6, 130.7, 133.5, 133.5, 135.6, 139.3, 143.8, 149.4, 150.7, 155.2, 156.4, 161.6, 163.0, 175.0, 190.4. LCMS (ES+) $m/z = 690.2$ ($[M + H]^+$, $t_R = 1.73$ min). HRMS (ESI+) $m/z = 690.2476$ $[M + H]^+$ found, $C_{39}H_{36}O_9N_3^+$ required 690.2446.

(*E*)-6-((1-(2-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)-2-methoxyphenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4*H*-chromen-4-one (**101**). A mixture of alkyne flavone **31** (179 mg, 0.648 mmol), azide chalcone **67** (246 mg, 0.641 mmol), $CuSO_4 \cdot 5H_2O$ (188 mg, 0.753 mmol) and sodium ascorbate (322 mg, 1.63 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **101** (366 mg, 87%) as a bright orange crystalline solid. m.p. 128–130 °C. TLC $R_f = 0.34$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2940w (C-H str), 2831w (C-H str), 1637s (C=O str), 1618m, 1595s (C=C str), 1571s (C=C str), 1510s (C=C str), 1481m, 1454s, 1419m, 1360s, 1257s, 1235m, 1198m, 1140s, 1023s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.92 (3H, s, -OCH₃), 3.93 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 4.47 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 4.86 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 5.29 (2H, s, -OCH₂CN-), 6.79 (1H, s, -C=CH), 6.85 (1H, d, $J = 8.8$ Hz, ArH), 6.89 (1H, d, $J = 8.4$ Hz, ArH), 7.14 (1H, d, $J = 1.6$ Hz, ArH), 7.22 (1H, dd, $J = 8.4, 2.0$ Hz, ArH), 7.33 (1H, dd, $J = 9.2, 3.2$ Hz, ArH), 7.36 (1H, d, $J = 15.2$ Hz, -CH=CHCO-), 7.49–7.52 (4H, m, ArH), 7.59–7.61 (2H, m, ArH), 7.71 (1H, d, $J = 3.2$ Hz, ArH), 7.73 (1H, d, $J = 16.0$ Hz, -CH=CHCO-), 7.88–7.91 (2H, m, ArH), 8.04 (1H, s, -CHN-). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.7, 55.9, 56.0, 62.3, 67.5, 106.3, 106.7, 110.1, 111.1, 111.5, 112.3, 119.4, 119.7, 122.5, 123.0, 123.9, 124.5, 124.6, 126.2, 127.8, 129.0, 131.5, 131.7, 132.7, 143.3, 144.5, 149.2, 149.7, 151.2, 151.2, 151.3, 155.5, 163.2, 178.1, 188.5. LCMS (ES+) $m/z = 660.2$ ($[M + H]^+$, $t_R = 1.81$ min). HRMS (ESI+) $m/z = 682.2153$ $[M + Na]^+$ found, $C_{38}H_{33}O_8N_3Na^+$ required 682.2160.

(*E*)-6-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4*H*-chromen-4-one (**102**). A mixture of alkyne flavone **31** (211 mg, 0.763 mmol), azide chalcone **69** (317 mg, 0.767 mmol), $CuSO_4 \cdot 5H_2O$ (211 mg, 0.843 mmol) and sodium ascorbate (382 mg, 1.93 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **102** (397 mg, 75%) as a bright yellow-orange flaky solid. m.p. 128–130 °C. TLC $R_f = 0.25$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2941w (C-H str), 2838w (C-H str), 1739w, 1640s (C=O str), 1598s (C=C str), 1569s (C=C str), 1517m (C=C str), 1455s, 1363m, 1320m, 1279m, 1261m, 1201s, 1154s, 1122s, 1035s, 1025s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.84 (3H, s, -OCH₃), 3.89 (6H, s, 2 × -OCH₃), 3.92 (3H, s, -OCH₃), 4.45 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 4.85 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 5.28 (2H, s, -OCH₂CN-), 6.12 (2H, s, ArH), 6.79 (1H, s, -C=CH), 6.84 (1H,

d, $J = 8.4$ Hz, ArH), 7.33 (1H, dd, $J = 9.2, 3.2$ Hz, ArH), 7.48–7.51 (4H, m, ArH), 7.57 (1H, dd, $J = 8.0, 1.6$ Hz, ArH), 7.61 (1H, d, $J = 1.6$ Hz, ArH), 7.71 (1H, d, $J = 2.8$ Hz, ArH), 7.84 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.88–7.91 (2H, m, ArH), 8.06 (1H, s, $-\text{CHN}-$), 8.21 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.7, 55.3, 55.7, 55.9, 62.3, 67.5, 90.5, 106.2, 106.5, 106.7, 111.6, 112.4, 119.6, 121.4, 122.3, 123.9, 124.4, 124.6, 126.2, 128.9, 131.5, 131.7, 133.6, 135.5, 143.3, 149.4, 150.6, 151.2, 155.6, 161.6, 163.0, 163.2, 178.1, 190.3. LCMS (ES+) $m/z = 690.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.88$ min). HRMS (ESI+) $m/z = 690.2426$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{39}\text{H}_{36}\text{O}_9\text{N}_3^+$ required 690.2446.

(*E*)-6-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-2-phenyl-4H-chromen-4-one (**103**). A mixture of alkyne flavone **31** (201 mg, 0.729 mmol), azide chalcone **68** (304 mg, 0.735 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (208 mg, 0.831 mmol) and sodium ascorbate (383 mg, 1.93 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **103** (382 mg, 76%) as a pale yellow flaky solid. m.p. 138–140 °C. TLC $R_f = 0.32$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2939w (C-H str), 2839w (C-H str), 1740w, 1640s (C=O str), 1619m, 1593m (C=C str), 1573s (C=C str), 1516m (C=C str), 1495m, 1482m, 1455s, 1415m, 1360s, 1259s, 1200m, 1157m, 1095s, 1026s. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.89 (3H, s, $-\text{OCH}_3$), 3.90 (3H, s, $-\text{OCH}_3$), 3.93 (3H, s, $-\text{OCH}_3$), 3.94 (3H, s, $-\text{OCH}_3$), 4.47 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.86 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.29 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.72 (1H, d, $J = 8.8$ Hz, ArH), 6.80 (1H, s, $-\text{C}=\text{CH}$), 6.86 (1H, d, $J = 8.0$ Hz, ArH), 7.34 (1H, dd, $J = 9.2, 3.2$ Hz, ArH), 7.37 (1H, d, $J = 8.8$ Hz, ArH), 7.49–7.52 (4H, m, ArH), 7.53 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.58–7.61 (2H, m, ArH), 7.71 (1H, d, $J = 3.2$ Hz, ArH), 7.89–7.92 (2H, m, ArH), 7.96 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 8.05 (1H, s, $-\text{CHN}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.7, 56.0, 56.0, 60.9, 61.3, 62.3, 67.5, 106.3, 106.8, 107.5, 111.5, 112.3, 119.7, 120.8, 122.0, 122.4, 123.8, 123.9, 124.5, 124.6, 126.2, 129.0, 131.5, 131.7, 132.8, 139.6, 142.4, 143.3, 149.6, 151.1, 151.2, 153.7, 155.6, 155.7, 163.2, 178.1, 188.9. LCMS (ES+) $m/z = 690.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.94$ min). HRMS (ESI+) $m/z = 690.2452$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{39}\text{H}_{36}\text{N}_3\text{O}_9^+$ required 690.2452.

(*E*)-7-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-2-phenyl-4H-chromen-4-one (**104**). A mixture of alkyne flavone **32** (202 mg, 0.730 mmol), azide chalcone **69** (304 mg, 0.735 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (218 mg, 0.872 mmol) and sodium ascorbate (386 mg, 1.95 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **104** (324 mg, 64%) as a pale yellow-white powdery solid. m.p. 168–170 °C. TLC $R_f = 0.25$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2941w (C-H str), 2841w (C-H str), 1736w, 1634s (C=O str), 1599s (C=C str), 1566s (C=C str), 1512m (C=C str), 1451m, 1441m, 1336s, 1302w, 1279m, 1261m, 1204m, 1175m, 1160w, 1122s, 1092w, 1053w, 1037m, 1016w. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.87 (3H, s, $-\text{OCH}_3$), 3.91 (6H, s, $2 \times -\text{OCH}_3$), 3.93 (3H, s, $-\text{OCH}_3$), 4.48 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.87 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.35 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.14 (2H, s, ArH), 6.77 (1H, s, $-\text{C}=\text{CH}$), 6.86 (1H, d, $J = 8.0$ Hz, ArH), 7.06 (1H, dd, $J = 8.8, 2.0$ Hz, ArH), 7.14 (1H, d, $J = 2.0$ Hz, ArH), 7.49–7.53 (3H, m, ArH), 7.59 (1H, dd, $J = 8.4, 2.0$ Hz, ArH), 7.63 (1H, d, $J = 1.6$ Hz, ArH), 7.84 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.90–7.92 (2H, m, ArH), 8.07 (1H, s, $-\text{CHN}-$), 8.15 (1H, d, $J = 8.8$ Hz, ArH), 8.23 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.8, 55.3, 55.7, 55.8, 62.3, 67.4, 90.4, 101.4, 106.4, 107.3, 111.6, 112.4, 114.8, 118.0, 121.3, 122.3, 124.7, 126.1, 127.0, 128.9, 131.4, 131.6, 133.6, 135.6, 143.0, 149.4, 150.5, 157.8, 161.6, 162.6, 163.0, 163.1, 177.7, 190.2. LCMS (ES+) $m/z = 690.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.70$ min). HRMS (ESI+) $m/z = 690.2471$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{39}\text{H}_{36}\text{O}_9\text{N}_3^+$ required 690.2446.

(*E*)-2-(4-(2-(4-((2-(3-(Ferrocenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-hydroxy-7-methoxy-4H-chromen-4-one (**105**). A mixture of alkyne chalcone **26** (310 mg, 0.838 mmol), azide flavonol **80** (296 mg, 0.838 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (273 mg, 1.09 mmol) and sodium ascorbate (496 mg, 2.50 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) to afford triazole hybrid **105** (238 mg, 40%) as

a dark red powdery solid. m.p. 118–120 °C. TLC R_f = 0.44 (5% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 3340w (O-H str), 3088w (C-H str), 2929w (C-H str), 1735m (C=O str), 1597s (C=C str), 1541m (C=C str), 1506m (C=C str), 1484m, 1449m, 1403m, 1235s, 1206s, 1171s, 1117m, 1106m, 1044w, 1025s. ¹H-NMR (500 MHz, CDCl₃): δ 3.96 (3H, s, -OCH₃), 4.12 (5H, s, -C₅H₅), 4.35 (2H, t, J = 4.5 Hz, -OCH₂CH₂N-), 4.43 (2H, t, J = 1.5 Hz, -C₅H₄), 4.48 (2H, t, J = 1.5 Hz, -C₅H₄), 4.67 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 5.33 (2H, br s, -OCH₂CN-), 6.95–6.97 (4H, m, ArH and OH), 6.96 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.01 (1H, dd, J = 9.0, 2.0 Hz, ArH), 7.09 (1H, t, J = 7.5 Hz, ArH), 7.14 (1H, d, J = 8.5 Hz, ArH), 7.46 (1H, dd, J = 7.5, 1.0 Hz, ArH), 7.50 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.60 (1H, dd, J = 7.5, 1.5 Hz, ArH), 7.77 (1H, br s, -CHN-), 8.14 (1H, d, J = 9.0 Hz, ArH), 8.19 (2H, d, J = 8.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.6, 55.8, 63.0, 66.1, 68.9, 69.8, 71.3, 79.0, 99.9, 113.1, 114.5, 114.6, 114.7, 121.4, 124.0, 124.7, 126.7, 129.3, 130.1, 130.2, 132.4, 137.4, 144.1, 145.5, 156.3, 157.2, 158.8, 164.2, 172.6, 192.3. LCMS (ES+) m/z = 724.2 ([M + H]⁺, t_R = 2.01 min). HRMS (ESI+) m/z = 724.1711 [M + H]⁺ found, C₄₀H₃₄N₃O₇Fe⁺ required 724.1746.

(*E*)-2-(4-(2-(4-((4-(3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-hydroxy-4H-chromen-4-one (**106**). A mixture of alkyne chalcone **25** (308 mg, 0.769 mmol), azide flavonol **79** (252 mg, 0.779 mmol), CuSO₄·5H₂O (209 mg, 0.835 mmol) and sodium ascorbate (395 mg, 1.99 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **106** (212 mg, 38%) as a dark-red powdery solid. m.p. 158–160 °C. TLC R_f = 0.26 (3% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 3429w (O-H str), 2943w (C-H str), 2873w (C-H str), 1735m (C=O str), 1645w, 1596s (C=C str), 1568s (C=C str), 1509s (C=C str), 1469m, 1418m, 1409m, 1348w, 1292w, 1254s, 1200w, 1180m, 1151m, 1108m, 1027m. ¹H-NMR (500 MHz, CDCl₃): δ 3.97 (3H, s, -OCH₃), 4.17 (5H, s, -C₅H₅), 4.46–4.48 (4H, m, -C₅H₄ and -OCH₂CH₂N-), 4.57 (2H, t, J = 2.0 Hz, -C₅H₄), 4.83 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 5.43 (2H, s, -OCH₂CN-), 6.94 (1H, br s, OH), 6.98 (2H, d, J = 9.0 Hz, ArH), 7.12 (1H, d, J = 15.0 Hz, -CH=CHCO-), 7.15 (1H, d, J = 8.5 Hz, ArH), 7.43 (1H, t, J = 8.0 Hz, ArH), 7.57 (1H, dd, J = 8.0, 1.5 Hz, ArH), 7.59 (1H, d, J = 8.5 Hz, ArH), 7.63 (1H, d, J = 2.0 Hz, ArH), 7.71 (1H, t, J = 8.0 Hz, ArH), 7.73 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.90 (1H, br s, -CHN-), 8.22 (2H, d, J = 9.0 Hz, ArH), 8.25 (1H, dd, J = 8.0, 1.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 56.1, 62.9, 66.3, 68.9, 69.7, 71.2, 79.3, 111.2, 112.3, 114.5, 118.2, 118.5, 120.7, 122.4, 124.3, 124.5, 124.6, 125.4, 129.6, 132.3, 133.5, 137.8, 143.8, 144.7, 146.0, 149.5, 151.3, 155.2, 159.0, 173.2, 187.9. LCMS (ES+) m/z = 724.2 ([M + H]⁺, t_R = 2.04 min). HRMS (ESI+) m/z = 724.1723 [M + H]⁺ found, C₄₀H₃₄N₃O₇Fe⁺ required 724.1746.

(*E*)-2-(3-(2-(4-((4-Bromo-2-(3-(1-methyl-1H-indol-3-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-ethoxy)-4-methoxyphenyl)-3-hydroxy-4H-chromen-4-one (**107**). A mixture of alkyne chalcone **21** (339 mg, 0.859 mmol), azide flavonol **82** (301 mg, 0.853 mmol), CuSO₄·5H₂O (542 mg, 2.17 mmol) and sodium ascorbate (202 mg, 1.02 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **107** (258 mg, 40%) as a brown powdery solid. m.p. 158–160 °C. TLC R_f = 0.44 (5% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 3351w (O-H str), 2920m (C-H str), 2852w (C-H str), 1640m (C=O str), 1589s (C=C str), 1559m (C=C str), 1514m (C=C str), 1492m, 1471m, 1397m, 1374m, 1333w, 1269s, 1204m, 1180m, 1130s, 1074w, 1047m, 1020m. ¹H-NMR (500 MHz, CDCl₃): δ 3.64 (3H, s, -NCH₃), 3.83 (3H, s, -OCH₃), 4.02 (2H, t, J = 4.5 Hz, -OCH₂CH₂N-), 4.49 (2H, t, J = 4.5 Hz, -OCH₂CH₂N-), 5.36 (2H, br s, -OCH₂CN-), 6.96 (1H, d, J = 9.0 Hz, ArH), 7.02 (1H, br s, OH), 7.07 (1H, d, J = 8.5 Hz, ArH), 7.10–7.13 (1H, m, ArH), 7.18 (1H, s, ArH), 7.23 (2H, d, J = 3.5 Hz, ArH), 7.38 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.45 (1H, t, J = 7.5 Hz, ArH), 7.50 (1H, d, J = 1.5 Hz, ArH), 7.53 (1H, d, J = 7.5 Hz, ArH), 7.56 (1H, dd, J = 8.5, 2.5 Hz, ArH), 7.60 (1H, d, J = 8.5 Hz, ArH), 7.73 (1H, t, J = 7.0 Hz, ArH), 7.77 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.83 (1H, d, J = 2.5 Hz, ArH), 7.90 (1H, dd, J = 8.5, 1.5 Hz, ArH), 8.06 (1H, br s, -CHN-), 8.27 (1H, d, J = 8.0 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 33.0, 49.5, 55.9, 63.5, 67.1, 109.9, 111.4, 112.6, 113.2, 114.0, 114.8, 118.1, 120.5, 120.6, 121.4, 121.6, 122.6, 123.0, 123.3, 123.7, 124.6, 124.8, 125.4, 125.7, 131.9, 133.3, 133.6, 134.8, 134.9, 137.7, 137.8, 138.0, 144.5,

146.9, 151.3, 155.1, 155.8, 173.0, 190.5. LCMS (ES+) $m/z = 749.2$ ($[M + H]^+$, $t_R = 1.99$ min). HRMS (ESI+) $m/z = 769.1232$ $[M + Na]^+$ found, $C_{39}H_{31}O_7N_4BrNa^+$ required 769.1268.

(*E*)-2-(4-(2-(4-((4-Bromo-2-(3-(furan-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-3-methoxyphenyl)-3-hydroxy-4H-chromen-4-one (**108**). A mixture of alkyne chalcone **24** (289 mg, 0.872 mmol), azide flavonol **81** (304 mg, 0.860 mmol), $CuSO_4 \cdot 5H_2O$ (234 mg, 0.936 mmol) and sodium ascorbate (476 mg, 2.40 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **108** (245 mg, 42%) as a dark yellow-brown powdery solid. m.p. 118–120 °C. TLC $R_f = 0.41$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3275w (O-H str), 3110w (C-H str), 2926w (C-H str), 1650m (C=O str), 1598s (C=C str), 1549m (C=C str), 1515s (C=C str), 1481s, 1422w, 1398m, 1267s, 1232m, 1207s, 1177m, 1145s, 1111m, 1041m, 1017m, 1008m. 1H -NMR (500 MHz, $CDCl_3$): δ 3.90 (3H, s, -OCH₃), 4.43 (2H, t, $J = 4.0$ Hz, -OCH₂CH₂N-), 4.75 (2H, t, $J = 4.0$ Hz, -OCH₂CH₂N-), 5.33 (2H, br s, -OCH₂CN-), 6.47 (1H, d, $J = 1.5$ Hz, ArH), 6.64 (1H, d, $J = 3.0$ Hz, ArH), 6.89 (1H, d, $J = 8.5$ Hz, ArH), 7.01 (1H, s, ArH), 7.06–7.08 (1H, m, ArH), 7.25 (1H, d, $J = 16.0$ Hz, -CH=CHCO-, overlain by $CDCl_3$), 7.36 (1H, d, $J = 15.5$ Hz, -CH=CHCO-), 7.44 (1H, t, $J = 7.5$ Hz, ArH), 7.52 (1H, s, ArH), 7.54 (1H, d, $J = 6.5$ Hz, ArH), 7.61 (1H, d, $J = 8.5$ Hz, ArH), 7.72 (1H, d, $J = 7.0$ Hz, ArH), 7.74 (1H, d, $J = 2.0$ Hz, ArH), 7.82 (1H, d, $J = 8.5$ Hz, ArH), 7.84 (1H, s, -CHN-), 8.09 (1H, br s, OH), 8.26 (1H, d, $J = 7.5$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.9, 55.8, 63.2, 67.5, 111.4, 112.7, 113.6, 113.9, 115.1, 116.1, 118.2, 120.6, 121.1, 124.0, 124.5, 125.2, 125.4, 129.6, 131.1, 133.0, 133.5, 135.4, 137.9, 144.6, 145.0, 148.7, 149.4, 151.4, 155.2, 155.7, 173.1, 190.2. LCMS (ES+) $m/z = 686.2$ ($[M + H]^+$, $t_R = 2.00$ min). HRMS (ESI+) $m/z = 684.0955$ $[M + H]^+$ found, $C_{34}H_{27}O_8N_3Br^+$ required 684.0976.

6-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one (**109**). A mixture of alkyne flavone **30** (277 mg, 1.00 mmol), azide flavone **85** (307 mg, 0.998 mmol), $CuSO_4 \cdot 5H_2O$ (303 mg, 1.21 mmol) and sodium ascorbate (492 mg, 2.48 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) to afford triazole hybrid **109** (534 mg, 92%) as a white powdery solid. m.p. 234–236 °C. TLC $R_f = 0.36$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3145w (C-H str), 2940w (C-H str), 1736w, 1643s (C=O str), 1627s, 1600m, 1570m (C=C str), 1561m (C=C str), 1482m, 1470m, 1455s, 1398m, 1361s, 1293m, 1197s, 1187m, 1148m, 1087m, 1047m, 1026w. 1H -NMR (500 MHz, $CDCl_3$): δ 4.41 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 4.73 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 5.34 (2H, s, -OCH₂CN-), 6.83 (1H, s, -C=CH), 7.25 (1H, dd, $J = 9.2, 3.2$ Hz, ArH, overlain by $CDCl_3$), 7.41–7.46 (4H, m, ArH), 7.51–7.55 (5H, m, ArH), 7.58 (1H, d, $J = 3.2$ Hz, ArH), 7.70 (1H, t, $J = 7.2$ Hz, ArH), 7.81 (1H, s, -CHN-), 7.92–7.94 (2H, m, ArH), 8.01–8.04 (2H, m, ArH), 8.29 (1H, d, $J = 7.2$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.4, 65.1, 66.7, 105.9, 106.9, 118.0, 119.9, 123.8, 124.1, 124.5, 124.8, 125.7, 126.2, 128.3, 128.7, 129.0, 130.7, 131.6, 131.7, 133.5, 139.5, 144.0, 151.4, 155.1, 155.3, 156.4, 163.3, 175.1, 178.0. LCMS (ES+) $m/z = 584.1$ ($[M + H]^+$, $t_R = 1.91$ min). HRMS (ESI+) $m/z = 606.1610$ $[M + Na]^+$ found, $C_{35}H_{25}O_6N_3Na^+$ required 606.1636.

3-Hydroxy-2-(4-(2-(4-(((4-oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-4H-chromen-4-one (**110**). A mixture of alkyne flavone **30** (272 mg, 0.984 mmol), azide flavonol **79** (311 mg, 0.961 mmol), $CuSO_4 \cdot 5H_2O$ (274 mg, 1.10 mmol) and sodium ascorbate (557 mg, 2.81 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **110** (272 mg, 47%) as an off-white powdery solid. m.p. 148–150 °C. TLC $R_f = 0.34$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3254w(br) (O-H str), 2964w (C-H str), 1602s (C=O str), 1564m (C=C str), 1549m (C=C str), 1509s (C=C str), 1481m, 1469s, 1427m, 1403s, 1282m, 1250s, 1198m, 1183s, 1150w, 1116m, 1109m, 1041m. 1H -NMR (500 MHz, $CDCl_3$): δ 4.39 (2H, t, $J = 5.5$ Hz, -OCH₂CH₂N-), 4.73 (2H, t, $J = 5.5$ Hz, -OCH₂CH₂N-), 5.33 (2H, s, -OCH₂CN-), 6.99 (3H, d, $J = 9.0$ Hz, ArH and OH), 7.41–7.46 (5H, m, ArH), 7.53 (1H, dd, $J = 8.0, 0.5$ Hz, ArH), 7.59 (1H, d, $J = 8.0$ Hz, ArH), 7.68–7.72 (2H, m, ArH), 7.85 (1H, s, -CHN-), 8.01–8.03 (2H, m, ArH), 8.23 (2H, d, $J = 9.0$ Hz, ArH), 8.25 (1H, dd, $J = 8.0$,

1.5 Hz, ArH), 8.29 (1H, dd, $J = 8.0, 1.5$ Hz, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.5, 65.1, 66.2, 114.5, 118.1, 118.2, 120.7, 124.1, 124.5, 124.5, 124.8, 125.0, 125.4, 125.7, 128.4, 128.7, 129.6, 130.7, 133.5, 133.6, 137.8, 139.5, 144.1, 144.8, 155.3, 155.3, 156.4, 159.1, 173.2, 175.1. LCMS (ES+) $m/z = 600.0$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.75$ min). HRMS (ESI+) $m/z = 600.1755$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{35}\text{H}_{26}\text{O}_7\text{N}_3^+$ required 600.1765.

3-Hydroxy-2-(4-((1-(2-(4-(3-hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)phenyl)-4H-chromen-4-one (111). A mixture of alkyne flavonol **36** (273 mg, 0.933 mmol), azide flavonol **79** (310 mg, 0.958 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (296 mg, 1.19 mmol) and sodium ascorbate (461 mg, 2.33 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **111** (82.7 mg, 14%) as a dark brown powdery solid. m.p. 218–220 °C. TLC $R_f = 0.41$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3284w (O-H str), 3087w (C-H str), 2924w (C-H str), 1600s (C=O str), 1563m (C=C str), 1543m (C=C str), 1508s (C=C str), 1491s, 1424s, 1409s, 1248s, 1209m, 1180s, 1108s, 1043m, 1014w. ^1H -NMR (500 MHz, $\text{DMSO}-d_6$): δ 4.53 (2H, t, $J = 4.5$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.85 (2H, t, $J = 4.5$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.29 (2H, s, $-\text{OCH}_2\text{CN}-$), 7.11 (2H, d, $J = 8.5$ Hz, ArH), 7.25 (2H, d, $J = 8.5$ Hz, ArH), 7.43–7.47 (2H, m, ArH), 7.71–7.80 (4H, m, ArH), 8.09 (2H, t, $J = 6.5$ Hz, ArH), 8.17 (2H, d, $J = 9.0$ Hz, ArH), 8.21 (2H, d, $J = 9.0$ Hz, ArH), 8.39 (1H, s, $-\text{CHN}-$), 9.47 (1H, s, OH), 9.48 (1H, s, OH). ^{13}C -NMR (500 MHz, $\text{DMSO}-d_6$): δ 49.0, 61.1, 66.3, 114.6, 114.8, 115.4, 118.3, 121.3, 123.9, 124.1, 124.5, 124.7, 125.4, 129.4, 129.6, 133.4, 133.5, 138.2, 142.4, 145.3, 145.4, 154.4, 158.9, 159.1, 172.6. LCMS (ES+) $m/z = 616.1$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.68$ min). HRMS (ESI+) $m/z = 616.1722$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{35}\text{H}_{26}\text{N}_3\text{O}_8^+$ required 616.1720.

3-(4-Methoxyphenyl)-7-((1-(2-((4-oxo-2-phenyl-4H-chromen-6-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-4H-chromen-4-one (112). A mixture of alkyne isoflavone **46** (280 mg, 0.914 mmol), azide flavone **85** (282 mg, 0.919 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (279 mg, 1.12 mmol) and sodium ascorbate (503 mg, 2.54 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **112** (531 mg, 95%) as a white powdery solid. m.p. 234–236 °C. TLC $R_f = (3\%$ MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3082w (C-H str), 2941w (C-H str), 1641s, 1625s (C=O str), 1608s, 1567s (C=C str), 1515s (C=C str), 1497w, 1483w, 1456s, 1443s, 1359s, 1292s, 1252s, 1204m, 1192m, 1185s, 1137w, 1099m, 1084m, 1047s, 1032s. ^1H -NMR (500 MHz, CDCl_3): δ 3.83 (3H, s, $-\text{OCH}_3$), 4.50 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.86 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.36 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.82 (1H, s, $-\text{C}=\text{CH}$), 6.95 (2H, d, $J = 8.4$ Hz, ArH), 7.01 (1H, d, $J = 2.0$ Hz, ArH), 7.07 (1H, dd, $J = 8.8, 2.0$ Hz, ArH), 7.18 (1H, dd, $J = 8.8, 3.2$ Hz, ArH), 7.48–7.56 (6H, m, ArH), 7.59 (1H, d, $J = 3.2$ Hz, ArH), 7.86 (1H, s, $-\text{CHN}-$), 7.90–7.92 (3H, m, $-\text{C}=\text{CH}$ and ArH), 8.22 (1H, d, $J = 8.4$ Hz, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.8, 55.3, 62.4, 66.8, 101.3, 106.2, 106.9, 113.9, 115.0, 118.8, 119.9, 123.4, 124.0, 124.1, 124.6, 124.9, 126.3, 127.9, 129.1, 130.1, 131.7, 143.3, 151.5, 152.1, 155.0, 157.7, 159.6, 162.3, 163.5, 175.8, 178.0. LCMS (ES+) $m/z = 614.2$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 1.94$ min). HRMS (ESI+) $m/z = 614.1942$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{36}\text{H}_{28}\text{N}_3\text{O}_7^+$ required 614.1927.

(E)-7-Methoxy-3-(4-((1-(2-(2-methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-4H-chromen-4-one (113). A mixture of alkyne isoflavone **45** (236 mg, 0.770 mmol), azide chalcone **69** (308 mg, 0.744 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (210 mg, 0.843 mmol) and sodium ascorbate (363 mg, 1.83 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH/PE to afford triazole hybrid **113** (167 mg, 31%) as a pale yellow-orange powdery solid. m.p. 118–120 °C. TLC $R_f = 0.33$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2942w (C-H str), 2840w (C-H str), 1637m (C=O str), 1595s (C=C str), 1559s (C=C str), 1511s (C=C str), 1438m, 1418m, 1336m, 1300m, 1244s, 1201m, 1153s, 1177s, 1118s, 1037s, 1024s. ^1H -NMR (500 MHz, CDCl_3): δ 3.86 (3H, s, $-\text{OCH}_3$), 3.90 (6H, s, 2 \times $-\text{OCH}_3$), 3.90 (3H, s, $-\text{OCH}_3$), 3.93 (3H, s, $-\text{OCH}_3$), 4.46 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.84 (2H, t, $J = 5.2$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.26 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.13 (2H, s, ArH), 6.83 (1H, d, $J = 0.4$ Hz, ArH), 6.84 (1H, d, $J = 6.0$ Hz, ArH), 6.97 (1H, dd, $J = 8.8, 2.4$ Hz, ArH), 7.04 (2H,

d, $J = 8.8$ Hz, ArH), 7.48 (2H, d, $J = 8.8$ Hz, ArH), 7.58 (1H, dd, $J = 8.4, 2.0$ Hz, ArH), 7.62 (1H, d, $J = 2.0$ Hz, ArH), 7.84 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.88 (1H, s, $-\text{CHN}-$), 8.02 (1H, s, $-\text{C}=\text{CH}$), 8.19 (1H, d, $J = 8.8$ Hz, ArH), 8.21 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.7, 55.0, 55.4, 55.8, 55.9, 62.1, 67.6, 90.5, 100.0, 106.6, 111.7, 112.5, 114.5, 114.8, 118.4, 121.6, 122.3, 122.9, 124.4, 127.7, 130.1, 133.7, 135.6, 144.3, 149.5, 150.7, 152.1, 157.9, 158.2, 158.3, 161.6, 163.0, 163.9, 175.7, 190.3. LCMS (ES+) $m/z = 720.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.69$ min). HRMS (ESI+) $m/z = 720.2529$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{40}\text{H}_{38}\text{O}_{10}\text{N}_3^+$ required 720.2552.

(*E*)-7-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)-methoxy)-3-(4-methoxyphenyl)-4*H*-chromen-4-one (**114**). A mixture of alkyne isoflavone **46** (226 mg, 0.738 mmol), azide chalcone **68** (301 mg, 0.728 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (204 mg, 0.818 mmol) and sodium ascorbate (393 mg, 1.98 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **114** (331 mg, 63%) as a pale yellow-green powdery solid. m.p. 98–100 °C. TLC $R_f = 0.39$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2937w (C-H str), 2838w (C-H str), 1623s (C=O str), 1594s (C=C str), 1576s (C=C str), 1512s (C=C str), 1494s, 1463m, 1442m, 1416m, 1247s, 1196m, 1178m, 1094s, 1027m. ^1H -NMR (500 MHz, CDCl_3): δ 3.83 (3H, s, $-\text{OCH}_3$), 3.89 (3H, s, $-\text{OCH}_3$), 3.91 (3H, s, $-\text{OCH}_3$), 3.93 (3H, s, $-\text{OCH}_3$), 3.95 (3H, s, $-\text{OCH}_3$), 4.47 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.86 (2H, t, $J = 4.8$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.32 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.72 (1H, d, $J = 8.4$ Hz, ArH), 6.85 (1H, d, $J = 8.4$ Hz, ArH), 6.95 (2H, d, $J = 8.8$ Hz, ArH), 7.01 (1H, d, $J = 2.0$ Hz, ArH), 7.04 (1H, dd, $J = 8.8, 2.0$ Hz, ArH), 7.38 (1H, d, $J = 8.8$ Hz, ArH), 7.49 (2H, d, $J = 8.8$ Hz, ArH), 7.53 (1H, d, $J = 15.6$ Hz, $-\text{CH}=\text{CHCO}-$), 7.60 (1H, d, $J = 8.4, 1.6$ Hz, ArH), 7.62 (1H, d, $J = 0.8$ Hz, ArH), 7.90 (1H, s, $-\text{C}=\text{CH}$), 7.98 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 8.06 (1H, s, $-\text{CHN}-$), 8.20 (1H, d, $J = 9.2$ Hz, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.8, 55.3, 56.0, 56.0, 60.9, 61.4, 62.4, 67.5, 101.2, 107.6, 111.5, 112.4, 113.9, 114.8, 118.7, 120.7, 122.0, 122.4, 123.9, 124.1, 124.7, 124.8, 127.9, 130.1, 133.0, 139.7, 142.4, 143.1, 149.6, 151.0, 152.1, 153.7, 155.7, 157.7, 159.5, 162.4, 175.7, 188.9. LCMS (ES+) $m/z = 720.3$ ($[\text{M} + \text{H}]^+$, $t_R = 1.84$ min). HRMS (ESI+) $m/z = 720.2533$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{40}\text{H}_{38}\text{O}_{10}\text{N}_3^+$ required 720.2552.

3-Hydroxy-2-(4-(2-(4-(((3-(4-methoxyphenyl)-4-oxo-4*H*-chromen-7-yl)oxy)methyl)-1*H*-1,2,3-triazol-1-yl)-ethoxy)phenyl)-4*H*-chromen-4-one (**115**). A mixture of alkyne isoflavone **46** (183 mg, 0.597 mmol), azide flavonol **79** (189 mg, 0.585 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (271 mg, 1.09 mmol) and sodium ascorbate (493 mg, 2.49 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **115** (42.9 mg, 12%) as a yellow-green powdery solid. m.p. 252–254 °C. TLC $R_f = 0.30$ (3% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3371w(br) (O-H str), 3064w (C-H str), 2928w (C-H str), 1640m, 1626m (C=O str), 1601s, 1563m (C=C str), 1512m (C=C str), 1484w, 1444m, 1409m, 1290w, 1247s, 1201m, 1183m, 1121m, 1049m, 1027m. ^1H -NMR (500 MHz, CDCl_3): δ 3.83 (3H, s, $-\text{OCH}_3$), 4.48 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.86 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.36 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.92 (2H, d, $J = 9.0$ Hz, ArH), 6.97 (3H, d, $J = 9.0$ Hz, ArH and OH), 7.00 (1H, d, $J = 1.5$ Hz, ArH), 7.07 (1H, dd, $J = 8.5, 2.0$ Hz, ArH), 7.42 (1H, t, $J = 7.5$ Hz, ArH), 7.47 (2H, d, $J = 8.5$ Hz, ArH), 7.57 (1H, d, $J = 8.0$ Hz, ArH), 7.70 (1H, t, $J = 8.5$ Hz, ArH), 7.89 (2H, s, $-\text{C}=\text{CH}$ and $-\text{CHN}-$), 8.21–8.25 (4H, m, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.8, 55.3, 62.4, 66.3, 101.3, 113.9, 114.5, 115.0, 118.2, 118.8, 120.6, 124.1, 124.5, 124.7, 124.9, 125.4, 127.9, 129.6, 130.0, 133.5, 137.8, 144.6, 152.1, 155.3, 157.7, 159.0, 159.5, 162.3, 173.2, 175.8. LCMS (ES+) $m/z = 630.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.77$ min). HRMS (ESI+) $m/z = 630.1861$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{36}\text{H}_{28}\text{O}_8\text{N}_3^+$ required 630.1871.

2-((*Z*)-4-(2-(4-(((2-Methoxy-4-((*E*)-3-(4-methoxyphenyl)acryloyl)phenoxy)methyl)-1*H*-1,2,3-triazol-1-yl)-ethoxy)benzylidene)benzofuran-3(2*H*)-one (**116**). A mixture of alkyne chalcone **20** (192 mg, 0.595 mmol), azide aurone **88** (187 mg, 0.609 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (289 mg, 1.16 mmol) and sodium ascorbate (548 mg, 2.77 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **116** (148 mg, 40%) as a bright yellow powdery solid. m.p. 128–130 °C.

TLC R_f = 0.33 (3% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 2941w (C-H str), 2835w (C-H str), 1695m (C=O str), 1647m, 1590s (C=C str), 1571s (C=C str), 1509s (C=C str), 1461m, 1422m, 1296m, 1250s, 1174s, 1147s, 1128s, 1110s, 1098m, 1025s. ¹H-NMR (500 MHz, CDCl₃): δ 3.85 (3H, s, -OCH₃), 3.97 (3H, s, -OCH₃), 4.43 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 4.80 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 5.42 (2H, s, -OCH₂CN-), 6.83 (1H, s, -C=CH), 6.89 (2H, d, J = 9.0 Hz, ArH), 6.91 (2H, d, J = 9.0 Hz, ArH), 7.12 (1H, d, J = 8.0 Hz, ArH), 7.22 (1H, t, J = 8.0 Hz, ArH), 7.33 (1H, d, J = 8.0 Hz, ArH), 7.39 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.56 (2H, d, J = 8.5 Hz, ArH), 7.60 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.64–7.67 (2H, m, ArH), 7.77 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.79–7.81 (1H, m, ArH), 7.86 (2H, d, J = 9.0 Hz, ArH), 7.87 (1H, br s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 55.4, 56.1, 62.9, 66.3, 111.1, 112.3, 112.6, 112.9, 114.3, 114.9, 119.1, 121.8, 122.6, 123.3, 124.3, 124.6, 126.1, 127.7, 130.1, 132.2, 133.1, 133.4, 136.6, 144.0, 146.1, 149.6, 151.4, 158.9, 161.5, 165.9, 184.5, 188.6. LCMS (ES+) m/z = 630.0 ([M + H]⁺, t_R = 1.72 min). HRMS (ESI+) m/z = 630.2217 [M + H]⁺ found, C₃₇H₃₂O₇N₃⁺ required 630.2235.

2-((Z)-4-(2-(4-((2-((E)-3-(Ferrocenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)benzylidene)benzofuran-3(2H)-one (**117**). A mixture of alkyne chalcone **26** (286 mg, 0.772 mmol), azide aurone **88** (248 mg, 0.806 mmol), CuSO₄·5H₂O (236 mg, 0.943 mmol) and sodium ascorbate (426 mg, 2.15 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **117** (409 mg, 78%) as a dark red-purple microcrystalline solid. m.p. 108–110 °C. TLC R_f = 0.48 (3% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 3090w (C-H str), 1699m (C=O str), 1646m, 1594s (C=C str), 1569m (C=C str), 1509s (C=C str), 1476w, 1459m, 1347w, 1297m, 1247m, 1208m, 1178s, 1127s, 1109s, 1097s, 1044m, 1025m, 1001w. ¹H-NMR (500 MHz, CDCl₃): δ 4.11 (5H, s, -C₅H₅), 4.32 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.42 (2H, t, J = 2.0 Hz, -C₅H₄), 4.47 (2H, t, J = 2.0 Hz, -C₅H₄), 4.65 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.32 (2H, s, -OCH₂CN-), 6.85 (1H, s, -C=CH), 6.88 (2H, d, J = 8.8 Hz, ArH), 6.95 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.08 (1H, t, J = 7.6 Hz, ArH), 7.13 (1H, d, J = 8.4 Hz, ArH), 7.22 (1H, t, J = 7.6 Hz, ArH), 7.34 (1H, d, J = 8.4 Hz, ArH), 7.44–7.46 (1H, m, ArH), 7.49 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.60 (1H, dd, J = 7.6, 1.6 Hz, ArH), 7.65 (1H, t, J = 8.4 Hz, ArH), 7.74 (1H, s, -CHN-), 7.81 (1H, dd, J = 7.6, 0.8 Hz, ArH), 7.86 (2H, d, J = 8.8 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.5, 62.9, 66.1, 68.9, 69.8, 71.2, 79.0, 112.8, 112.9, 113.1, 115.0, 121.4, 121.8, 123.3, 123.9, 124.6, 124.7, 125.9, 130.1, 130.2, 132.4, 133.4, 136.6, 144.1, 145.4, 146.0, 156.3, 159.0, 165.8, 184.5, 192.3. LCMS (ES+) m/z = 678.2 ([M + H]⁺, t_R = 2.11 min). HRMS (ESI+) m/z = 678.1677 [M + H]⁺ found, C₃₉H₃₂N₃O₅Fe⁺ required 678.1691.

6-Methoxy-2-((Z)-4-(2-(4-((2-methoxy-5-((E)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)benzylidene)benzofuran-3(2H)-one (**118**). A mixture of alkyne chalcone **22** (265 mg, 0.898 mmol), azide aurone **89** (304 mg, 0.900 mmol), CuSO₄·5H₂O (264 mg, 1.06 mmol) and sodium ascorbate (474 mg, 2.39 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **118** (270 mg, 48%) as a bright yellow powdery solid. m.p. 138–140 °C. TLC R_f = 0.46 (5% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 2934w (C-H str), 2884w (C-H str), 1700m (C=O str), 1656m, 1638m, 1596s (C=C str), 1562s (C=C str), 1510m (C=C str), 1483m, 1412m, 1330m, 1267s, 1198m, 1152s, 1132s, 1099s, 1056m, 1042s, 1022s. ¹H-NMR (500 MHz, CDCl₃): δ 3.74 (3H, s, -NCH₃), 3.94 (3H, s, -OCH₃), 3.96 (3H, s, -OCH₃), 4.42 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.79 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 5.41 (2H, s, -OCH₂CN-), 6.19–6.21 (1H, m, ArH), 6.74–6.80 (4H, m, ArH), 6.78 (1H, s, -C=CH), 6.87 (2H, d, J = 8.8 Hz, ArH), 7.11 (1H, d, J = 8.4 Hz, ArH), 7.27 (1H, d, J = 15.2 Hz, -CH=CHCO-, overlain by CDCl₃), 7.58 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.64 (1H, d, J = 2.0 Hz, ArH), 7.69 (1H, d, J = 8.8 Hz, ArH), 7.78 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.82 (2H, d, J = 8.8 Hz, ArH), 7.87 (1H, s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 34.3, 49.7, 56.0, 56.0, 62.8, 66.2, 96.6, 109.6, 111.0, 111.4, 112.0, 112.1, 112.3, 114.8, 114.9, 116.2, 122.3, 124.3, 125.6, 126.1, 127.6, 130.2, 131.6, 132.4, 133.1, 143.8, 147.0, 149.4, 151.2, 158.6, 167.2, 168.2, 182.8, 188.0. LCMS (ES+) m/z = 633.3 ([M + H]⁺, t_R = 1.94 min). HRMS (ESI+) m/z = 633.2352 [M + H]⁺ found, C₃₆H₃₃N₄O₇⁺ required 633.2349.

2-((Z)-4-(2-(4-((4-Bromo-2-((E)-3-(1-methyl-1H-indol-3-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)benzylidene)benzofuran-3(2H)-one (**119**). A mixture of alkyne chalcone **21** (308 mg, 0.781 mmol), azide aurone **88** (239 mg, 0.779 mmol), CuSO₄·5H₂O (261 mg, 1.04 mmol) and sodium ascorbate (397 mg, 2.00 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **119** (117 mg, 21%) as a pale yellow-brown powdery solid. m.p. 138–140 °C. TLC R_f = 0.44 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 2930w (C-H str), 1699m (C=O str), 1644m, 1590s (C=C str), 1525m (C=C str), 1508m (C=C str), 1460m, 1395w, 1373m, 1249m, 1177s, 1126m, 1096w, 1045w. ¹H-NMR (500 MHz, CDCl₃): δ 3.74 (3H, s, -NCH₃), 4.03 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.37 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 5.32 (2H, s, -OCH₂CN-), 6.71 (2H, d, J = 8.8 Hz, ArH), 6.82 (1H, s, -C=CH), 7.04 (1H, d, J = 8.8 Hz, ArH), 7.16–7.21 (1H, m, ArH), 7.23 (1H, t, J = 7.6 Hz, ArH), 7.29–7.30 (2H, m, ArH), 7.33–7.35 (2H, m, ArH), 7.38 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.54 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.64–7.69 (2H, m, ArH), 7.73 (1H, s, -CHN-), 7.77 (2H, d, J = 8.8 ArH), 7.80–7.82 (2H, m, ArH), 7.85 (1H, d, J = 15.6 Hz, -CH=CHCO-). ¹³C-NMR (500 MHz, CDCl₃): δ 33.2, 49.2, 63.3, 65.7, 110.0, 112.7, 112.7, 112.9, 114.0, 114.7, 114.9, 120.6, 121.7, 121.7, 121.8, 123.1, 123.4, 124.1, 124.6, 125.7, 125.8, 132.0, 133.1, 133.2, 134.8, 135.0, 136.7, 138.1, 138.1, 143.7, 146.0, 155.5, 158.8, 165.8, 184.5, 190.8. LCMS (ES+) *m/z* = 703.1 ([M + H]⁺, t_R = 5.05 min). HRMS (ESI+) *m/z* = 723.1189 [M + Na]⁺ found, C₃₈H₂₉O₅N₄BrNa⁺ required 723.1214.

(Z)-3-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-2-phenyl-4H-chromen-4-one (**120**). A mixture of alkyne flavone **30** (250 mg, 0.906 mmol), azide aurone **89** (316 mg, 0.936 mmol), CuSO₄·5H₂O (284 mg, 1.14 mmol) and sodium ascorbate (447 mg, 2.26 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **120** (351 mg, 63%) as a pale yellow-white powdery solid. m.p. 186–188 °C. TLC R_f = 0.38 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3056w (C-H str), 1698m (C=O str), 1654w, 1608s, 1595s (C=C str), 1509m (C=C str), 1470m, 1434m, 1397m, 1342m, 1272s, 1245s, 1198s, 1176m, 1147m, 1128s, 1109s, 1091s, 1042m. ¹H-NMR (500 MHz, CDCl₃): δ 3.93 (3H, s, -OCH₃), 4.35 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 4.71 (2H, t, J = 4.5 Hz, -OCH₂CH₂N-), 5.33 (2H, s, -OCH₂CN-), 6.74–6.77 (3H, m, ArH and -C=CH), 6.90 (2H, d, J = 9.0 Hz, ArH), 7.40–7.45 (4H, m, ArH), 7.52 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.69 (1H, t, J = 8.5 Hz, ArH), 7.70 (1H, d, J = 8.5 Hz, ArH), 7.83 (2H, d, J = 9.0 Hz, ArH), 7.83 (1H, s, -CHN-), 8.01–8.03 (2H, m, ArH), 8.28 (1H, dd, J = 8.0, 1.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.5, 56.0, 65.1, 66.2, 96.6, 111.5, 112.0, 114.9, 115.0, 118.1, 124.1, 124.8, 124.9, 125.7, 126.1, 128.3, 128.7, 130.7, 133.1, 133.5, 139.5, 144.0, 147.0, 155.3, 156.4, 158.8, 167.3, 168.3, 175.1, 182.8. LCMS (ES+) *m/z* = 614.2 ([M + H]⁺, t_R = 1.91 min). HRMS (ESI+) *m/z* = 614.1926 [M + H]⁺ found, C₃₆H₂₈N₃O₇⁺ required 614.1927.

(Z)-6-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-phenyl-4H-chromen-4-one (**121**). A mixture of alkyne flavone **31** (249 mg, 0.900 mmol), azide aurone **89** (309 mg, 0.916 mmol), CuSO₄·5H₂O (247 mg, 0.989 mmol) and sodium ascorbate (482 mg, 2.43 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **121** (269 mg, 49%) as a bright yellow-orange powdery solid. m.p. 148–150 °C. TLC R_f = 0.30 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3065w (C-H str), 2925w (C-H str), 1695m (C=O str), 1640s, 1594s (C=C str), 1568s (C=C str), 1510m (C=C str), 1496m, 1481m, 1454s, 1442s, 1360m, 1270m, 1250s, 1181s, 1131s, 1110s, 1095s, 1043m, 1027m. ¹H-NMR (500 MHz, CDCl₃): δ 3.92 (3H, s, -OCH₃), 4.43 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.82 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 5.30 (2H, s, -OCH₂CN-), 6.72–6.74 (2H, m, ArH), 6.75 (1H, s, -C=CH), 6.79 (1H, s, -C=CH), 6.89 (2H, d, J = 8.8 Hz, ArH), 7.33 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.48–7.52 (4H, m, ArH), 7.68 (1H, d, J = 9.2 Hz, ArH), 7.71 (1H, d, J = 3.2 Hz, ArH), 7.80 (2H, d, J = 8.8 Hz, ArH), 7.88–7.90 (3H, m, ArH and -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 56.0, 62.2, 66.3, 96.5, 106.4, 106.8, 111.4, 112.0,

114.8, 114.9, 120.0, 123.9, 124.2, 124.5, 125.7, 126.1, 126.2, 129.0, 131.5, 131.7, 133.1, 143.4, 146.9, 151.2, 155.4, 158.7, 163.2, 167.2, 168.2, 178.1, 182.8. LCMS (ES+) $m/z = 614.2$ ($[M + H]^+$, $t_R = 1.77$ min). HRMS (ESI+) $m/z = 614.1906$ $[M + H]^+$ found, $C_{36}H_{28}O_7N_3^+$ required 614.1922.

(*Z*)-3-Hydroxy-2-(4-((1-(2-(4-((3-oxobenzofuran-2(3*H*)-ylidene)methyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-4*H*-chromen-4-one (**122**). A mixture of alkyne flavonol **36** (391 mg, 1.34 mmol), azide aurone **88** (408 mg, 1.33 mmol), $CuSO_4 \cdot 5H_2O$ (435 mg, 1.74 mmol) and sodium ascorbate (682 mg, 3.44 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **122** (335 mg, 42%) as a yellow-brown powdery solid. m.p. 208–210 °C. TLC $R_f = 0.32$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3300w (O-H str), 3073w (C-H str), 2951w (C-H str), 1694m (C=O str), 1646w, 1604s, 1596s (C=C str), 1567w (C=C str), 1509s (C=C str), 1458w, 1426w, 1407w, 1299m, 1256s, 1178s, 1109s, 1051s. 1H -NMR (500 MHz, $CDCl_3$): δ 4.46 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 4.84 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 5.34 (2H, s, $-OCH_2CN-$), 6.82 (1H, s, $-C=CH$), 6.92 (2H, d, $J = 8.8$ Hz, ArH), 6.96 (1H, br s, OH), 7.15 (2H, d, $J = 8.8$ Hz, ArH), 7.22 (1H, t, $J = 7.6$ Hz, ArH), 7.31 (1H, d, $J = 8.4$ Hz, ArH), 7.39 (1H, t, $J = 7.6$ Hz, ArH), 7.56 (1H, d, $J = 8.8$ Hz, ArH), 7.63–7.71 (2H, m, ArH), 7.80 (1H, d, $J = 7.6$ Hz, ArH), 7.86 (3H, d, $J = 8.4$ Hz, ArH and $-CHN-$), 8.21–8.25 (3H, m, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.8, 62.1, 66.4, 112.6, 112.9, 114.9, 114.9, 118.1, 120.6, 121.8, 123.4, 124.1, 124.4, 124.6, 125.4, 126.1, 129.5, 133.0, 133.4, 136.5, 136.7, 137.7, 145.0, 146.1, 155.3, 157.4, 158.9, 159.5, 165.9, 173.1, 184.5. LCMS (ES+) $m/z = 600.0$ ($[M + H]^+$, $t_R = 4.68$ min). HRMS (ESI+) $m/z = 600.1751$ $[M + H]^+$ found, $C_{35}H_{26}O_7N_3^+$ required 600.1765.

(*Z*)-2-(4-(2-(4-((3-((4,6-Dimethoxy-3-oxobenzofuran-2(3*H*)-ylidene)methyl)phenoxy)methyl)-1*H*-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-hydroxy-7-methoxy-4*H*-chromen-4-one (**123**). A mixture of alkyne aurone **56** (192 mg, 0.571 mmol), azide flavonol **80** (210 mg, 0.595 mmol), $CuSO_4 \cdot 5H_2O$ (234 mg, 0.939 mmol) and sodium ascorbate (362 mg, 1.83 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **123** (54.3 mg, 14%) as a pale yellow-brown powdery solid. m.p. 178–180 °C. TLC $R_f = 0.29$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3302w (O-H str), 2939w (C-H str), 2845w (C-H str), 1692w, 1614s (C=O str), 1599s (C=C str), 1510m (C=C str), 1503m (C=C str), 1452m, 1403w, 1361w, 1346w, 1251m, 1215s, 1187w, 1156m, 1121w, 1092s, 1036w. 1H -NMR (500 MHz, $CDCl_3$): δ 3.91 (3H, s, $-OCH_3$), 3.92 (3H, s, $-OCH_3$), 3.95 (3H, s, $-OCH_3$), 4.46 (2H, t, $J = 4.5$ Hz, $-OCH_2CH_2N-$), 4.83 (2H, t, $J = 4.5$ Hz, $-OCH_2CH_2N-$), 5.34 (2H, s, $-OCH_2CN-$), 6.08 (1H, s, ArH), 6.41 (1H, s, ArH), 6.70 (1H, s, $-C=CH$), 6.93–6.95 (4H, m, ArH and OH), 6.99–7.03 (2H, m, ArH), 7.34 (1H, t, $J = 8.0$ Hz, ArH), 7.40 (1H, d, $J = 7.5$ Hz, ArH), 7.55 (1H, s, ArH), 7.85 (1H, br s, $-CHN-$), 8.12 (1H, d, $J = 9.0$ Hz, ArH), 8.16 (2H, d, $J = 8.5$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.8, 55.9, 56.2, 56.2, 62.2, 66.4, 89.3, 94.1, 99.9, 105.1, 110.3, 114.4, 114.6, 114.8, 116.2, 116.7, 121.9, 123.9, 124.5, 124.8, 126.7, 129.3, 129.8, 134.0, 137.4, 144.0, 148.0, 157.2, 158.3, 158.8, 159.3, 164.2, 169.1, 172.6, 180.6. LCMS (ES+) $m/z = 690.2$ ($[M + H]^+$, $t_R = 4.59$ min). HRMS (ESI+) $m/z = 690.2062$ $[M + H]^+$ found, $C_{38}H_{32}O_{10}N_3^+$ required 690.2082.

(*Z*)-7-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3*H*)-ylidene)methyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)-methoxy)-3-(4-methoxyphenyl)-4*H*-chromen-4-one (**124**). A mixture of alkyne isoflavone **46** (276 mg, 0.901 mmol), azide aurone **89** (301 mg, 0.892 mmol), $CuSO_4 \cdot 5H_2O$ (348 mg, 1.39 mmol) and sodium ascorbate (496 mg, 2.50 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **124** (317 mg, 55%) as a bright yellow powdery solid. m.p. 228–230 °C. TLC $R_f = 0.43$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3085w (C-H str), 2935w (C-H str), 1705m (C=O str), 1651m, 1629s, 1596s (C=C str), 1567m (C=C str), 1510s (C=C str), 1441s, 1347m, 1295m, 1249s, 1202m, 1179s, 1147s, 1098s, 1020s. 1H -NMR (500 MHz, $CDCl_3$): δ 3.83 (3H, s, $-OCH_3$), 3.93 (3H, s, $-OCH_3$), 4.44 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 4.83 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 5.34 (2H, s, $-OCH_2CN-$), 6.74–6.77 (2H, m, ArH), 6.76 (1H, s, $-C=CH$), 6.88 (2H, d,

$J = 8.8$ Hz, ArH), 6.93 (2H, d, $J = 8.8$ Hz, ArH), 6.97 (1H, d, $J = 2.4$ Hz, ArH), 7.06 (1H, dd, $J = 8.8$, 2.4 Hz, ArH), 7.47 (2H, d, $J = 8.8$ Hz, ArH), 7.69 (1H, d, $J = 8.4$ Hz, ArH), 7.82 (2H, d, $J = 8.8$ Hz, ArH), 7.87 (1H, s, -CHN-), 7.89 (1H, s, -C=CH), 8.23 (1H, d, $J = 8.8$ Hz, ArH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.8, 55.3, 56.0, 62.4, 66.3, 96.7, 101.3, 111.3, 112.1, 113.9, 114.8, 114.9, 118.8, 124.1, 124.2, 124.9, 125.7, 126.3, 127.9, 130.0, 133.1, 143.2, 147.0, 152.1, 157.7, 158.6, 159.5, 162.3, 167.3, 168.3, 175.8, 182.8. LCMS (ES+) $m/z = 644.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.86$ min). HRMS (ESI+) $m/z = 644.2011$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{37}\text{H}_{30}\text{O}_8\text{N}_3^+$ required 644.2027.

4,6-Dimethoxy-2-((Z)-3-((1-(2-(4-(((Z)-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzylidene)benzofuran-3(2H)-one (**125**). A mixture of alkyne aurone **56** (303 mg, 0.902 mmol), azide aurone **88** (278 mg, 0.905 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (263 mg, 1.05 mmol) and sodium ascorbate (462 mg, 2.33 mmol) in *t*-BuOH/ H_2O (1:1, 20 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **125** (491 mg, 85%) as a bright yellow-brown powdery solid. m.p. 148–150 °C. TLC $R_f = 0.36$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2942w (C-H str), 2843w (C-H str), 1694m (C=O str), 1651m, 1587s (C=C str), 1508m (C=C str), 1458m, 1423w, 1345m, 1298m, 1251m, 1234m, 1214s, 1177s, 1154s, 1128s, 1091s, 1036m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 3.90 (3H, s, -OCH₃), 3.92 (3H, s, -OCH₃), 4.42 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 4.81 (2H, t, $J = 4.8$ Hz, -OCH₂CH₂N-), 5.31 (2H, s, -OCH₂CN-), 6.09 (1H, d, $J = 1.6$ Hz, ArH), 6.40 (1H, d, $J = 1.2$ Hz, ArH), 6.68 (1H, s, -C=CH), 6.81 (1H, s, -C=CH), 6.88 (2H, d, $J = 8.4$ Hz, ArH), 7.00 (1H, dd, $J = 8.0$, 2.4 Hz, ArH), 7.21 (1H, t, $J = 7.6$ Hz, ArH), 7.30–7.34 (2H, m, ArH), 7.39 (1H, d, $J = 8.0$ Hz, ArH), 7.54 (1H, s, ArH), 7.64 (1H, t, $J = 7.6$ Hz, ArH), 7.79 (1H, d, $J = 7.6$ Hz, ArH), 7.82–7.85 (3H, m, ArH and -CHN-). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.7, 56.2, 62.2, 66.3, 89.3, 94.1, 105.1, 110.3, 112.7, 112.9, 114.3, 114.8, 116.3, 116.6, 121.8, 123.3, 123.9, 124.5, 124.5, 126.0, 129.8, 133.0, 133.4, 133.9, 136.7, 144.3, 146.1, 148.0, 158.3, 158.9, 159.3, 165.9, 169.0, 180.6, 184.5. LCMS (ES+) $m/z = 644.2$ ($[\text{M} + \text{H}]^+$, $t_R = 2.02$ min). HRMS (ESI+) $m/z = 644.2006$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{37}\text{H}_{30}\text{O}_8\text{N}_3^+$ required 644.2027.

(E)-4-((1-(2-(4-(3-(2-Hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (**126**). A mixture of alkyne coumarin **48** (207 mg, 1.03 mmol), azide chalcone **61** (302 mg, 0.975 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (292 mg, 1.17 mmol) and sodium ascorbate (508 mg, 2.56 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **126** (387 mg, 78%) as a bright yellow powdery solid. m.p. 194–196 °C. TLC $R_f = 0.43$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3083w (C-H str), 2929w (C-H str), 1725s (C=O str), 1641m, 1625m, 1607m, 1560s (C=C str), 1511s (C=C str), 1489s, 1424m, 1382m, 1273m, 1249s, 1202s, 1175s, 1156s, 1107m, 1056m, 1030m. $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 4.47 (2H, t, $J = 5.2$ Hz, -OCH₂CH₂N-), 4.87 (2H, t, $J = 5.2$ Hz, -OCH₂CH₂N-), 5.36 (2H, s, -OCH₂CN-), 5.87 (1H, s, -C=CH), 6.91–6.97 (3H, m, ArH), 7.03 (1H, d, $J = 8.4$ Hz, ArH), 7.23 (1H, t, $J = 8.0$ Hz, ArH), 7.31 (1H, d, $J = 8.4$ Hz, ArH), 7.48–7.54 (2H, m, ArH), 7.54 (1H, d, $J = 15.2$ Hz, -CH=CHCO-), 7.61 (2H, d, $J = 8.4$ Hz, ArH), 7.78 (1H, dd, $J = 8.0$, 1.6 Hz, ArH), 7.86 (1H, d, $J = 15.6$ Hz, -CH=CHCO-), 7.91 (1H, dd, $J = 8.0$, 1.2 Hz, ArH), 7.94 (1H, s, -CHN-), 12.87 (1H, s, OH). $^{13}\text{C-NMR}$ (500 MHz, CDCl_3): δ 49.9, 62.5, 66.3, 91.2, 115.0, 115.4, 116.8, 118.4, 118.6, 118.8, 120.0, 123.1, 123.9, 124.7, 128.5, 129.5, 130.6, 132.6, 136.3, 141.6, 144.7, 153.3, 159.8, 162.6, 163.5, 164.9, 193.6. LCMS (ES+) $m/z = 510.2$ ($[\text{M} + \text{H}]^+$, $t_R = 1.65$ min). HRMS (ESI+) $m/z = 510.1651$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{29}\text{H}_{24}\text{O}_6\text{N}_3^+$ required 510.1660.

4-((1-(2-(4-(3-Hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (**127**). A mixture of alkyne coumarin **48** (186 mg, 0.931 mmol), azide flavonol **79** (302 mg, 0.933 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (318 mg, 1.27 mmol) and sodium ascorbate (497 mg, 2.51 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) and recrystallized from MeOH to afford triazole hybrid **127** (77.9 mg, 16%) as an off-white powdery solid. m.p. 228–230 °C. TLC $R_f = 0.46$ (5% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3271w (O-H str), 3015w (C-H str), 2923w (C-H str), 1714s

(C=O str), 1622m, 1603s, 1565s (C=C str), 1509m (C=C str), 1480m, 1470w, 1428m, 1406w, 1376w, 1262s, 1228m, 1177m, 1140w, 1106m, 1043m. ¹H-NMR (500 MHz, CDCl₃): δ 4.52 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 4.89 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 5.37 (2H, s, -OCH₂CN-), 5.89 (1H, s, -C=CH), 6.97 (1H, br s, OH), 7.03 (2H, d, *J* = 9.0 Hz, ArH), 7.24 (1H, t, *J* = 8.0 Hz, ArH), 7.31 (1H, dd, *J* = 8.5, 1.0 Hz, ArH), 7.43 (1H, t, *J* = 8.0 Hz, ArH), 7.54 (1H, t, *J* = 8.5 Hz, ArH), 7.59 (1H, d, *J* = 8.5 Hz, ArH), 7.72 (1H, t, *J* = 8.5 Hz, ArH), 7.78 (1H, dd, *J* = 8.0, 1.5 Hz, ArH), 7.96 (1H, s, -CHN-), 8.23–8.27 (3H, m, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.9, 62.6, 66.3, 91.2, 114.5, 115.4, 116.8, 118.2, 120.7, 123.1, 123.9, 124.5, 124.7, 124.8, 125.4, 129.7, 132.5, 133.5, 137.8, 141.7, 144.6, 153.3, 155.3, 159.0, 162.6, 164.9, 173.2. LCMS (ES+) *m/z* = 524.2 ([M + H]⁺, *t*_R = 1.55 min). HRMS (ESI+) *m/z* = 524.1476 [M + H]⁺ found, C₂₉H₂₂N₃O₇⁺ required 524.1458.

4-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2H-chromen-2-one (**128**). A mixture of alkyne flavone **30** (310 mg, 1.12 mmol), azide coumarin **58** (256 mg, 1.11 mmol), CuSO₄·5H₂O (399 mg, 1.60 mmol) and sodium ascorbate (578 mg, 2.92 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **128** (354 mg, 63%) as a white fluffy solid. m.p. 268–270 °C. TLC *R*_f = 0.30 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3082w (C-H str), 2926w (C-H str), 1723s (C=O str), 1626s, 1567m (C=C str), 1494w, 1465m, 1400w, 1385m, 1274m, 1239s, 1197s, 1182s, 1148s, 1140m, 1111m, 1058w, 1030w. ¹H-NMR (500 MHz, CDCl₃): δ 4.47 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 4.85 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 5.31 (2H, s, -OCH₂CN-), 5.65 (1H, s, -C=CH), 7.24 (1H, t, *J* = 7.5 Hz, ArH, overlain by CDCl₃), 7.33 (1H, d, *J* = 8.5 Hz, ArH), 7.41–7.46 (4H, m, ArH), 7.51 (1H, d, *J* = 8.5 Hz, ArH), 7.55 (1H, t, *J* = 8.0 Hz, ArH), 7.68–7.73 (2H, m, ArH), 7.93 (1H, s, -CHN-), 8.02–8.04 (2H, m, ArH), 8.25 (1H, d, *J* = 7.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 48.7, 65.2, 67.0, 91.1, 115.0, 116.8, 118.1, 122.9, 124.0, 124.2, 124.7, 124.9, 125.6, 128.4, 128.7, 130.7, 130.8, 132.8, 133.7, 139.7, 144.7, 153.3, 155.3, 156.3, 162.2, 164.6, 175.1. LCMS (ES+) *m/z* = 508.3 ([M + H]⁺, *t*_R = 1.81 min). HRMS (ESI+) *m/z* = 508.1506 [M + H]⁺ found, C₂₉H₂₂N₃O₆⁺ required 508.1509.

(Z)-4-((1-(2-(4-(((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (**129**). A mixture of alkyne coumarin **48** (181 mg, 0.902 mmol), azide aurone **89** (302 mg, 0.895 mmol), CuSO₄·5H₂O (250 mg, 1.00 mmol) and sodium ascorbate (459 mg, 2.32 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and recrystallized from MeOH to afford triazole hybrid **129** (253 mg, 53%) as a bright yellow-orange microcrystalline solid. m.p. 138–140 °C. TLC *R*_f = 0.40 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3077w (C-H str), 2926w (C-H str), 1719s (C=O str), 1650m, 1623m, 1593s (C=C str), 1565m (C=C str), 1511m (C=C str), 1442m, 1399m, 1269m, 1247s, 1182s, 1130s, 1096s, 1042m, 1019m. ¹H-NMR (500 MHz, CDCl₃): δ 3.94 (3H, s, -OCH₃), 4.48 (2H, t, *J* = 4.5 Hz, -OCH₂CH₂N-), 4.87 (2H, t, *J* = 4.5 Hz, -OCH₂CH₂N-), 5.36 (2H, s, -OCH₂CN-), 5.88 (1H, s, -C=CH), 6.75–6.78 (2H, m, ArH), 6.76 (1H, s, -C=CH), 6.94 (2H, d, *J* = 9.0 Hz, ArH), 7.23 (1H, t, *J* = 8.0 Hz, ArH), 7.31 (1H, dd, *J* = 8.5, 1.0 Hz, ArH), 7.53 (1H, t, *J* = 8.5 Hz, ArH), 7.71 (1H, d, *J* = 9.0 Hz, ArH), 7.77 (1H, dd, *J* = 8.0, 1.5 Hz, ArH), 7.84 (2H, d, *J* = 8.5 Hz, ArH), 7.95 (1H, s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.9, 56.0, 62.5, 66.3, 91.2, 96.6, 111.3, 112.1, 114.8, 115.0, 115.4, 116.8, 123.1, 123.9, 124.7, 125.8, 126.3, 132.5, 133.1, 141.6, 147.1, 153.3, 158.6, 162.6, 164.9, 167.3, 168.3, 182.8. LCMS (ES+) *m/z* = 538.2 ([M + H]⁺, *t*_R = 1.78 min). HRMS (ESI+) *m/z* = 538.1617 [M + H]⁺ found, C₃₀H₂₄N₃O₇⁺ required 538.1614.

4-(2-(4-(((3-(4-Methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2H-chromen-2-one (**130**). A mixture of alkyne isoflavone **46** (301 mg, 0.983 mmol), azide coumarin **58** (232 mg, 1.00 mmol), CuSO₄·5H₂O (288 mg, 1.15 mmol) and sodium ascorbate (503 mg, 2.54 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **130** (363 mg, 69%) as an off-white powdery solid. m.p. 208–210 °C. TLC *R*_f = 0.28 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3085w (C-H str), 2927w (C-H str), 1730s (C=O str), 1621s, 1566m (C=C str), 1513m (C=C

str), 1495w, 1444m, 1379m, 1330w, 1279w, 1241s, 1198m, 1181s, 1144m, 1109m, 1031m. ¹H-NMR (500 MHz, CDCl₃): δ 3.85 (3H, s, -OCH₃), 4.58 (2H, t, *J* = 4.4 Hz, -OCH₂CH₂N-), 4.95 (2H, t, *J* = 4.4 Hz, -OCH₂CH₂N-), 5.35 (2H, s, -OCH₂CN-), 5.69 (1H, s, -C=CH), 6.97–6.99 (3H, m, ArH), 7.03 (1H, dd, *J* = 8.8, 2.0 Hz, ArH), 7.23 (1H, d, *J* = 7.6 Hz, ArH), 7.31 (1H, d, *J* = 8.0 Hz, ArH), 7.50 (2H, d, *J* = 8.4 Hz, ArH), 7.56 (1H, t, *J* = 8.0 Hz, ArH), 7.65 (1H, d, *J* = 8.0 Hz, ArH), 7.84 (1H, s, -CHN-), 7.90 (1H, s, -C=CH), 8.20 (1H, d, *J* = 8.8 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.0, 55.3, 62.4, 67.0, 91.3, 101.2, 114.0, 114.8, 114.9, 117.0, 118.9, 120.2, 122.4, 123.5, 124.0, 124.1, 125.0, 128.0, 130.1, 132.9, 143.7, 152.1, 153.3, 157.7, 159.6, 162.2, 164.4, 175.7. LCMS (ES+) *m/z* = 538.0 ([M + H]⁺, *t*_R = 4.19 min). HRMS (ESI+) *m/z* = 538.1624 [M + H]⁺ found, C₃₀H₂₄N₃O₇⁺ required 538.1614.

(*E*)-4-((1-(2-(4-(3-Oxo-3-(2-(prop-2-yn-1-yloxy)phenyl)prop-1-en-1-yl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)-2*H*-chromen-2-one (**131**). A mixture of biflavonoid **126** (264 mg, 0.517 mmol), propargyl bromide (0.130 mL, 1.46 mmol) and anhydrous K₂CO₃ (291 mg, 2.10 mmol) in dry acetone (50 mL) was reacted according to GP-B. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford alkyne biflavonoid **131** (229 mg, 81%) as a pale yellow-white powdery solid. m.p. 164–166 °C. TLC *R*_f = 0.15 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3239w (C≡C-H str), 3074w (C-H str), 2973w (C-H str), 2165w (C≡C str), 1723s (C=O str), 1651m, 1624m, 1600s (C=C str), 1566m (C=C str), 1510m (C=C str), 1482w, 1452m, 1401s, 1372m, 1328m, 1231s, 1175w, 1105m, 1028m. ¹H-NMR (500 MHz, CDCl₃): δ 2.54 (1H, t, *J* = 2.0 Hz, -OCH₂C≡CH), 4.45 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 4.79 (2H, d, *J* = 2.0 Hz, -OCH₂C≡CH), 4.85 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 5.35 (2H, s, -OCH₂CN-), 5.87 (1H, s, -C=CH), 6.88 (2H, d, *J* = 8.8 Hz, ArH), 7.09–7.13 (2H, m, ArH), 7.23 (1H, t, *J* = 7.6 Hz, ArH), 7.29 (1H, d, *J* = 13.2 Hz, -CH=CHCO-, overlain by CDCl₃), 7.32 (1H, t, *J* = 4.4 Hz, ArH), 7.49 (1H, t, *J* = 8.8 Hz, ArH), 7.53–7.58 (3H, m, ArH), 7.56 (1H, d, *J* = 15.6 Hz, -CH=CHCO-), 7.64 (1H, dd, *J* = 7.6, 1.2 Hz, ArH), 7.77 (1H, dd, *J* = 8.4, 0.8 Hz, ArH), 7.93 (1H, s, -CHN-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.9, 56.4, 62.5, 66.3, 76.1, 78.1, 91.2, 113.3, 114.8, 115.4, 116.8, 121.8, 123.1, 123.9, 124.6, 125.6, 129.0, 130.0, 130.2, 130.5, 132.6, 132.6, 141.6, 142.7, 153.3, 155.8, 159.3, 162.5, 164.9, 192.5. LCMS (ES+) *m/z* = 548.0 ([M + H]⁺, *t*_R = 4.38 min). HRMS (ESI+) *m/z* = 548.1803 [M + H]⁺ found, C₃₂H₂₆O₆N₃⁺ required 548.1816.

(*Z*)-2-(4-((1-(2-(4-((3-Oxobenzofuran-2(3*H*)-ylidene)methyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-3-(prop-2-yn-1-yloxy)-4*H*-chromen-4-one (**132**). A mixture of biflavonoid **122** (212 mg, 0.354 mmol), propargyl bromide (0.063 mL, 0.707 mmol) and anhydrous K₂CO₃ (153 mg, 1.11 mmol) in dry acetone (20 mL) was reacted according to GP-B. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford alkyne biflavonoid **132** (168 mg, 74%) as a bright yellow powdery solid. m.p. 150–152 °C. TLC *R*_f = 0.50 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3233w (C≡C-H str), 2939w (C-H str), 2115w (C≡C str), 1697s (C=O str), 1635m, 1606s, 1598s (C=C str), 1566m (C=C str), 1508s (C=C str), 1472m, 1395m, 1343w, 1301m, 1250s, 1198m, 1184s, 1148m, 1133w, 1047m, 1017w. ¹H-NMR (500 MHz, CDCl₃): δ 2.34 (1H, t, *J* = 2.4 Hz, -OCH₂C≡CH), 4.46 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 4.84 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 5.00 (2H, d, *J* = 2.4 Hz, -OCH₂C≡CH), 5.33 (2H, s, -OCH₂CN-), 6.83 (1H, s, -C=CH), 6.93 (2H, d, *J* = 8.8 Hz, ArH), 7.12 (2H, d, *J* = 9.2 Hz, ArH), 7.22 (1H, t, *J* = 7.6 Hz, ArH), 7.31 (1H, d, *J* = 8.4 Hz, ArH), 7.38 (1H, t, *J* = 7.6 Hz, ArH), 7.51 (1H, d, *J* = 8.4 Hz, ArH), 7.63–7.69 (2H, m, ArH), 7.80 (1H, d, *J* = 7.6 Hz, ArH), 7.86 (2H, d, *J* = 6.8 Hz, ArH), 7.87 (1H, s, -CHN-), 8.16 (2H, d, *J* = 8.8 Hz, ArH), 8.22 (1H, dd, *J* = 8.0, 1.6 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.8, 59.0, 62.0, 66.3, 76.0, 78.7, 112.6, 112.9, 114.6, 114.9, 117.9, 121.8, 123.4, 123.8, 123.9, 124.1, 124.6, 124.7, 125.7, 126.1, 130.7, 133.4, 136.7, 138.0, 146.1, 155.1, 156.4, 158.9, 160.1, 165.8, 174.7, 184.5. LCMS (ES+) *m/z* = 638.1 ([M + H]⁺, *t*_R = 4.82 min). HRMS (ESI+) *m/z* = 638.1902 [M + H]⁺ found, C₃₈H₂₈O₇N₃⁺ required 638.1922.

(*E*)-1-(4-Methoxy-2-(prop-2-yn-1-yloxy)phenyl)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((*E*)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)prop-2-en-1-one (**133**). A mixture of biflavonoid **92** (111 mg, 0.148 mmol), propargyl bromide (0.050 mL, 0.561 mmol) and anhydrous K₂CO₃ (113 mg, 0.815 mmol) in dry acetone (50 mL) was reacted according to GP-B. The crude

residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford alkyne biflavonoid **133** (107 mg, 92%) as a bright yellow powdery solid. m.p. 170–172 °C. TLC R_f = 0.29 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3286w (C≡C-H str), 3002w (C-H str), 2936w (C-H str), 2841w (C-H str), 2160w (C≡C str), 1650m (C=O str), 1599s (C=C str), 1511m (C=C str), 1458m, 1441w, 1432w, 1418w, 1399w, 1377w, 1337m, 1321m, 1301m, 1259s, 1205w, 1159m, 1124m, 1027m. ¹H-NMR (500 MHz, CDCl₃): δ 2.64 (1H, t, J = 2.4 Hz, -OCH₂C≡CH), 3.87 (6H, s, 2 × -OCH₃), 3.89 (3H, s, -OCH₃), 3.91 (9H, s, 3 × -OCH₃), 4.45 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.83 (2H, t, J = 4.8 Hz, -OCH₂CH₂N-), 4.84 (2H, d, J = 2.4 Hz, -OCH₂C≡CH), 5.33 (2H, s, -OCH₂CN-), 6.15 (2H, s, ArH), 6.61–6.63 (2H, m, ArH), 6.83 (1H, d, J = 8.0 Hz, ArH), 6.87 (1H, d, J = 8.0 Hz, ArH), 7.18 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.39 (1H, d, J = 1.6 Hz, ArH), 7.46 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.56–7.64 (2H, m, ArH), 7.61 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.79 (1H, d, J = 9.2 Hz, ArH), 7.85 (1H, d, J = 15.6 Hz, -CH=CHCO-), 8.03 (1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 55.6, 55.8, 55.9, 55.9, 56.5, 63.1, 67.5, 76.3, 78.1, 90.5, 100.1, 106.4, 106.6, 111.5, 111.7, 112.4, 112.8, 121.6, 122.3, 122.8, 124.0, 124.6, 125.3, 128.5, 132.9, 133.7, 135.6, 142.1, 144.1, 147.7, 149.5, 150.6, 151.5, 158.2, 158.3, 161.6, 163.0, 163.8, 190.0, 190.3. LCMS (ES+) m/z = 790.3 ([M + H]⁺, t_R = 4.71 min). HRMS (ESI+) m/z = 790.2949 [M + H]⁺ found, C₄₄H₄₄O₁₁N₃⁺ required 790.2970.

2-(4-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one (**134**). A mixture of biflavonoid **110** (161 mg, 0.268 mmol), propargyl bromide (0.045 mL, 0.500 mmol) and anhydrous K₂CO₃ (111 mg, 0.803 mmol) in dry acetone (20 mL) was reacted according to GP-B. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford alkyne biflavonoid **134** (161 mg, 94%) as a pale yellow-white powdery solid. m.p. 118–120 °C. TLC R_f = 0.34 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3233w (C≡C-H str), 2939w (C-H str), 2116w (C≡C str), 1631s (C=O str), 1613s, 1600s, 1559m (C=C str), 1508m (C=C str), 1467s, 1392s, 1287w, 1252m, 1239m, 1184s, 1146m, 1123w, 1109w, 1042w. ¹H-NMR (500 MHz, CDCl₃): δ 2.33 (1H, t, J = 2.4 Hz, -OCH₂C≡CH), 4.39 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.73 (2H, t, J = 5.2 Hz, -OCH₂CH₂N-), 4.99 (2H, d, J = 2.4 Hz, -OCH₂C≡CH), 5.33 (2H, s, -OCH₂CN-) 6.97 (2H, d, J = 9.2 Hz, ArH), 7.39–7.45 (5H, m, ArH), 7.53 (1H, d, J = 8.0 Hz, ArH), 7.54 (1H, d, J = 8.0 Hz, ArH), 7.67–7.72 (2H, m, ArH), 7.85 (1H, s, -CHN-), 8.02–8.04 (2H, m, ArH), 8.15 (2H, d, J = 9.2 Hz, ArH), 8.25 (1H, dd, J = 8.0, 1.2 Hz, ArH), 8.28 (1H, dd, J = 8.0, 1.2 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.5, 59.0, 65.1, 66.2, 76.1, 78.6, 114.3, 117.9, 118.1, 124.0, 124.1, 124.3, 124.7, 124.8, 124.9, 125.7, 128.3, 128.7, 130.7, 130.8, 133.4, 133.6, 138.1, 139.5, 144.1, 155.1, 155.3, 156.2, 156.4, 159.6, 174.7, 175.1. LCMS (ES+) m/z = 638.1 ([M + H]⁺, t_R = 4.70 min). HRMS (ESI+) m/z = 638.1905 [M + H]⁺ found, C₃₈H₂₈O₇N₃⁺ required 638.1922.

(E)-2-(4-(2-(4-(((3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one (**135**). A mixture of biflavonoid **106** (190 mg, 0.263 mmol), propargyl bromide (0.047 mL, 0.526 mmol) and anhydrous K₂CO₃ (127 mg, 0.920 mmol) in dry acetone (20 mL) was reacted according to GP-B. The crude residue was purified by flash column chromatography (SiO₂, 1% MeOH/CH₂Cl₂) to afford alkyne biflavonoid **135** (95.5 mg, 48%) as a dark red powdery solid. m.p. 108–110 °C. TLC R_f = 0.37 (5% MeOH/CH₂Cl₂). IR ν_{max} (neat)/cm⁻¹: 3292w (C≡C-H str), 2937w (C-H str), 2245w (C≡C str), 1636m (C=O str), 1598s (C=C str), 1576s (C=C str), 1509s (C=C str), 1467m, 1419m, 1395m, 1349w, 1258s, 1198m, 1184m, 1150m, 1029w, 1000w. ¹H-NMR (500 MHz, CDCl₃): δ 2.33 (1H, t, J = 2.5 Hz, -OCH₂C≡CH), 3.96 (3H, s, -OCH₃), 4.17 (5H, s, -C₅H₅), 4.45–4.47 (4H, m, -C₅H₄ and -OCH₂CH₂N-), 4.57 (2H, t, J = 2.0 Hz, -C₅H₄), 4.82 (2H, t, J = 5.0 Hz, -OCH₂CH₂N-), 4.98 (2H, d, J = 2.5 Hz, -OCH₂C≡CH), 5.42 (2H, s, -OCH₂CN-), 6.96 (2H, d, J = 9.0 Hz, ArH), 7.13 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.15 (1H, d, J = 8.5 Hz, ArH), 7.41 (1H, t, J = 8.5 Hz, ArH), 7.54 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.58 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.63 (1H, d, J = 2.0 Hz, ArH), 7.69 (1H, t, J = 8.5 Hz, ArH), 7.73 (1H, d, J = 15.0 Hz, -CH=CHCO-), 7.90 (1H, s, -CHN-), 8.14 (2H, d, J = 9.0 Hz, ArH), 8.25 (1H, dd, J = 8.0, 1.5 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.7, 56.1, 59.0, 62.8, 66.2, 68.9, 69.7, 71.2, 76.1, 78.6, 79.3, 111.2, 112.3, 114.2, 117.9, 118.5, 122.4, 124.0, 124.3, 124.4, 124.7,

125.7, 130.8, 132.3, 133.4, 138.1, 143.8, 146.0, 149.5, 151.3, 155.1, 156.1, 159.5, 174.7, 187.9. LCMS (ES+) $m/z = 762.1$ ($[M + H]^+$, $t_R = 4.88$ min). HRMS (ESI+) $m/z = 762.1878$ $[M + H]^+$ found, $C_{43}H_{36}O_7N_3Fe^+$ required 762.1897.

(*E*)-4-((1-(2-(4-(3-Oxo-3-(2-((1-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)prop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (**136**). A mixture of alkyne biflavonoid **131** (205 mg, 0.375 mmol), azide flavone **86** (123 mg, 0.399 mmol), $CuSO_4 \cdot 5H_2O$ (115 mg, 0.459 mmol) and sodium ascorbate (192 mg, 0.969 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) to afford triazole hybrid **136** (214 mg, 67%) as a pale yellow-white powdery solid. m.p. 78–80 °C. TLC $R_f = 0.37$ (7% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 3080w (C-H str), 2923w (C-H str), 1708s (C=O str), 1622s, 1597s (C=C str), 1567s (C=C str), 1509w (C=C str), 1493w, 1449m, 1356m, 1274w, 1237m, 1173m, 1139w, 1105w, 1043w, 1026w. 1H -NMR (500 MHz, $CDCl_3$): δ 4.38 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N-$), 4.41 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N-$), 4.70 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N-$), 4.82 (2H, t, $J = 5.2$ Hz, $-OCH_2CH_2N-$), 5.34 (2H, s, $-OCH_2CN-$), 5.34 (2H, s, $-OCH_2CN-$), 5.85 (1H, s, $-C=CH$), 6.75 (1H, s, $-C=CH$), 6.77–6.80 (3H, m, ArH), 6.85 (1H, d, $J = 2.4$ Hz, ArH), 7.08 (1H, t, $J = 7.6$ Hz, ArH), 7.14 (1H, d, $J = 8.4$ Hz, ArH), 7.20 (1H, t, $J = 8.0$ Hz, ArH), 7.26 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$, overlain by $CDCl_3$), 7.28 (1H, d, $J = 4.0$ Hz, ArH), 7.38 (2H, d, $J = 8.4$ Hz, ArH), 7.46–7.54 (5H, m, ArH), 7.50 (1H, d, $J = 16.0$ Hz, $-CH=CHCO-$), 7.62 (1H, dd, $J = 8.8, 1.6$ Hz, ArH), 7.74 (1H, dd, $J = 8.0, 1.2$ Hz, ArH), 7.77 (1H, s, $-CHN-$), 7.89 (2H, dd, $J = 7.6, 1.6$ Hz, ArH), 7.96 (1H, s, $-CHN-$), 8.03 (1H, d, $J = 8.8$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.4, 49.8, 62.5, 62.8, 66.2, 66.6, 91.2, 101.4, 107.5, 113.1, 114.1, 114.8, 115.4, 116.7, 118.5, 121.5, 123.1, 123.9, 124.0, 124.8, 125.7, 126.2, 127.3, 128.7, 129.1, 129.8, 130.1, 130.4, 131.6, 131.6, 132.5, 132.9, 141.6, 142.4, 144.1, 153.3, 156.5, 157.6, 159.3, 161.9, 162.5, 163.2, 164.9, 177.6, 192.6. LCMS (ES+) $m/z = 855.3$ ($[M + H]^+$, $t_R = 4.57$ min). HRMS (ESI+) $m/z = 855.2743$ $[M + H]^+$ found, $C_{49}H_{39}O_9N_6^+$ required 855.2773.

(*Z*)-7-(2-(4-(((4-Oxo-2-(4-((1-(2-(4-((3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one (**137**). A mixture of alkyne biflavonoid **132** (145 mg, 0.227 mmol), azide flavone **86** (73.5 mg, 0.239 mmol), $CuSO_4 \cdot 5H_2O$ (70.1 mg, 0.281 mmol) and sodium ascorbate (129 mg, 0.651 mmol) in *t*-BuOH/ H_2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO_2 , 1%–5% MeOH/ CH_2Cl_2) to afford triazole hybrid **137** (106 mg, 49%) as a bright yellow powdery solid. m.p. 198–200 °C. TLC $R_f = 0.33$ (7% MeOH/ CH_2Cl_2). IR ν_{max} (neat)/ cm^{-1} : 2931w (C-H str), 2874w (C-H str), 1698w, 1628s (C=O str), 1602s, 1594s (C=C str), 1508s (C=C str), 1466m, 1449m, 1423w, 1396w, 1374m, 1299w, 1288w, 1249s, 1178s, 1148w, 1128w, 1110w, 1096w, 1041m. 1H -NMR (500 MHz, $CDCl_3$): δ 4.44–4.46 (4H, m, $2 \times -OCH_2CH_2N-$), 4.78 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 4.83 (2H, t, $J = 4.8$ Hz, $-OCH_2CH_2N-$), 5.28 (2H, s, $-OCH_2CN-$), 5.33 (2H, s, $-OCH_2CN-$), 6.75 (1H, s, $-C=CH$), 6.81 (1H, s, $-C=CH$), 6.91–6.94 (4H, m, ArH), 7.04 (2H, d, $J = 9.2$ Hz, ArH), 7.21 (1H, d, $J = 7.6$ Hz, ArH), 7.30 (1H, d, $J = 8.4$ Hz, ArH), 7.37 (1H, d, $J = 7.6$ Hz, ArH), 7.47–7.53 (4H, m, ArH), 7.62–7.67 (2H, m, ArH), 7.79 (1H, d, $J = 7.6$ Hz, ArH), 7.84 (2H, d, $J = 8.8$ Hz, ArH), 7.87–7.90 (3H, m, $-CHN-$ and ArH), 7.94 (1H, s, $-CHN-$), 8.04 (2H, d, $J = 8.8$ Hz, ArH), 8.11 (1H, d, $J = 8.8$ Hz, ArH), 8.23 (1H, dd, $J = 8.0, 1.2$ Hz, ArH). ^{13}C -NMR (500 MHz, $CDCl_3$): δ 49.3, 49.7, 61.9, 65.0, 66.3, 66.7, 101.5, 107.6, 112.7, 112.9, 114.2, 114.7, 114.9, 117.9, 118.5, 121.8, 123.4, 123.6, 124.0, 124.1, 124.6, 124.7, 125.0, 125.6, 126.1, 126.2, 127.4, 129.0, 130.5, 131.5, 131.7, 133.4, 133.4, 136.7, 139.0, 143.7, 144.3, 146.1, 155.1, 156.1, 157.7, 159.0, 160.0, 162.1, 163.2, 165.9, 174.9, 177.7, 184.5. LCMS (ES+) $m/z = 945.4$ ($[M + H]^+$, $t_R = 4.89$ min). HRMS (ESI+) $m/z = 945.2851$ $[M + H]^+$ found, $C_{55}H_{41}O_{10}N_6^+$ required 945.2879.

7-Methoxy-2-(4-(2-(4-((5-methoxy-2-((*E*)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((*E*)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-4H-chromen-4-one (**138**). A mixture of alkyne biflavonoid **133** (107 mg, 0.135 mmol), azide flavone **87** (49.3 mg, 0.146 mmol), $CuSO_4 \cdot 5H_2O$ (66.0 mg, 0.264 mmol) and sodium ascorbate

(72.8 mg, 0.367 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **138** (8.00 mg, 5%) as a pale yellow-white powdery solid. m.p. 128–130 °C. TLC *R*_f = 0.19 (5% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 2927w (C-H str), 2846w (C-H str), 1736w, 1627m (C=O str), 1600s (C=C str), 1510s (C=C str), 1454m, 1439m, 1423m, 1375w, 1355w, 1338w, 1258s, 1204m, 1162m, 1123s, 1023s. ¹H-NMR (500 MHz, DMSO-*d*₆): δ 3.76 (6H, s, 2 × -OCH₃), 3.85 (6H, s, 2 × -OCH₃), 3.90 (9H, s, 3 × -OCH₃), 4.38 (2H, t, *J* = 4.4 Hz, -OCH₂CH₂N-), 4.50 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 4.71 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 4.82 (2H, t, *J* = 4.8 Hz, -OCH₂CH₂N-), 5.24 (2H, s, -OCH₂CN-), 5.38 (2H, s, -OCH₂CN-), 6.29 (2H, s, ArH), 6.57–6.66 (1H, m, ArH), 6.81 (1H, s, -C=CH), 6.82–6.85 (1H, m, ArH), 6.92–6.98 (3H, m, ArH), 7.02–7.11 (3H, m, ArH), 7.20 (1H, d, *J* = 8.8 Hz, ArH), 7.27 (1H, dd, *J* = 5.6, 2.4 Hz, ArH), 7.47 (1H, d, *J* = 15.6 Hz, -CH=CHCO-), 7.48 (1H, d, *J* = 8.0 Hz, ArH), 7.54–7.64 (2H, m, ArH), 7.56 (1H, d, *J* = 15.2 Hz, -CH=CHCO-), 7.82 (1H, d, *J* = 16.0 Hz, -CH=CHCO-), 7.87–8.06 (3H, m, ArH and -CHN-), 8.02 (1H, d, *J* = 16.0 Hz, -CH=CHCO-), 8.28 (1H, d, *J* = 6.4 Hz, ArH), 8.31 (1H, s, -CHN-). ¹³C-NMR (500 MHz, DMSO-*d*₆): δ 48.9, 49.0, 55.5, 55.7, 56.0, 61.5, 61.7, 66.2, 67.1, 91.0, 99.8, 100.9, 105.1, 105.4, 106.6, 111.0, 111.3, 111.8, 112.0, 112.7, 114.5, 114.9, 114.9, 115.0, 115.0, 117.1, 120.2, 122.1, 123.8, 125.3, 126.1, 127.6, 127.9, 128.0, 132.0, 132.1, 134.4, 137.4, 141.4, 142.3, 142.7, 147.7, 148.9, 149.8, 151.0, 151.1, 157.4, 157.9, 158.6, 160.4, 161.3, 162.0, 163.2, 163.7, 176.3, 188.3, 189.1. LCMS (ES+) *m/z* = 1128.0 ([M + H]⁺, *t*_R = 1.87 min). HRMS (ESI+) *m/z* = 1127.4014 [M + H]⁺ found, C₆₂H₅₉O₁₅N₆⁺ required 1127.4033.

(*Z*)-3-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(4-(2-(4-(((4-oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-4H-chromen-4-one (**139**). A mixture of alkyne biflavonoid **134** (134 mg, 0.210 mmol), azide aurone **89** (83.5 mg, 0.248 mmol), CuSO₄·5H₂O (70.8 mg, 0.284 mmol) and sodium ascorbate (131 mg, 0.659 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) to afford triazole hybrid **139** (73.9 mg, 36%) as a bright yellow powdery solid. m.p. 98–100 °C. TLC *R*_f = 0.39 (7% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 3001w (C-H str), 2929w (C-H str), 2874w (C-H str), 1693m (C=O str), 1632m, 1600s (C=C str), 1509m (C=C str), 1466m, 1444w, 1395m, 1343w, 1248s, 1181s, 1146m, 1129m, 1110m, 1096w, 1044m. ¹H-NMR (500 MHz, CDCl₃): δ 3.93 (3H, s, -OCH₃), 4.34–4.37 (4H, m, 2 × -OCH₂CH₂N-), 4.69–4.72 (4H, m, 2 × -OCH₂CH₂N-), 5.32 (4H, s, 2 × -OCH₂CN-), 6.77 (1H, d, *J* = 5.6 Hz, ArH), 6.77 (1H, s, -C=CH), 6.88 (2H, d, *J* = 8.8 Hz, ArH), 6.90 (2H, d, *J* = 8.8 Hz, ArH), 7.40–7.45 (6H, m, ArH), 7.51 (1H, d, *J* = 3.6 Hz, ArH), 7.53 (1H, d, *J* = 3.6 Hz, ArH), 7.67–7.72 (3H, m, ArH), 7.81 (2H, d, *J* = 9.2 Hz, ArH), 7.84 (1H, s, -CHN-), 7.88 (1H, s, -CHN-), 8.01–8.05 (4H, m, ArH), 8.27 (2H, dd, *J* = 8.0, 1.6 Hz, ArH). ¹³C-NMR (500 MHz, CDCl₃): δ 49.4, 49.5, 56.0, 64.9, 65.2, 66.2, 66.3, 96.6, 111.5, 112.1, 114.3, 114.9, 115.0, 118.0, 118.1, 124.0, 124.1, 124.1, 124.8, 124.8, 124.9, 125.0, 125.7, 125.7, 125.7, 126.1, 128.4, 128.7, 130.6, 130.7, 133.1, 133.4, 133.6, 139.0, 139.6, 144.0, 144.1, 147.0, 155.2, 155.3, 156.0, 156.4, 158.8, 159.5, 167.3, 168.3, 175.0, 175.1, 182.8. LCMS (ES+) *m/z* = 975.4 ([M + H]⁺, *t*_R = 4.94 min). HRMS (ESI+) *m/z* = 975.2956 [M + H]⁺ found, C₅₆H₄₃O₁₁N₆⁺ required 975.2984.

2-(4-(2-(4-(((*E*)-3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-((1-(2-(4-(((*Z*)-6-methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4H-chromen-4-one (**140**). A mixture of alkyne biflavonoid **135** (71.6 mg, 0.0940 mmol), azide aurone **89** (38.1 mg, 0.113 mmol), CuSO₄·5H₂O (46.1 mg, 0.185 mmol) and sodium ascorbate (58.0 mg, 0.293 mmol) in *t*-BuOH/H₂O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO₂, 1%–5% MeOH/CH₂Cl₂) and further purified by preparative HPLC to afford triazole hybrid **140** (2.80 mg, 3%) as a bright red powdery solid. m.p. 158–160 °C. TLC *R*_f = 0.35 (7% MeOH/CH₂Cl₂). IR ν_{\max} (neat)/cm⁻¹: 2917w (C-H str), 2852w (C-H str), 1737w, 1605s (C=O str), 1509m (C=C str), 1465m, 1443w, 1378w, 1353w, 1260s, 1198m, 1151m, 1133w, 1113w, 1042w, 1015w. ¹H-NMR (500 MHz, CDCl₃): δ 3.94 (3H, s, -OCH₃), 3.96 (3H, s, -OCH₃), 4.17 (5H, br s, -C₅H₅), 4.38 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 4.42 (2H, t, *J* = 5.0 Hz, -OCH₂CH₂N-), 4.47

(2H, br s, $-\text{C}_5\text{H}_4$), 4.57 (2H, br s, $-\text{C}_5\text{H}_4$), 4.73 (2H, t, $J = 5.0$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 4.80 (2H, t, $J = 4.5$ Hz, $-\text{OCH}_2\text{CH}_2\text{N}-$), 5.30 (2H, s, $-\text{OCH}_2\text{CN}-$), 5.41 (2H, s, $-\text{OCH}_2\text{CN}-$), 6.76–6.79 (2H, m, ArH and $-\text{C}=\text{CH}$), 6.77 (1H, d, $J = 14.5$ Hz, $-\text{CH}=\text{CHCO}-$), 6.89 (2H, d, $J = 9.0$ Hz, ArH), 6.90 (2H, d, $J = 8.5$ Hz, ArH), 7.14 (1H, d, $J = 8.0$ Hz, ArH), 7.43 (1H, t, $J = 8.0$ Hz, ArH), 7.53 (1H, d, $J = 8.5$ Hz, ArH), 7.58 (1H, d, $J = 8.2$ Hz, ArH), 7.62 (1H, s, ArH), 7.70 (1H, t, $J = 8.5$ Hz, ArH), 7.70 (1H, d, $J = 16.0$ Hz, $-\text{CH}=\text{CHCO}-$), 7.71 (2H, d, $J = 8.5$ Hz, ArH), 7.84 (2H, d, $J = 9.0$ Hz, ArH), 7.89 (1H, s, $-\text{CHN}-$), 7.94 (1H, s, $-\text{CHN}-$), 8.05 (2H, d, $J = 9.0$ Hz, ArH), 8.27 (1H, dd, $J = 8.0, 1.5$ Hz, ArH). ^{13}C -NMR (500 MHz, CDCl_3): δ 49.6, 49.7, 56.1, 61.2, 62.8, 66.2, 66.3, 68.9, 69.8, 71.3, 79.3, 96.6, 111.2, 111.6, 111.8, 112.1, 112.3, 114.3, 114.3, 114.9, 118.0, 118.6, 121.3, 122.5, 122.5, 124.1, 124.1, 124.3, 124.4, 124.8, 125.1, 125.7, 125.7, 125.8, 130.6, 133.0, 133.2, 133.5, 138.3, 144.0, 146.0, 149.6, 151.4, 155.1, 157.4, 158.8, 159.5, 167.5, 167.7, 179.2, 182.9, 187.9. LCMS (ESI+) $m/z = 1098.8$ ($[\text{M} + \text{H}]^+$, $t_{\text{R}} = 2.02$ min). HRMS (ESI+) $m/z = 1099.2960$ $[\text{M} + \text{H}]^+$ found, $\text{C}_{61}\text{H}_{51}\text{FeN}_6\text{O}_{11}^+$ required 1099.2921.

3.4. Biological Screening

3.4.1. A β Preparation

A β_{42} (1 mg) was purchased from Eurogentec Ltd. (Hampshire, UK) as a lyophilised powder. The peptide was dissolved in trifluoroacetic acid (TFA, 1 mL), sonicated in an ice-water bath for 60 s, then the TFA removed in a vacuum desiccator. Ice cold 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, 1 mL) was added to re-suspend the lyophilised peptide. The sample was sonicated for 60 s at 0 °C, then aliquoted into 20 μL portions. The HFIP was removed in the vacuum desiccator overnight and the lyophilised samples were stored at -80 °C until use. The required concentration of A β_{42} was prepared by dissolving the sample in dimethyl sulfoxide (DMSO) (5% of total solvent volume), then adding sodium phosphate buffer (50 mM, pH 7.4). The solution was sonicated at 0 °C for 3 min, then centrifuged at 13,400 rpm for 30 min at 0 °C to separate any aggregated species.

3.4.2. Thioflavin T (ThT) Assay

ThT was purchased from AbCam (Cambridge, UK). Final concentrations of 10 μM A β_{42} , 20 μM ThT and 50 μM compound in sodium phosphate buffer (50 mM, pH 7.4) were used for all samples. The assay samples (100 μL) were mixed in a black non-binding 96-well plate (Greiner Bio-One, Stonehouse, UK) which was sealed (Nunc™ polyolefin acrylate film Nunc, ThermoFisher) and loaded into the fluorescence plate reader (Tecan, Männedorf, Switzerland) at 37 °C. Fluorescence kinetics were measured at 5 min reading intervals, with 15 s shaking before each read. The excitation and emission wavelengths were 440 and 480 nm respectively.

4. Conclusions

Herein, we have described a highly modular branching-type strategy for the synthesis of biologically interesting and rare triazole-linked flavonoid dimers and trimers by the varied combination of readily-accessible flavonoid building blocks. Application of this strategy enabled concise and highly step-efficient access to a structurally diverse library of 46 final compounds, with six different biologically-relevant flavonoid structural subclasses (chalcone, flavonol, aurone, flavone, coumarin and isoflavone) successfully incorporated into the library. Each library member features structural motifs that are associated with biological activity (at least two flavonoid units and a 1,2,3-triazole linkage) and many also incorporate additional potential biomolecular-interacting elements (for example, hydrogen-bonding motifs). Many library compounds also feature groups that could provide synthetic handles for further elaboration or diversification. The synthetic strategy could conceivably be applied on a larger scale using a greater range of building blocks. However, this current strategy is limited to the installation of one linker type between the flavonoid units. It may be possible to adapt the strategy to allow for greater variation in the linker motif (for example, the use of an alternate type of building block may allow the alkyl chain length to be varied and 1,5-triazole linkages could conceivably be accessed

though ruthenium-mediated ‘click’ cycloaddition conditions). Such variety may be of value in the context of biological screening; for example, previous studies of flavonoid dimers have suggested that linker length variation had a significant effect upon biological activity [14,16]. Preliminary biological screening of a representative sub-set of compounds has revealed that a selection of the triazole-linked dimers exhibit moderate inhibitory activity against the aggregation of A β ₄₂, a process closely linked with the development of Alzheimer’s disease. Such findings prompt for continued screening of the entire library and further study of the active scaffolds identified. Milligram (typically multimilligram) quantities of most final library compounds were isolated, which should provide ample material for screening in a wider range of biological assays; the systematic modification of any compounds with interesting properties should be facilitated by the conciseness and inherent modularity of the synthetic strategy [55]. More detailed biological assessment of the compound library is currently ongoing and notable results will be reported in due course.

Supplementary Materials: Supplementary materials can be accessed at: <http://www.mdpi.com/1420-3049/21/9/1230/s1>.

Acknowledgments: We thank the Cambridge Commonwealth Trust for the awards of scholarships to T.H.S. and T.J.S. The research leading to these results has received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013)/ERC grant agreement No. [279337/DOS]. The authors also thank AstraZeneca, the European Union (EU), the Engineering and Physical Sciences Research Council (EPSRC), the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC), and the Wellcome Trust for funding. Data accessibility: all data supporting this study are included in the paper and provided as Supporting Information accompanying this paper.

Author Contributions: D.R.S., T.H.S. and T.J.S. conceived and designed the synthetic experiments; F.H. and S.C. conceived and designed the biological experiments, T.H.S. and T.J.S. performed the synthetic experiments; S.C. performed the biological experiments; T.H.S. and T.J.S. analyzed the chemical data; D.R.S. supervised the project; T.H.S., T.J.S., W.R.J.D.G. and D.G.T. co-wrote the manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Sum, T.H.; Sum, T.J.; Stokes, J.E.; Galloway, W.R.J.D.; Spring, D.R. Divergent and concise total syntheses of dihydrochalcones and 5-deoxyflavones recently isolated from *Tacca species* and *Mimosa diplotricha*. *Tetrahedron* **2015**, *71*, 4557–4564. [[CrossRef](#)]
2. Wu, B.; Zhang, W.; Li, Z.; Gu, L.; Wang, X.; Wang, P.G. Concise synthesis of 5-methoxy-6-hydroxy-2-methylchromone-7-O- and 5-hydroxy-2-methylchromone-7-O-rutinosides. Investigation of their cytotoxic activities against several human tumor cell lines. *J. Org. Chem.* **2011**, *76*, 2265–2268. [[CrossRef](#)] [[PubMed](#)]
3. Briot, A.; Baehr, C.; Brouillard, R.; Wagner, A.; Mioskowski, C. Concise synthesis of dihydrochalcones via palladium-catalyzed coupling of aryl halides and 1-aryl-2-propen-1-ols. *J. Org. Chem.* **2004**, *69*, 1374–1377. [[CrossRef](#)] [[PubMed](#)]
4. Silva, D.H.; Zhang, Y.; Santos, L.A.; Bolzani, V.S.; Nair, M.G. Lipoperoxidation and cyclooxygenases 1 and 2 inhibitory compounds from *Iryanthera juruensis*. *J. Agric. Food Chem.* **2007**, *55*, 2569–2574. [[CrossRef](#)] [[PubMed](#)]
5. Snijman, P.W.; Joubert, E.; Ferreira, D.; Li, X.C.; Ding, Y.; Green, I.R.; Gelderblom, W.C. Antioxidant activity of the dihydrochalcones Aspalathin and Nothofagin and their corresponding flavones in relation to other Rooibos (*Aspalathus linearis*) Flavonoids, Epigallocatechin Gallate, and Trolox. *J. Agric. Food Chem.* **2009**, *57*, 6678–6684. [[CrossRef](#)] [[PubMed](#)]
6. Hermoso, A.; Jimenez, I.A.; Mamani, Z.A.; Bazzocchi, I.L.; Pinero, J.E.; Ravelo, A.G.; Valladares, B. Antileishmanial activities of dihydrochalcones from piper elongatum and synthetic related compounds. Structural requirements for activity. *Bioorg. Med. Chem.* **2003**, *11*, 3975–3980. [[CrossRef](#)]
7. Sum, T.J.; Sum, T.H.; Galloway, W.R. J.D.; Spring, D.R. Divergent total syntheses of flavonoid natural products isolated from *Rosa rugosa* and *Citrus unshiu*. *Synlett* **2016**, *27*, 1725–1727.

8. Meguellati, A.; Ahmed-Belkacem, A.; Nurisso, A.; Yi, W.; Brillet, R.; Berqouch, N.; Chavoutier, L.; Fortune, A.; Pawlotsky, J.-M.; Boumendjel, A.; et al. New pseudodimeric aurones as palm pocket inhibitors of Hepatitis C virus RNA-dependent RNA polymerase. *Eur. J. Med. Chem.* **2016**, *115*, 217–229. [[CrossRef](#)] [[PubMed](#)]
9. Sashidhara, K.V.; Kumar, A.; Kumar, M.; Sarkar, J.; Sinha, S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7205–7211. [[CrossRef](#)] [[PubMed](#)]
10. Chow, L.M.C.; Chan, T.; Chan, K.F.; Wong, I.L.K.; Man, C. Preparation of Alkyne-, Azide- and Triazole-Containing Flavonoids as Modulators for Multidrug Resistance in Cancer. WO 2013127361 A1, 6 September 2013.
11. Pingaew, R.; Saekee, A.; Mandi, P.; Nantasenamat, C.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents. *Eur. J. Med. Chem.* **2014**, *85*, 65–76. [[CrossRef](#)] [[PubMed](#)]
12. Yan, C.S.; Wong, I.L.; Chan, K.F.; Kan, J.W.; Chong, T.C.; Law, M.C.; Zhao, Y.; Chan, S.W.; Chan, T.H.; Chow, L.M. A new class of safe, potent, and specific P-gp modulator: Flavonoid dimer FD18 reverses P-gp-mediated multidrug resistance in human breast xenograft in vivo. *Mol. Pharm.* **2015**, *12*, 3507–3517. [[CrossRef](#)] [[PubMed](#)]
13. Chan, T.-H.; Chow, L.M.-C. Preparation of Flavonoid Dimers for Reducing P-glycoprotein Based Multidrug Resistance. WO 2007135592 A1, 29 November 2007.
14. Wong, I.L.; Chan, K.F.; Chen, Y.F.; Lun, Z.R.; Chan, T.H.; Chow, L.M. In vitro and in vivo efficacy of novel flavonoid dimers against cutaneous leishmaniasis. *Antimicrob. Agents Chemother.* **2014**, *58*, 3379–3388. [[CrossRef](#)] [[PubMed](#)]
15. Chan, K.F.; Wong, I.L.; Kan, J.W.; Yan, C.S.; Chow, L.M.; Chan, T.H. Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: Structure-activity relationship and mechanism of modulation. *J. Med. Chem.* **2012**, *55*, 1999–2014. [[CrossRef](#)] [[PubMed](#)]
16. Wong, I.L.K.; Chan, K.-F.; Burkett, B.A.; Zhao, Y.; Chai, Y.; Sun, H.; Chan, T.H.; Chow, L.M.C. Flavonoid dimers as bivalent modulators for pentamidine and sodium stibogluconate resistance in *leishmania*. *Antimicrob. Agents Chemother.* **2007**, *51*, 930–940. [[CrossRef](#)] [[PubMed](#)]
17. Chan, K.-F.; Zhao, Y.; Chow, T.W.S.; Yan, C.S.W.; Ma, D.L.; Burkett, B.A.; Wong, I.L.K.; Chow, L.M.C.; Chan, T.H. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: Structure-activity relationships. *ChemMedChem* **2009**, *4*, 594–614. [[CrossRef](#)] [[PubMed](#)]
18. Hou, J.; Liu, X.; Shen, J.; Zhao, G.; Wang, P.G. The impact of click chemistry in medicinal chemistry. *Expert Opin. Drug Discov.* **2012**, *7*, 489–501. [[CrossRef](#)] [[PubMed](#)]
19. Fujii, H.; Watanabe, A.; Nemoto, T.; Narita, M.; Miyoshi, K.; Nakamura, A.; Suzuki, T.; Nagase, H. Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: μ , κ , and putative ϵ opioid receptor antagonists. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 438–441. [[CrossRef](#)] [[PubMed](#)]
20. Njogu, P.M.; Gut, J.; Rosenthal, P.J.; Chibale, K. Design, synthesis, and antiplasmodial activity of hybrid compounds based on (2R,3S)-N-benzoyl-3-phenylisoserine. *ACS Med. Chem. Lett.* **2013**, *4*, 637–641. [[CrossRef](#)] [[PubMed](#)]
21. Hein, J.E.; Fokin, V.V. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: New reactivity of copper(I) acetylides. *Chem. Soc. Rev.* **2010**, *39*, 1302–1315. [[CrossRef](#)]
22. Zhang, J.; Fu, X.-L.; Yang, N.; Wang, Q.-A. Synthesis and cytotoxicity of chalcones and 5-deoxyflavonoids. *Sci. World J.* **2013**, *2013*, 649485. [[CrossRef](#)] [[PubMed](#)]
23. Xiong, Y.; Schaus, S.E.; Porco, J.A., Jr. Metal-catalyzed cascade rearrangements of 3-alkynyl flavone ethers. *Org. Lett.* **2013**, *15*, 1962–1965. [[CrossRef](#)] [[PubMed](#)]
24. Liu, J.; Taylor, S.F.; Dupart, P.S.; Arnold, C.L.; Sridhar, J.; Jiang, Q.; Wang, Y.; Skripnikova, E.V.; Zhao, M.; Foroozesh, M. Pyranoflavones: A group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1. *J. Med. Chem.* **2013**, *56*, 4082–4092. [[CrossRef](#)] [[PubMed](#)]
25. Yeap, G.-Y.; Yam, W.-S.; Takeuchi, D.; Osakada, K.; Gorecka, E.; Mahmood, W.A.K.; Boey, P.-L.; Hamid, S.A. Synthesis, thermal stabilities, and anisotropic properties of some new isoflavone-based esters 7-decanoyloxy-3-(4'-substitutedphenyl)-4H-1-benzopyran-4-ones. *Liq. Cryst.* **2008**, *35*, 315–323. [[CrossRef](#)]
26. Beney, C.; Mariotte, A.-M.; Boumendjel, A. An efficient synthesis of 4,6-dimethoxyaurones. *Heterocycles* **2001**, *55*, 967–972.

27. Zheng, Y.C.; Duan, Y.C.; Ma, J.L.; Xu, R.M.; Zi, X.; Lv, W.L.; Wang, M.M.; Ye, X.W.; Zhu, S.; Mobley, D.; et al. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. *J. Med. Chem.* **2013**, *56*, 8543–8560. [[CrossRef](#)] [[PubMed](#)]
28. Li, S.Y.; Wang, X.B.; Xie, S.S.; Jiang, N.; Wang, K.D.; Yao, H.Q.; Sun, H.B.; Kong, L.Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, β -amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. *Eur. J. Med. Chem.* **2013**, *69*, 632–646. [[CrossRef](#)] [[PubMed](#)]
29. Detsi, A.; Majdalani, M.; Kontogiorgis, C.A.; Hadjipavlou-Litina, D.; Kefalas, P. Natural and synthetic 2'-hydroxy-chalcones and aurones: Synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity. *Bioorg. Med. Chem.* **2009**, *17*, 8073–8085. [[CrossRef](#)] [[PubMed](#)]
30. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. *N. Engl. J. Med.* **2010**, *362*, 329–344. [[CrossRef](#)] [[PubMed](#)]
31. Citron, M. Alzheimer's disease: Strategies for disease modification. *Nat. Rev. Drug Discov.* **2010**, *9*, 387–398. [[CrossRef](#)] [[PubMed](#)]
32. Ehrnhoefer, D.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. *Nat. Struct. Mol. Biol.* **2008**, *15*, 558–566. [[CrossRef](#)] [[PubMed](#)]
33. Necula, M.; Kaye, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. *J. Biol. Chem.* **2007**, *282*, 10311–10324. [[CrossRef](#)] [[PubMed](#)]
34. Ladiwala, A.R.; Dordick, J.S.; Tessier, P.M. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. *J. Biol. Chem.* **2011**, *286*, 3209–3218. [[CrossRef](#)] [[PubMed](#)]
35. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease. *J. Neurochem.* **2003**, *87*, 172–181. [[CrossRef](#)] [[PubMed](#)]
36. Thapa, A.; Woo, E.-R.; Chi, E.Y.; Sharoar, G.; Jin, H.-G.; Shin, S.Y.; Park, I.-S. Biflavonoids Are Superior to Monoflavonoids in Inhibiting Amyloid-B Toxicity and Fibrillogenesis via Accumulation of Nontoxic Oligomer-like Structures. *Biochemistry* **2011**, *50*, 2445–2455. [[CrossRef](#)] [[PubMed](#)]
37. Zammit, S.C.; Cox, A.J.; Gow, R.M.; Zhang, Y.; Gilbert, R.E.; Krum, H.; Kelly, D.J.; Williams, S.J. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 7003–7006. [[CrossRef](#)] [[PubMed](#)]
38. Sagrera, G.; Bertucci, A.; Vazquez, A.; Seoane, G. Synthesis and antifungal activities of natural and synthetic biflavonoids. *Bioorg. Med. Chem.* **2011**, *19*, 3060–3073. [[CrossRef](#)] [[PubMed](#)]
39. Kakade, K.P. Synthesis and characterization of some bromo substituted chalcone by the green synthesis way (grinding method) and aurones 2-benzylidene-1-benzofuran-3-one by cyclization method. *World J. Pharm. Pharm. Sci.* **2015**, *4*, 1591–1597.
40. Tiwari, N.T.; Monserrat, J.-P.; de Montigny, F.; Jaouen, G.; Rager, M.-N.; Hillard, E. Synthesis and structural characterization of ferrocenyl-substituted aurones, flavones, and flavonols. *Organometallics* **2011**, *30*, 5424–5432. [[CrossRef](#)]
41. Hans, R.H.; Guantai, E.M.; Lategan, C.; Smith, P.J.; Wan, B.; Franzblau, S.G.; Gut, J.; Rosenthal, P.J.; Chibale, K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 942–944. [[CrossRef](#)] [[PubMed](#)]
42. Yadav, D.K.; Gautam, A.K.; Kureel, J.; Srivastava, K.; Sahai, M.; Singh, D.; Chattopadhyay, N.; Maurya, R. Synthetic analogs of daidzein, having more potent osteoblast stimulating effect. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 677–681. [[CrossRef](#)] [[PubMed](#)]
43. Vontzalidou, A.; Zoidis, G.; Chaita, E.; Makropoulou, M.; Aliannis, N.; Lambrinidis, G.; Mikros, E.; Skaltsounis, A.L. Design, synthesis and molecular simulation studies of dihydrostilbene derivatives as potent tyrosinase inhibitors. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 5523–5526. [[CrossRef](#)] [[PubMed](#)]
44. Yadav, S.K. Process for the preparation of chromones, isoflavones and homoisoflavones using Vilsmeier reagent generated from phthaloyl dichloride and DMF. *Int. J. Org. Chem.* **2014**, *4*, 236–246. [[CrossRef](#)]
45. Daniel, V.; Rao, Y.J.; Kumar, K.S.; Krupadanam, G.L.D. A facile synthesis of angular and linear 8/2-methyl-furo[2,3-*h*]/[3,2-*g*] chromones and angular pyrano[2,3-*f*] isoflavones from 7-propargyloxy chromones and isoflavones. *Heterocycl. Commun.* **2008**, *14*, 337–344. [[CrossRef](#)]
46. Rao, Ch.P.; Srimannarayana, G. Claisen rearrangement of 4-propargyloxycoumarins: Formation of 2*H*,5*H*-pyrano[3,2-*c*][1]benzopyran-5-ones. *Synth. Commun.* **1990**, *20*, 535–540. [[CrossRef](#)]

47. Bolek, D.; Gutschow, M. Preparation of 4,6,3',4'-tetrasubstituted aurones via aluminium oxide-catalyzed condensation. *J. Heterocycl. Chem.* **2005**, *42*, 1399–1403. [[CrossRef](#)]
48. Haudecoeur, R.; Ahmed-Belkacem, A.; Yi, W.; Fortune, A.; Brillet, R.; Belle, C.; Nicolle, E.; Pallier, C.; Pawlowsky, J.M.; Boumendjel, A. Discovery of naturally occurring aurones that are potent allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. *J. Med. Chem.* **2011**, *54*, 5395–5402. [[CrossRef](#)] [[PubMed](#)]
49. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszczak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. *J. Med. Chem.* **2004**, *47*, 6792–6803. [[CrossRef](#)] [[PubMed](#)]
50. Zhang, C.; Zhao, J.; Wu, S.; Wang, Z.; Wu, W.; Ma, J.; Guo, S.; Huang, L. Intramolecular RET enhanced visible light-absorbing bodipy organic triplet photosensitizers and application in photooxidation and triplet-triplet annihilation upconversion. *J. Am. Chem. Soc.* **2013**, *135*, 10566–10578. [[CrossRef](#)] [[PubMed](#)]
51. Chen, C.Y.; Chen, C.T. A PNIPAM-based fluorescent nanothermometer with ratiometric readout. *Chem. Commun.* **2011**, *47*, 994–996. [[CrossRef](#)] [[PubMed](#)]
52. Rao, N.S.; Kistareddy, C.; Bhavani, B.; Bhavani, R. Synthesis, antibacterial and antifungal activity of some novel chalcone derivatives derived from Apocynin. *Chem. J.* **2013**, *3*, 143–148.
53. Senthilkumar, N.; Somannavar, W.S.; Reddy, S.B.; Sinha, B.K.; Narayan, G.K.A.S.S.; Dandala, R.; Mukkanti, K. Synthesis of active metabolites of Carvedilol, an antihypertensive drug. *Synth. Commun.* **2011**, *41*, 268–276. [[CrossRef](#)]
54. Sridhar, J.; Ellis, J.; Dupart, P.; Liu, J.; Stevens, C.L.; Foroozesh, M. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2. *Drug Metab. Lett.* **2012**, *6*, 275–284. [[CrossRef](#)] [[PubMed](#)]
55. Isidro-Llobet, A.; Hadje Georgiou, K.; Galloway, W.R.J.D.; Giacomini, E.; Hansen, M.R.; Mendez-Abt, G.; Tan, Y.S.; Carro, L.; Sore, H.F.; Spring, D.R. A diversity-oriented synthesis strategy enabling the combinatorial-type variation of macrocyclic peptidomimetic scaffolds. *Org. Biomol. Chem.* **2015**, *13*, 4570–4580. [[CrossRef](#)] [[PubMed](#)]

Sample Availability: Samples of final library compounds are available from the authors.



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).